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Chapter 1 
 
General introduction 
At the beginning of last century, Brodie (1900) described in an extensive study that 
injection of blood serum causes vasoconstriction and a vagally-mediated reflex 
resulting in a reversible bradycardia, hypotension and arrest of the respiration, while 
injection of blood plasma was devoid of these effects.  About 50 years ago, the 
hormone and neurotransmitter serotonin (5-hydroxytryptamine; 5-HT) was isolated 
from blood serum and named due to its origin and vascular action (sero=serum and 
tonin=vasoconstriction) (Rapport et al., 1948).  Similarly, another endogenous 
substance from the enterochromaffin cells (present in gastrointestinal mucosa) was 
isolated, functionally characterised and named enteramine (Erspamer & Asero, 1952).  
The functional properties of enteramine were mainly smooth muscle contraction and 
further investigations revealed that enteramine and serotonin were chemically and 
pharmacologically similar (Erspamer, 1954).   
Classification and nomenclature of 5-HT receptors 
At the end of 1950’s, it was reported that serotonin produces smooth muscle 
contraction in guinea pig ileum that was mediated by two different receptors, one 
sensitive to morphine (5-HT-M) and another to dibenzyline (phenoxybenzamine; 
5-HT-D); this was the first evidence for the existence of multiple receptors for 
serotonin (Gaddum & Picarelli, 1957).  For nearly three decades, the further 
characterisation of these receptor types was hampered, although some report stated 
that non-5-HT-M/D receptors were involved in canine carotid vasoconstriction 
(Saxena, 1972). 
The discovery of radioligand binding techniques provided important 
information for further characterisation of 5-HT receptors.  Thus, the presence of two 
different receptor subtypes (5-HT1 and 5-HT2), preferentially labelled by [3H]5-HT 
and [3H]spiperone, respectively, were reported in the brain homogenate (Peroutka & 
Snyder, 1979).   
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Figure 1.1.  NC-IUPHAR serotonin (5-HT) receptor classification 
(Alexander & Peter, 1999).  The highlighted boxes are discussed in more detail 
(see text).  Lower case letters represent recombinant receptors without 
well-known functional characterisation, whereas upper case letters denote 
well-characterised receptors (Hoyer et al., 1994). 
 
In 1986, Bradley et al. proposed a different classification and nomenclature for 
5-HT receptors, where three different 5-HT receptor subtypes were identified, 
namely: 1) ‘5-HT1-like’ receptors, which displayed high affinity for 
5-carboxamidotryptamine and could be labelled with [3H]5-HT; 2) 5-HT2 receptors, 
being identical to the 5-HT-D receptor and displayed high affinity for ketanserin; and 
5-HT1 
5-HT2 
 
5-HT1A 5-HT1B 5-HT1D 5-ht1E 5-ht1F 
5-HT2A 5-HT2B 5-HT2C
5-HT3 
5-HT4 
5-ht5 
5-ht6 
5-HT7 
5-ht5A 5-ht5B 
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3) 5-HT3 receptors, which are ion channels and identical to the 5-HT-M receptor 
(Bradley et al., 1986).  However, with the introduction of several molecular biological 
tools and their application together with biochemical and functional techniques in the 
last decade led to an integrated approach for characterising receptors on the basis of 
amino acid composition, linkage to second messengers as well as functional 
responses.   Several novel 5-HT receptors were identified, characterised and even 
sometime named differently in different laboratories (e.g. 5-HT1B receptors were also 
known as 5-HT1Dβ or S12) (Levy et al., 1992; Weinshank et al., 1992).  To overcome 
this ambiguity, the Serotonin Receptor Nomenclature Committee of the International 
Union of Pharmacology (NC-IUPHAR) reclassified 5-HT receptors into seven 
subclasses, based on the modern criteria (Figure 1.1, Hoyer et al., 1994). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2.  Schematic representation of a GPCR.  The circles represent amino 
acids and both N- and C-terminals are given as NH2- and COOH-group, 
respectively. 
 
Basically on the basis of their molecular structure (see Figure 1.2), all 5-HT 
receptors (except 5-HT3 receptor) are members of the G-protein-coupled receptor 
H2N 
HOOC
Extracellular
Intracellular 
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superfamily (GPCRs), which consist of integral membrane proteins and interact with 
a large variety of hormones and neurotransmitters (Iismaa et al., 1995).  A common 
feature of GPCRs is the seven transmembrane domains spanning the cell membrane, 
having the N-terminal on the extracellular side, while the C-terminal is present on the 
intracellular side.  Mainly the C-terminal cytoplasmatic tail appears to be important as 
phoshorylation site where specific kinase enzyme catalyse the coupling of phosphate 
groups (for details, see Iismaa et al., 1995).  Furthermore, it has become clear that the 
active binding site for ligands (agonists and antagonists) in these proteins are mainly 
located in the transmembrane regions (called α-helices) of the protein, as observed by 
site directed mutagenesis and chimeric receptors, e.g. in 5-HT1 receptors (Adham et 
al., 1994; Oksenberg et al., 1992; Wurch et al., 1998).   
After receptor activation and G-protein coupling, a number of possible signal 
transduction pathways have been described for GPCRs (for details, see Iismaa et al., 
1995).  The 5-HT receptors couple to the enzymes adenylyl cyclase (which promotes 
the production of cyclic adenosine monophosphate) and phospholipase C (which 
promotes the production of inositol triphosphate and increases intracellular calcium) 
or ion channels (e.g. potassium channels).  Since these effector systems are present in 
every cell, GPCRs play a major important role in the regulation of physiological 
responses and actions of around 80% of all neurotransmitters and hormones 
(Birnbaumer et al., 1990). 
Physiological responses produced by serotonin 
5-HT is synthesised both in the intestines and brain from the essential amino acid 
L-tryptophan.  Interestingly, since 5-HT cannot cross the blood-brain barrier, there is a 
clear distinction between its central and its peripheral functions.  In the central 
nervous system, 5-HT plays an important role as neurotransmitter (Saxena, 1995) and 
is involved in appetite, sleep, memory, thermoregulation, sexual behaviour, 
hallucinations, anxiety and depression.  In the periphery, 5-HT plays a role in the 
aggregations of thrombocytes, smooth muscle contraction, presynaptic transmitter 
release (neurotransmitter and neuropeptide) and stimulation of nerve fibres (Martin, 
1994).  As discussed later, it may be important to note that certain 5-HT1 receptor 
subtypes mediate (among others) cranial vasoconstriction and inhibition of 
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neuropeptides release (e.g. substance P, CGRP, neurokinin A), which may be 
important for their role in migraine therapy (De Vries et al., 1999). 
In the last decades, it has become clear that the cardiovascular effects of 5-HT 
are complex and they consist of bradycardia or tachycardia, hypotension or 
hypertension, vasodilatation and vasoconstriction (Saxena & Villalon, 1990; 1991).  
In most species, 5-HT-induced bradycardia involves 5-HT3 receptors, via the 
so-called von Bezold-Jarisch reflex (Paintal, 1973).  On the other hand, tachycardia 
produced by 5-HT is species-dependent, including a direct or indirect action at 5-HT2 
(rat, dog), 5-HT3 (rabbit, dog), 5-HT4 (pig, human) and 5-HT7 (cat) receptors or by 
tyramine-like (guinea pig) and unidentified mechanisms (Saxena & Villalon, 1990; 
Villalón et al., 1997).  With respect to the blood pressure changes, intravenous 
administration of 5-HT causes a triphasic response in anaesthetised animals (with 
intact vagal nerve), which comprises of: (i) an initial 5-HT1A receptor-mediated 
hypotension, also due to the bradycardia; (ii) a 5-HT2A receptor-mediated 
hypertension; and (iii) a long-lasting 5-HT7 receptor-mediated hypotension (De Vries 
et al., 1997; De Vries et al., 1999; Kalkman et al., 1984; 1991; Saxena & Villalon, 
1990).  To date, it is known that 5-HT can act at a wide range of receptor, 
5-HT1A/B/D/F, 5-HT2A/B, 5-HT3, 5-HT4, 5-ht5A/B, 5-ht6 and 5-HT7 receptors (Figure 1.1), 
by which it can influence different physiological responses.  Furthermore, because 
these receptor subtypes are widely distributed throughout the body, 5-HT has been 
implicated in the (patho)physiology of several diseases, including depression, 
migraine, schizophrenia or eating disorders (Hoyer et al., 1994; Saxena, 1995; Saxena 
& Villalon, 1990).  With the development of more selective ligands at these receptors 
(agonists and antagonists) and with the application of several molecular biological and 
pharmacological assays, it may hopefully be possible to elucidate the importance of 
5-HT receptor subtypes as potential therapeutic target in the near future.  In the 
following sections, the possible role of specific 5-HT receptors as potential targets for 
the development of antimigraine agents has been explored in more detail. 
Serotonin and migraine 
Migraine is a syndrome that affects a substantial fraction of the world’s population, 
with a higher prevalence in women (15-18%) than in men (6%) (Lipton & Stewart, 
1997).  According to the diagnostic criteria proposed by the Headache Classification 
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of the International Headache Society (IHS, 1988), a migraine attack can be divided 
into distinct phases (predromitory phase, aura phase, headache phase, resolution and 
recovery phase) and is characterised by an intense, pulsating and throbbing headache, 
nausea, vomiting and photo- and/or phonopobia. 
Based on different lines of experimental evidence, migraine has been regarded 
as a “low-serotonin syndrome”, indicating that serotonin may play an important role 
in its pathophysiology and/or treatment, such as: 
• Reduction of urinary serotonin and elevation of its major metabolite 
5-hydroxyindole acetic acid during a migraine attack (Curran et al., 1965). 
• Platelet serotonin levels were found to drop rapidly during the onset of a 
migraine attack (Anthony et al., 1967). 
• Potent centrally active 5-HT-depleting agents (e.g. reserpine) can precipitate 
a migraine attack (Carroll & Hilton, 1974). 
• Intravenous injection of serotonin has been shown to lower headache in 
migraineurs, as demonstrated in both prophylactic and acute clinical trials 
(Kimball et al., 1960). 
 
The above-mentioned observations provided the basis for the hypothesis that specific 
5-HT receptors could be targets for antimigraine agents.  The development of the 
acute antimigraine drug sumatriptan, a 5-HT1 receptor agonist, further identified the 
important role of serotonin receptors in migraine therapy (Humphrey et al., 1990). 
Pathophysiology of migraine  
Currently available acute antimigraine agents, besides the ergot alkaloids (ergotamine 
and dihydroergotamine) include the triptans (sumatriptan, naratriptan, rizatriptan, 
zolmitriptan, eletriptan, almotriptan).  In order to explain their clinical antimigraine 
efficacy in an appreciable manner, the vascular and neurogenic hypothesis have been 
proposed (see below and Figure 1.3). 
Vascular hypothesis 
Although, exact mechanisms of the initiation of a migraine attack are still not clear, 
the pulsatile and throbbing nature of migraine pain suggests the involvement of extra- 
and intracranial blood vessels (Goadsby, 1999; Humphrey et al., 1990; May & 
Goadsby, 2001; Saxena & Tfelt-Hansen, 2000).  Earlier, Graham & Wolff (1938) 
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postulated that vasodilatation of cranial blood vessels may play an important role in 
the pathophysiology of migraine.  These pioneers in migraine research have shown 
that relief of migraine headache was accomplished by ergotamine-induced 
vasoconstriction of the temporal artery.  Further studies, performed by Heyck (1969), 
indicated that primarily carotid arteriovenous anastomoses are involved.   
Furthermore, other observations confirming the vascular hypothesis have been, for 
example, that mechanical distension of cranial arteries or administration of potent 
vasodilators, such as organic nitrates, cause headache (Dahl et al., 1990; Nichols et 
al., 1990).  However, these organic nitrates not only dilate blood vessels but also 
release neuropeptides, probably via neuronal events raising the possibility that a part 
from vasodilatation some other mechanisms can also be involved in migraine pain 
(Goadsby & Edvinsson, 1993).  Nevertheless, independent of underlying mechanisms 
of action, a general feature of all acute antimigraine agents (e.g. triptans and ergot 
alkaloids) is their vasoconstrictor property.  In this sense, the discovery of acute 
antimigraine drug sumatriptan and its therapeutic effect was proposed to be due to 
constriction of dilated (cranial) blood vessels (Humphrey & Feniuk, 1991; Saxena & 
Tfelt-Hansen, 2000).  Indeed, both ergot alkaloids and triptans produce similar 
vasoconstriction in the carotid circulation of different species, including the pig and 
dog.  Using this experimental animal model predictive for antimigraine activity 
(De Vries et al., 1999; Saxena, 1995) and other in vitro studies (Bouchelet et al., 
2000; Bouchelet et al., 1996; Longmore et al., 1997; Verheggen et al., 1998), it has 
been clearly demonstrated that 5-HT1B receptors exclusively mediate the 
vasoconstrictor actions of sumatriptan (De Vries et al., 1998; Saxena & Tfelt-Hansen, 
2000; Willems et al., 1998).  Additionally, the 5-HT1B receptor has been localised 
(Longmore et al., 1997) and functionally characterised to produce contraction of 
peripheral blood vessels, such as human isolated coronary artery (Longmore et al., 
1997; MaassenVanDenBrink et al., 1998).  It may be noted that contraction of human 
isolated arteries by the triptans may explain the associated chest pain in clinical 
migraine trials (Saxena & Tfelt-Hansen, 2000). 
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Figure 1.3.  Diagrammatic representation of the possible site of acutely acting 
antimigraine drugs, based on De Vries et al. (1999).  Site of action of antimigraine 
agents are believed to antimigraine action by direct vasoconstriction of dilated cranial 
blood vessels (1), inhibition of trigeminal stimulation induced cranial vasodilatation 
(2), plasma protein extravasation (3) and/or central neuronal activity (4). It may be 
mentioned that the plasma protein extravasation model has been questioned as being 
predictive for antimigraine activity (De Vries et al., 1999). TNC represents trigeminal 
nucleus caudalis. 
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Neurogenic hypothesis 
An alternate mechanism to explain the genesis of a migraine attack involves the 
central nervous system, in particular the trigeminovascular system (Goadsby & 
Edvinsson, 1993; Moskowitz, 1992).  According to this hypothesis, migraine arises 
due to abnormal neuronal firing and neurotransmitter release in the brain neurones, 
possibly leading to cortical spreading depression and neurogenic inflammation and 
after subsequent cascades producing headache and other accompanying symptoms (as 
described above); while vasodilatation is an epiphenomenon.  During neurogenic 
inflammation, the trigeminal ganglion is stimulated and induces neurogenic protein 
extravasation, which involves the release of the neuropeptide calcitonin gene-related 
peptide (CGRP), substance P and neurokinin A (Goadsby, 1999).  Several animal 
studies have demonstrated that inhibition of neurogenic protein extravasation by 
acute antimigraine agents, such as sumatriptan, is mainly mediated by 5-HT1D and/or 
5-ht1F receptors (Bouchelet et al., 2000; Goadsby & Edvinsson, 1993).  However, of 
several possible neuropeptides involved, only circulating CGRP levels are elevated 
after trigeminal ganglion stimulation in cats, indicating that CGRP may play a major 
role in migraine headache (Goadsby & Edvinsson, 1993).  Additionally, CGRP 
produces potent neurogenic dural vasodilatation in guinea pigs, a response that can be 
markedly attenuated by stimulation of presynaptic 5-HT1D and/or 5-ht1F receptor 
agonists (Bouchelet et al., 2000; Goadsby & Edvinsson, 1993).  It may be important 
to note that 5-HT1D and/or 5-ht1F receptor agonists are devoid of vasoconstrictor 
actions (Bouchelet et al., 2000; Villalón et al., 1999), however, it also remains 
unclear whether these compounds are efficacious in migraine treatment (McCall, 
1999).  Considering both above-mentioned hypotheses (see Figure 1.3), it appears 
that both vascular and neuronal effects are important to explain the therapeutic action 
of antimigraine drugs; future studies may hopefully elucidate whether individual 
mechanisms are sufficient for antimigraine efficacy. 
Role of 5-HT1 and 5-HT7 receptors in migraine therapy 
As mentioned above, a combination of vascular and neurogenic hypotheses explains 
pathophysiology of migraine in a reasonable manner and the possible mechanisms of 
actions of acutely acting antimigraine drugs within the trigeminovascular system have 
been summarised in Figure 1.3.  Due to the clinical antimigraine efficacy of triptans, 
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it is evident that the 5-HT1 receptor subfamily is a general target for antimigraine 
activity, with special emphasis on the 5-HT1B, 5-HT1D and/or 5-ht1F receptor.  
Furthermore, selective 5-HT7 receptor antagonists may be efficacious in prophylactic 
migraine therapy.  The molecular and pharmacological aspects of these receptors 
have been discussed in more detail in the following sections, whereas Table 1.1 
provides an overall summary. 
Serotonin 5-HT1B receptor 
Until two decades ago, 5-HT1B receptors were observed only in the rat brain where 
high affinity binding sites were found for [3H]5-HT, while spiperone was used to 
discriminate 5-HT1A binding sites (Pedigo et al., 1981).  Much later, it was established 
that the rat 5-HT1B receptor (Adham et al., 1992; Voigt et al., 1991) displayed a high 
affinity for β-adrenoceptor antagonists (cyanopindolol, pindolol and propranolol).   
A similar pharmacological profile was observed in mice (Maroteaux et al., 
1992) and opossum (Cerutis et al., 1994).  In contrast, the 5-HT1B receptor in other 
species (human, dog and guinea pig) did not recognise β-adrenoceptor antagonists 
(Hoyer & Middlemiss, 1989).  At that time, it was thought that both receptors, which 
shared comparable pharmacological properties, signal-transduction mechanisms and 
tissue distribution, may be species homologous of the same single gene product 
(Hoyer & Middlemiss, 1989).  This possibility was negated with the presence of both 
5-HT1B and 5-HT1D receptors in same species, e.g. human (Weinshank et al., 1992), 
rat (Adham et al., 1992; Voigt et al., 1991), rabbit (Bard et al., 1996; Harwood et al., 
1995), guinea pig (Zgombick et al., 1997) and dog (Branchek et al., 1995). 
Molecular aspects of 5-HT1B receptor 
During the early nineties of last century, cloning of human 5-HT1B receptor was 
reported from several laboratories and was named the 5-HT1Dβ receptor (Hamblin & 
Metcalf, 1991; Weinshank et al., 1992).  The human 5-HT1B receptor is localised on 
chromosome 6, region 6q13 and consists of a 390 amino acid protein (Jin et al., 
1992).  At around the same time, the 5-HT1B receptor was also cloned from rat, mouse 
and opossum and, interestingly, showed three amino acids missing in its receptor 
structure (Maroteaux et al., 1992; Voigt et al., 1991).  The 5-HT1B receptor gene has 
no introns and consists of seven transmembrane domains that are important for ligand 
binding and activation (Jin et al., 1992; Weinshank et al., 1992).  The receptor 
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contains two sites for N-linked glycosylation on the N-terminal region and three 
protein kinase sites in different positions.   
 
Table 1.1.  Characteristic pharmacological properties of some important serotonin 
(5-HT) receptors that may be relevant for the development of antimigraine drugs 
 
Receptor 5-HT1B 5-HT1D 5-ht1F 5-HT7 
Receptor code 2.1.5HT.01B 2.1.5HT.01D 2.1.5HT.01F 2.1.5HT.07 
Previous 
names 
5-HT1-like, 
5-HT1X, 
5-HT1Dβ 
5-HT1-like, 
5-HT1X, 
5-HT1Dα 
5-HT1Eβ, 
5-HT6 
5-HT1-like, 
5-HT1Y, orphan 
Structural 
information 
7TM 
h390aa, 
chr.6q13 
r386aa 
7TM 
h377aa, 
chr.1p34.3-36.3 
r374aa 
7TM 
h366aa, 
chr.3p11 
r366aa 
7TM 
h445aa, 
chr.10q23.3-24.3 
r448aa 
Signal 
transduction 
mechanism 
 
Gi/Go, 
inhibit cAMP 
formation, 
elevated [Ca2+]i 
Gi/Go, 
inhibit cAMP 
formation, 
elevated [Ca2+]i 
Gi/Go, 
inhibit cAMP 
formation. 
 
Gs, 
increases cAMP 
formation. 
Selective 
agonists 
Sumatriptan 
CP93129 
(rodents) 
Sumatriptan 
PNU109291 
LY344864 
LY344370 
None 
Selective 
antagonists 
GR127935* 
SB224289 
GR127935* 
BRL15572 
none SB258719 
Receptor 
Distribution 
Vascular smooth 
muscle, substantia 
nigra, autonomic 
terminals, raphe 
nuclei 
Trigeminal 
ganglion, dorsal 
raphe, autonomic 
and trigeminal 
nerve terminals 
Cortex, 
hippocampus, 
claustrum, spinal 
cord, uterus, 
mesentery 
Hypothalamus, 
raphe nuclei, 
gastrointestinal 
and vascular 
smooth muscle, 
sympathetic 
ganglion 
Tissue 
Functions 
Vasocontraction, 
autoreceptor in 
hippocampus, 
raphe nuclei 
Autoreceptor in 
hippocampus, 
raphe nuclei; 
heteroreceptor in 
trigeminal 
ganglion 
Trigeminal 
neuro-inhibition 
Smooth muscle 
relaxation, 
circadian phase 
shifts 
*, GR127935 is considered to be a selective 5-HT1B/1D receptor antagonist.  Please see the 
list of abbreviations for further details. 
 
The alignment of amino acid sequences of different mammalian species showed high 
overall homology (88-94%), which was even higher in the transmembrane domains 
(Adham et al., 1992; Hamblin et al., 1992; Jin et al., 1992; Maroteaux et al., 1992; 
Voigt et al., 1991; Weinshank et al., 1992).  The presence of a threonine residue in the 
seventh transmembrane domain (at position 355) was observed in human, rabbit, dog 
and guinea pig 5-HT1B receptor and proved to be an important feature for the 
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pharmacological profile (Adham et al., 1992; Oksenberg et al., 1992).  For example, 
the 5-HT1B receptor cloned from other species (e.g. rat, mouse and opossum) showed 
an asparagine residue at this position, which drastically changed their 
pharmacological profile compared to that observed with those in mammalian 
homologues (Maroteaux et al., 1992; Voigt et al., 1991).  For several years, it has 
been questioned whether the 5-HT1B receptor in rodents and mammalian species are 
different.  According to recent classification of 5-HT receptors (NC-IUPHAR), the 
5-HT1B receptor in rodents is a species homologue for that in human and have been 
termed r5-HT1B (formerly 5-HT1Dα) and h5-HT1B (formerly 5-HT1Dβ) receptor, 
respectively (Hoyer et al., 1994).  The latter nomenclature of 5-HT receptors will be 
used in the following sections of present dissertation. 
Binding profile of 5-HT1B receptor ligands 
The 5-HT1B receptor was originally described in rodents by its high affinity for 
β-adrenoceptor antagonists (e.g. propranolol or pindolol) with the presumption for its 
absence in other species (Adham et al., 1992; Voigt et al., 1991).  However, this latter 
assumption proved to be wrong, since the 5-HT1B receptor was also cloned from other 
mammalian homologues (e.g. rat, mouse, dog, rabbit or human) (Branchek et al., 
1995; Hamblin et al., 1992; Harwood et al., 1995; Maroteaux et al., 1992; Voigt et 
al., 1991; Weinshank et al., 1992).  Competitive binding assays revealed a binding 
affinity profile for 5-HT1B receptor as follows: 5-hydroxytryptamine > serotonin > 
sumatriptan > 8-OH-DPAT > pindolol, which was similar to that described for 
5-HT1D receptors (Weinshank et al., 1992).  Subsequently, the pharmacological 
profiles of the 5-HT1B receptor in rodents and human were found to be considerably 
different with regards to their interaction with above-mentioned β-adrenergic 
antagonists (Hoyer et al., 1994; Metcalf et al., 1992; Oksenberg et al., 1992; Parker et 
al., 1993).  Interestingly, this difference in pharmacological profiles between human 
and rodent 5-HT1B receptor has been proved to be due to a single amino acid 
difference (threonine or asparagine at residue 355) in the seventh transmembrane 
domain (Oksenberg et al., 1992). 
Even though, recombinant human 5-HT1B and 5-HT1D receptors display nearly 
indistinguishable pharmacological properties (Weinshank et al., 1992), some 
compounds (e.g. ketanserin or methysergide) are more potent at human 5-HT1D than 
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5-HT1B receptors (Peroutka, 1994); see Table 1.2).  Later, on the basis of both their 
molecular entities and individual pharmacological profiles these receptors were 
identified as independent targets for the drug development of antimigraine agents (see 
below).   
 
Table 1.2.  Binding affinity constants (pKi values) of several compounds at recombinant 
5-HT1B receptor from different species 
 
Ligand Humana Guinea 
pigb 
Rabbitc Ratd Mousee Dogd 
 
Agonists 
      
5-HT 7.94 8.28 8.52 8.56 7.40 8.42 
5-CT 8.06 8.54 9.24 8.94 8.00 8.90 
L694247 9.50d - - 10.02 - 9.71 
Ergotamine 8.12 - - - - - 
DHE 8.09 9.08 8.64i 10.56g - 8.82h 
CP122288 8.31d - - 6.81 - 8.13 
Zolmitriptan 7.61 9.18 8.28 7.29 - 8.02 
Sumatriptan 7.14 6.87 7.54 7.35 - 7.29 
8-OH-DPAT 6.63d 6.59 7.01 5.12 4.50 6.42 
 
Antagonists 
      
GR127935 8.53 8.53 9.74 8.78 - 8.71 
Methiothepin 8.44 8.14 9.32 7.21 - 7.67 
SB224289 8.22 - - - - - 
Ketanserin 6.85 6.15 6.91 <5.1 5.20 5.28h 
Ritanserin 5.76 6.92 - - - - 
BRL15572 5.51 - - - - - 
Metergoline 7.82c 7.97 7.71i 9.05g - 7.45h 
(-)-Propranolol 5.64d - - 7.71  5.36 
(-)-Pindolol 5.31f 5.27 7.19 7.57 7.20 5.18 
Data are means from radioligand displacement experiments, using recombinant receptors 
expressed in different cell lines: a, (Pauwels et al., 1996); b, (Zgombick et al., 1997); 
c, (Wurch et al., 1997) ; d, (Beer et al., 1998); e, (Maroteaux et al., 1992); f, (Weinshank et 
al., 1992); g, (Hamblin et al., 1992); h, (Branchek et al., 1995); i, (Bard et al., 1996). 
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Recently, the potent and selective antagonist (SB224289) of human 
5-HT1B receptor revealed that sumatriptan induced contraction of vascular smooth 
muscle is mainly mediated mainly by 5-HT1B, rather than 5-HT1D, receptors (De Vries 
et al., 1999; Verheggen et al., 1998). 
Signal transduction mechanisms of 5-HT1B receptor 
After activation of 5-HT1B receptors, their functions are mediated by a variety of 
G-proteins, including Gi and Gs (Hoyer et al., 1994).  It has been shown that one of 
the signal transduction pathways, mediated by these receptors, involves negative 
coupling to adenylate cyclase, attenuating cAMP production in target cells (Hoyer et 
al., 1994).  In this sense, inhibition of forskolin-stimulated adenylate cyclase by 5-HT 
was reported in Chinese Hamster Ovary (CHO) or HeLa cells expressing human 
5-HT1B receptors (Hamblin et al., 1992; Veldman & Bienkowski, 1992).  Similarly, 
activation of 5-HT1B receptors by 5-HT, 5-carboxytryptamine and sumatriptan 
decreases forskolin-induced accumulation of cAMP in LM(tK-) cells (Levy et al., 
1992; Weinshank et al., 1992).  Apart from inhibition of adenylate cyclase, other 
studies also show that 5-HT1B receptor activation (via Gs-proteins) also stimulates 
phospholipase C (Hoyer et al., 1994).  Activation of this enzyme will result in the 
generation of inositol (1,4,5)-triphosphate (IP3), which acts on the IP3 receptor in the 
endoplasmatic reticulum to release stored Ca2+ and diacylglycerol that (together with 
Ca2+) can activate protein kinase C.  For example, Zgombick et. al. have demonstrated 
that stimulation of human 5-HT1B receptor in stable expressed LM(tK-) cells or in 
fibroblasts of mice elevates the inositol phosphate level via stimulation of 
phospholipase C (Zgombick et al., 1993).  On the contrary, no changes in intracellular 
Ca2+ levels were observed after activation of human 5-HT1B receptors expressed in 
stable LM(tK-) cells (Levy et al., 1992).  Production of these second messengers 
results in smooth muscle contraction in particular vascular and non-vascular tissues.  
Besides investigating the production of these second messengers, it is also possible to 
study the effects of 5-HT1B receptor activation at the G-protein level, by means of 
quantifying G-protein binding, using the [35S]GTPγS binding assay (Beer et al., 1998; 
Pauwels et al., 1997); described in Chapter 3, we have used [35S]GTPγS binding assay 
for functional receptor characterisation. 
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Tissue distribution of 5-HT1B receptor 
As described by Hoyer (1994) and Bouchelet (1996), 5-HT1B receptors are found 
throughout central as well as peripheral tissues.  Regarding its central distribution, 
Northern blot analysis revealed high expression of 5-HT1B receptor mRNA in 
striatum, moderate in hippocampus and frontal cortex and barely detectable 
expression was found in cerebellum (Jin et al., 1992).  In the same study, in situ 
hybridisation experiments demonstrated a widespread expression of 5-HT1B receptors 
in human and rat brain tissue, mainly in striatum (nucleus caudatus), putamen and 
purkinje cells of the cerebellum.  Other studies showed that the distribution of 5-HT1B 
receptor mRNA in rat brain tissue was profoundly observed in pyramidal cells of 
hippocampus as well as in subiculum and parasubiculum (Voigt et al., 1991).  Earlier, 
autoradiographical studies, using radiolabelled [3H]5-HT in rat brain tissues, showed 
high density of 5-HT1B receptors in the basal ganglion and cortical areas (Pazos & 
Palacios, 1985).  In peripheral tissue, the presence of 5-HT1B receptor mRNA was 
demonstrated by the RT-PCR technique in various blood vessels of rat (aorta, renal 
artery, vena cava, portal, femoral and jugular veins), porcine (pulmonary, coronary 
and cerebral arteries and cerebral vein) and human (cerebral and coronary arteries) 
(Bouchelet et al., 1996; Nilsson et al., 1999; Ullmer et al., 1995).  The use of selective 
antibodies showed a more precise localisation of 5-HT1B receptor proteins with very 
profound signals in smooth muscle layer and faint signals in the endothelium of 
human coronary and cerebral arteries (Nilsson et al., 1999; Nilsson et al., 1999).  
These findings were in agreement with functional studies using selective 5-HT1B and 
5-HT1D receptor antagonists, both in vitro and in vivo experiments (De Vries et al., 
1998; De Vries et al., 1999; Kaumann et al., 1994; Verheggen et al., 1998).   
Physiological functions of 5-HT1B receptor 
Since a decade, mainly molecular and pharmacological studies (see above) have 
provided important information regarding the physiological role of 5-HT1B receptor.  
The exact role of 5-HT1B receptors in animals and human was hampered mainly due 
to the fact that recombinant clones as well as selective compounds were not available.  
Nevertheless, it has been demonstrated that activation of central 5-HT1B receptors can 
serve as an sympatho-regulatory role (inhibiting noradrenaline release) in both rat 
vena cava (Göthert et al., 1986) as well as within the carotid circulation of 
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anaesthetised dogs (Villalón et al., 2001).  Moreover, activation of postsynaptic 
5-HT1B receptors produces vasoconstriction of rat isolated caudal artery (Craig & 
Martin, 1993) or carotid circulation (De Vries et al., 1998; Villalón et al., 1999).  It is 
important to mention that the rat 5-HT1B receptor displays a different molecular 
structure and pharmacological profile as compared to its human homologue (see 
above).  According to the nomenclature and classification assigned by Bradley et al., 
(1986), 5-HT1B receptors mediating certain responses (e.g. contraction of cranial 
blood vessels, prejunctional inhibition of neuronal transmitter release, smooth muscle 
relaxation and tachycardia in the cat) belonged for a long time to the 
5-HT1-like receptors category (Bradley et al., 1986).  Subsequently, with the use of 
selective 5-HT1B/1D receptor antagonists, e.g. GR127935, it became apparent that 
5-HT1B/1D receptors mediate some of these responses (vasoconstriction of cranial 
blood vessels and neuronal release), while others are mediated by 5-HT7 receptors 
(see later) (Saxena et al., 1998).  Using the selective 5-HT1B receptor antagonist 
SB224289, it became clear that mainly 5-HT1B receptors can mediate constriction in 
the cranial (e.g. carotid arteriovenous anastomoses, temporal or middle meningeal 
artery) as well as in the peripheral circulation (e.g. coronary artery, saphenous vein) 
(De Vries et al., 1998; De Vries et al., 1999; MaassenVanDenBrink et al., 1998; 
Saxena & Tfelt-Hansen, 2000; Verheggen et al., 1998).  Interestingly, the latter 
observations were in agreement with those obtained from molecular and 
immunohistochemical studies (Bouchelet et al., 2000).  On the other hand, potent and 
selective 5-HT1D receptor agonists (e.g. PNU109291, L-775,606) are devoid of 
vasoconstrictor activity in human and bovine isolated blood vessels (Bouchelet et al., 
2000).  A vasodilator role of 5-HT1B receptors has also been suggested, mainly based 
on the presence of its mRNA in cultured endothelium cells of human coronary artery 
(Ullmer et al., 1995) and its role in endothelium-dependent relaxation in pig coronary 
arteries (Schoeffter & Hoyer, 1990).   
Serotonin 5-HT1D receptor  
The 5-HT1D receptor was first identified in bovine caudate, using the radioligand 
[3H]5-HT and different ligands at 5-HT1A, 5-HT1B and 5-HT1C (now called 5-HT2C) 
receptors (Herrick-Davis & Titeler, 1989; Heuring & Peroutka, 1987).  The first 
cDNA sequence of 5-HT1D receptor was identified in canine thyroid cDNA library 
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(Libert et al., 1989) and later this receptor was pharmacologically characterised by 
ligand binding in transfected Cos-7 cells and LM (tK- cells) (Maenhaut et al., 1991; 
Zgombick et al., 1991).  As described later, an important physiological feature of 
5-HT1D receptors is their regulatory role in the release of several transmitters (e.g. 
neuropeptides) and may be involved in the clinical efficacy of several antimigraine 
agents. 
Molecular aspect of 5-HT1D receptor 
The molecular cloning of dog 5-HT1D receptor (RDC4) showed an intronless gene 
consist of a single open reading frame (1131bp sequence) encoding a protein of 377 
amino acids (Libert et al., 1989; Zgombick et al., 1991).  The human 5-HT1D 
(formerly called 5-HT1Dα) receptor consisted also of 377 amino acids and was 
localised on the chromosome 1, region 1p34.3-36.3 (Jin et al., 1992; Weinshank et al., 
1992).  This receptor showed a typical G-protein couple structure with seven 
transmembrane domains along with putative N-glycosylation, protein kinase A and C 
phoshorylation sites.  At a later stage, the 5-HT1D receptor was also cloned from other 
mammalian homologues, such as rabbit (Harwood et al., 1995), guinea pig (Wurch et 
al., 1997; Zgombick et al., 1997), rat and mouse (Hamblin et al., 1992; Wurch et al., 
1997).  Even though the differences in amino acid sequence (three amino acids are 
missing near the N-terminal extracellular region), as observed in the rat and mouse 
5-HT1D receptor, overall this receptor displays a high homology across other species 
(Wurch et al., 1997). 
Binding profile of 5-HT1D receptor ligands 
Recombinant 5-HT1D receptor showed high affinity for the radioligands [3H]5-HT and 
[3H]LSD in mammalian Cos-7 or Chinese hamster ovary (CHO) cell lines 
(Weinshank et al., 1992).  Competitive binding assay revealed a binding affinity 
profile for 5-HT1D receptor, as follows: 5-hydroxytryptamine > serotonin > 
sumatriptan > 8-OH-DPAT > pindolol, which was similar to that described for 
5-HT1B receptors (Weinshank et al., 1992).  The pharmacological characterisation of 
5-HT1D receptors was largely hampered due to the unavailability of selective agonist 
and/or agonists at these receptors.  To overcome this problem, different compounds 
were used that can discriminate between these receptors, e.g. the 5-HT2 receptor 
antagonists ketanserin and ritanserin, which showed higher affinity at 5-HT1D as 
Chapter 1 Introduction 
26 
compared to 5-HT1B receptors (Hoyer et al., 1994).  Nevertheless, the latter property 
of ketanserin is not so apparent in dogs (Table 1.3) (Branchek et al., 1995).  
Additionally, dihydroergotamine (DHE) also shows high affinity for 5-HT1D receptor 
as compare to 5-HT1B receptor (Bard et al., 1996; Peroutka, 1994).   
 
Table 1.3.  Binding affinity constants (pKi values) of several compounds at recombinant 
5-HT1D receptor from different species 
 
Ligand Humana Guinea pigb Rabbitc Ratd Doge 
 
Agonists 
     
5-HT 8.33 8.02 7.88 8.60 8.30 
5-CT 8.91 8.55 8.53 9.43h 9.04 
L694247 8.98 - - - - 
Ergotamine 8.01 - - - - 
DHE 8.09 9.21 9.22 10.19h - 
CP122288 8.10 - - - - 
Zolmitriptan 9.01 9.18h - 9.10 - 
Sumatriptan 8.24 7.26 7.12 7.84 8.79 
8-OH-DPAT 6.92f 6.73 6.45 7.18 7.07 
 
Antagonists 
     
GR127935 8.20 8.24 - 8.88 - 
SB224289 6.63k - - - - 
BRL15572 7.55l - - - - 
Methiothepin 9.00 7.47 6.64 8.97 - 
Ketanserin 7.66 6.86 7.66 7.98 5.52j 
Ritanserin 7.82 6.81 - 7.96 - 
Metergoline 8.32g 7.82 7.76 8.86 - 
(-)-Propranolol  - - 7.71i <5.00 
(-)-Pindolol 5.39f 5.26 - - <5.00 
Data are means from radioligand displacement experiments using recombinant receptors 
expressed in different cell lines: a, (Pauwels et al., 1996); b, (Zgombick et al., 1997); 
c, (Bard et al., 1996); d, (Wurch et al., 1997); e, (Zgombick et al., 1991); f, (Weinshank et 
al., 1992); g, (Zgombick et al., 1996); h, (Hamblin et al., 1992); i, (Bach et al., 1993); 
j, (Branchek et al., 1995); k, (Hagan et al., 1997); l, (Price et al., 1997). 
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However, although methiothepin did not distinguish between the human 5-HT1B and 
5-HT1D receptor, it showed several fold less affinity for rabbit 5-HT1D as compare to 
5-HT1B receptor (Bard et al., 1996).  Such species difference of the same receptor 
makes it very important to carefully extrapolate the drug receptor interaction from 
animal to human. 
Recently, potent and selective antagonists at 5-HT1B (SB224289) and 5-HT1D 
(BRL15572) receptors have become available (Hagan et al., 1997; Price et al., 1997) 
and have been used in several studies to reveal their individual functional properties 
(see below); see Tables 1.2 and 1.3 for their affinity constants at 5-HT1B and 
5-HT1D receptors. 
Signal transduction mechanisms of 5-HT1D receptor 
In a similar manner as described for the 5-HT1B receptor, 5-HT1D receptors are part of 
the G-protein-coupled receptor superfamily and mediate its responses largely through 
actions of Gi proteins (Pauwels et al., 1996).  It has been shown that serotonin (5-HT) 
as well as the 5-HT1B/1D receptor agonist sumatriptan produced a pertussin 
toxin-sensitive attenuation of cAMP production in different transfected cell lines, e.g. 
Chinese hamster ovary or LM (tK-), rat C6-glial cells or dog y1 adrenal (y1 Kin-8) 
cells (Hamblin & Metcalf, 1991; Pauwels et al., 1996; Weinshank et al., 1992).  
Interestingly, other reports have mentioned that 5-HT produces an increase, rather 
than a decrease, in cAMP production in Cos-7 cells and Xenopus oocytes expressing 
the 5-HT1D receptor (Maenhaut et al., 1991).  The latter opposite effect of 5-HT may 
be explained by either a difference in receptor coupling or by the different cell line 
used.  Most of the studies using recombinant 5-HT1D receptor cell lines were based on 
inhibition of adenylate cyclase activity as a functional assay for the receptor.  
However, the GTPγS binding assay has also been used to deduce the intrinsic activity 
and functional properties of serotonergic drugs at recombinant human 5-HT1D 
receptor expressed in the stable transfected rat C6-glial cell lines (Pauwels et al., 
1997).  Besides inhibition of adenylyl cyclase, another well known effector that 
couples to the G-protein-coupled-receptor complex is activation of phospholipase C, 
as reported in LM(tk-) cells (Zgombick et al., 1993).  Activation of this particular 
enzyme, e.g. by 5-HT, results in an elevated production of inositol triphosphate and 
intracellular Ca2+ release (Hoyer et al., 1994).  It has been suggested that elevation of 
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the intracellular Ca2+, rather than inhibition of cAMP production, is responsible for 
the contraction of vascular smooth muscle cells in the presence of a 5-HT1D receptor 
agonist (Sumner et al., 1992). 
Tissue distribution of 5-HT1D receptor 
Compare to the 5-HT1B receptor, less expression of 5-HT1D receptor mRNA has been 
detected both in the central nervous system as well as in the periphery (Bruinvels et 
al., 1994; Longmore et al., 1997; Nilsson et al., 1999).  Earlier, weak mRNA signals 
of 5-HT1D receptor were detected in rat brain parts, e.g. primary olfactory cortex, 
accumbens nucleus, caudate putamen, dorsal raphe nucleus and medial vestibular 
nucleus (Bach et al., 1993; Bruinvels et al., 1994).  Similarly, these signals were also 
found in guinea pig brain, trigeminal ganglion and dorsal raphe (Bonaventure et al., 
1998; Bonaventure et al., 1998) and in human trigeminal ganglion (Bouchelet et al., 
1996).  In the periphery, immunohistochemical studies failed to show the presence of 
5-HT1D receptor protein in the human coronary artery, neither on its smooth muscles 
nor in the endothelium (Nilsson et al., 1999).  Additionally, the RT-PCR technique 
did not show 5-HT1D receptor signals in a variety of blood vessels in different species, 
including the dog (large coronary arteries, saphenous vein), rat (aorta, renal artery, 
vena cava, portal, femoral and jugular vein) and pig (pulmonary, coronary and 
cerebral artery and cerebral vein), in human endothelial or smooth muscle cell 
cultures (Sgard et al., 1996; Ullmer et al., 1995).  Some reports, however, indicate a 
minor presence of 5-HT1D receptor mRNA in a few samples of human coronary artery 
(Ishida et al., 1999).   
Physiological function of 5-HT1D receptor 
Sumatriptan as well as the second generation of triptans display high affinity for 
5-HT1D receptor, besides at 5-HT1B and 5-ht1F receptors.  Earlier, the functional 
properties of 5-HT1B/1D receptors were deduced by using the non-selective antagonist 
GR127935 that antagonises sumatriptan-induced contraction in dog isolated basilar 
artery and saphenous vein (Skingle et al., 1996) and sumatriptan-induced constriction 
within porcine and canine carotid circulation (De Vries et al., 1998; De Vries et al., 
1999).  However, due to the non-discriminating nature of GR127935 and the almost 
similar pharmacological profiles of these receptors, selective antagonists at either 
5-HT1B or 5-HT1D receptors turned out to be necessary to elucidate their physiological 
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roles.  With the use of selective 5-HT1B (SB224289, Hagan et al., 1997) and 5-HT1D 
receptor antagonists (BRL15572, Price et al., 1997), it has been demonstrated that the 
vascular responses of sumatriptan are primarily mediated by 5-HT1B receptors in 
different vascular beds, including human isolated arteries (Bouchelet et al., 2000; 
Morecroft et al., 1999; Verheggen et al., 1998) as well as porcine (De Vries et al., 
1999; Saxena & Tfelt-Hansen, 2000) and canine carotid circulations (Centurion et al., 
2001; Villalón et al., 2001).  In agreement with the latter, 5-HT1D receptor agonists 
(e.g. PNU109291 (Ennis et al., 1998) or L775606 (MacLeod et al., 1997)) are devoid 
of vasoconstrictor responses in both bovine and human isolated blood vessels 
(Bouchelet et al., 2000) as well as the canine carotid circulation (Centurion et al., 
2001).  Moreover, 5-HT1D receptor mRNA or protein localisation confirmed the 
presence of this receptor preferably in neural rather than vascular tissues (Bouchelet et 
al., 2000; Nilsson et al., 1999).  The neuronal effect of triptans possibly involves 
inhibition of trigeminovascular system (Moskowitz, 1992).  It has been shown that the 
triptans inhibit dural plasma protein extravasation following electrical stimulation of 
the trigeminal ganglion in guinea pig (Ennis et al., 1998).  Other studies using 
experimental animal models predictive for antimigraine activity showed that 
stimulation of trigeminal ganglion leads to elevated levels of several neuropeptides, 
including calcitonin gene related peptide (CGRP) (Goadsby & Edvinsson, 1994).  The 
latter finding was confirmed in humans, since it has been demonstrated in migraineurs 
that only CGRP levels are elevated during a migraine attack (Goadsby et al., 1990).  
Additionally, in the same study it was shown that treatment of these patients with 
sumatriptan or dihydroergotamine reduced CGRP concentration to physiological level 
(Goadsby et al., 1990).  Interestingly, the selective CGRP receptor antagonist, 
h-CGRP(8-37) markedly reduced trigeminal-evoked cerebral vasodilator response 
(Goadsby, 1993), showing the possible importance of CGRP receptor antagonists as a 
potential antimigraine agents.  The clinical results of the recently developed, stable 
CGRP receptor antagonist BIBN4096BS (Doods et al., 2000; Wu et al., 2000) are 
awaited with great interest.  Thus, it seems likely that the proposed acute antimigraine 
properties of 5-HT1D receptor agonists are due to inhibition of neuropeptides 
(Goadsby, 1999), rather than cranial vasoconstriction.  
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Serotonin 5-ht1F receptor 
The 5-ht1F receptor, the ‘last’ classified member of the 5-HT1 receptor subfamily, has 
been identified only less than a decade ago (Adham et al., 1993).  Several interesting 
papers have submerged on its pharmacological properties and, possible therapeutic 
applications (Cohen & Schenck, 1999; Phebus et al., 1997).  In this sense, the acute 
antimigraine agent sumatriptan displays appreciable affinity at these receptors (see 
above and Table 1.4), besides at other members of this subfamily, as discussed in 
previous sections.  Because it is still not completely clear which 5-HT1 receptor 
subtype (5-HT1B, 5-HT1D and/or 5-ht1F) mediates underlying mechanisms of its 
antimigraine efficacy, it may be possible that sumatriptan (and other antimigraine 
drugs) acts via 5-ht1F receptors.  With the current developments and understanding of 
this 5-HT1 receptor subtype, other therapeutic applications may be possible in the near 
future (Saxena & Tfelt-Hansen, 2000).  It may be important to mention that upper 
case letters are used for fully characterised (e.g. 5-HT1B and 5-HT1D) receptors, while 
others (e.g. 5-ht1F) that await complete characterisation have been designated by lower 
case letters.  Unfortunately, selective 5-ht1F receptor antagonists are still not available. 
Molecular aspects of 5-ht1F receptor 
As described by Amlaiky et. al. (1992), the 5-ht1F receptor was first identified in 
mouse brain cDNA library, using a 5-HT1B receptor probe under low stringency 
screening (Amlaiky et al., 1992).  It was reported that the 5-ht1F receptor showed a 
higher amino acid homology with the 5-HT1E (76%), than with 5-HT1B (63%) and 
5-HT1D (60%) receptors.  Subsequently, the 5-ht1F receptor was cloned and 
pharmacologically characterised from human, rat and guinea pig (Adham et al., 1997; 
Adham et al., 1993; Lovenberg et al., 1993).  The human 5-ht1F receptor gene 
encodes for a protein of 366 amino acids.  The receptor gene did not show any introns 
in its molecular structure same as observed in other 5-HT1 receptor subtypes (see 
above).  Similar to the 5-HT1B or 5-HT1D receptor, the presence of asparagine linked 
glycosylation sites and putative phosphorylation sites for protein kinase C were also 
observed in the 5-ht1F receptor. 
Binding profile of 5-ht1F receptor ligands 
As shown in Table 1.4, the endogenous neurotransmitter serotonin (5-HT) displays 
high affinity at human 5-ht1F receptors, while that of 5-carboxytryptamine was 
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expectedly lower (from IUPHAR guidelines, see Hoyer et al., 1994).  Competition 
binding studies in human 5-ht1F receptor revealed the following rank order of 
potencies for serotonergic ligands: 5-HT > sumatriptan >> 5-CT > 8-OH-DAPT > 
spiperone. (Adham et al., 1993). Interestingly, the rather high affinity of sumatriptan 
at these receptors was comparable to that observed at 5-HT1B and 5-HT1D receptor.  
The latter observation, together with the fact that 5-ht1F receptor mRNA is present in 
the trigeminal ganglion (where it may regulate plasma protein extravasation and 
neurogenic inflammation), strongly indicates the above-mentioned possibility for 
5-ht1F receptors as therapeutic target in acute migraine therapy. 
 
Table 1.4.  Binding affinity constants (pKi values) of several compounds at 
recombinant 5-ht1F receptor from different species 
 
Ligands Humana Guinea pigb Ratc Moused 
 
Agonists 
    
5-HT 8.00 7.40 7.17 6.90 
5-CT 6.14 5.63 5.61 5.50 
Sumatriptan 7.64 7.27 7.19 7.10 
LY334370 8.70e - - - 
Ergotamine 6.77 - 7.28 7.30 
DHE 6.56 6.96 - - 
8-OH-DPAT 5.75 - <6.00 5.80 
 
Antagonists 
    
Methysergide 7.47 7.64 8.20 7.87 
Methiothepin 6.19 6.43 - - 
Yohimbine 7.04 - 6.22 7.20 
Metergoline 6.47 6.62 6.27 - 
Data are means from radioligand displacement experiments using recombinant receptors 
expressed cell lines: a, (Adham et al., 1993); b, (Adham et al., 1997); c, (Lovenberg et 
al., 1993); d, (Amlaiky et al., 1992); e, Pauwels P.J. (personal communication). 
 
Recently, the development of the potent 5-ht1F receptor agonists LY344864 and 
LY334370 may help to elucidate the functional properties of 5-ht1F receptors as well 
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as to distinguish these from 5-HT1B and 5-HT1D receptor in the near future (Phebus et 
al., 1997). 
Signal transduction mechanisms of 5-ht1F receptor 
It has been shown that one of signal transduction mechanisms of 5-ht1F receptors 
involves a negative coupling to adenylyl cyclase, as observed in two different cell 
lines (NIH 3T3 and LM (tK-) fibroblasts) (Adham et al., 1993).  Moreover, in 
comparison to LM (tK-) cells, the NIH 3T3 cells expressing 5-ht1F receptor showed 
higher inhibition of adenylyl cyclase activity in presence of 5-HT; thus, revealing 
cell-type dependent coupling.  In the case of mouse or rat 5-ht1F receptor, similar 
(negative) coupling to adenylyl cyclase activity was observed in stable NIH-3T3 or 
HeLa cells lines expressing this recombinant receptor (Amlaiky et al., 1992; 
Lovenberg et al., 1993).  In addition, above-mentioned signal transduction 
mechanisms involve Gi-proteins, since their actions were found to be sensitive to 
pertussin toxin (Adham et al., 1993).  As also described for 5-HT1B and 5-HT1D 
receptors, an additional signalling pathway is stimulation of phospholipase C, as 
measured by an increase of inositol phosphates accumulation and increase in 
intracellular Ca2+ ions concentration (Adham et al., 1993). 
Tissue distribution of 5-ht1F receptor 
The tissue distribution of 5-ht1F receptor has been studied at mRNA level by Northern 
blotting, reverse transcriptase polymerase chain reaction (RT-PCR) and in situ 
hybridisation studies.  Using the RT-PCR technique, human, mouse and rat 5-ht1F 
receptor mRNA signals were detected in the brain (cortex, striatum, hippocampus, 
thalamus, pons, hypothalamus, cerebellum), uterus (endometrium and myometrium) 
and mesentery, but were absent in kidney, liver, lung, spleen, heart, pancreas or testes 
(Adham et al., 1993; Amlaiky et al., 1992; Lovenberg et al., 1993).  Northern blot 
analysis also confirmed these findings in mice by demonstrating that mRNA signals 
for 5-ht1F receptor were not detected in the brain, liver, kidney, lung, heart, spleen, 
and intestine tissue (Amlaiky et al., 1992; Lovenberg et al., 1993).  Bouchelet and 
colleagues have shown that mRNA signals for 5-ht1F receptor were detected in both 
neural as well as in vascular tissues, suggesting the possible physiological role of this 
receptor in central nervous system and in the periphery (Bouchelet et al., 1996).  On 
the contrary, microvascular cultures from human cerebral blood vessels did not show 
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any signals for 5-ht1F receptors (Cohen et al., 1999).  In contrast, in situ hybridisation 
studies have revealed the presence of 5-ht1F receptor mRNA signals in trigeminal and 
dorsal root ganglions, cerebral cortex and hippocampus in guinea pigs (Adham et al., 
1997; Adham et al., 1993).  Autoradiography studies using [3H]5-HT in human brain 
showed high signal of the receptor in globus pallidus = substantia nigra > cortex > 
putamen > hippocampus (Pascual et al., 1996).  Although 5-ht1F receptor has been 
localised both in the brain and peripheral tissues, limited amount of studies have 
demonstrated its role in peripheral tissues.  Nevertheless, it seems likely that 5-ht1F 
receptors are involved in the regulation of neurogenic plasma extravasation and 
neurogenic inflammation (Johnson et al., 1997). 
Physiological function of 5-ht1F receptor 
The antimigraine drug sumatriptan, launched as a potent and selective 5-HT1B/1D 
receptor agonist, also displays appreciable affinity 5-ht1F receptors (see Table 1.4).  
As mentioned before, this feature may indicate the possibility of 5-ht1F receptor 
agonist as an acute antimigraine drug for the treatment of migraine disease (Johnson 
et al., 1997; Leysen et al., 1996).  Furthermore, the presence of 5-ht1F receptor in the 
trigeminal ganglion of human and guinea pig predicts its presynaptic involvement in 
the regulation of neuropeptide release at the level of the cranial vasculature, thereby 
blocking the development of neurogenic inflammation (Adham et al., 1997; 
Bouchelet et al., 1996).  The pharmacological profile of human 5-ht1F receptor, using 
the [35S]GTPγS binding assay, showed a significant correlation with its inhibitory role 
on dural plasma extravasation produced by trigeminal nerve stimulation in guinea pigs 
(Wainscott et al., 1998).  This finding was supported by potent inhibitory effects of 
the 5-ht1F receptor agonist, LY344864, on dural plasma extravasation as well as its 
attenuation of c-fos expression in rat trigeminal nucleus caudalis (Mitsikostas et al., 
1999; Phebus et al., 1997).  Interestingly, while 5-ht1F receptor agonists (LY344864 
and LY334370) failed to induce vasoconstriction in rabbit saphenous vein (Cohen & 
Schenck, 1999) as well as in human and bovine cerebral arteries (Bouchelet et al., 
2000), the mRNA signals for these receptors were detected in these tissues.  Most 
triptans show high affinity for 5-ht1F receptors, some of them, such as rizatriptan 
(Wainscott et al., 1998) and alniditan (Leysen et al., 1996), display low affinity at 
these receptors, while still being effective in migraine treatment.  On this basis, it may 
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be questioned whether the role of 5-ht1F receptors is important for the acute treatment 
of migraine of the triptans.  Nevertheless, the studies mentioned above may suggest 
the possibility that selective 5-ht1F receptor agonists may represent a new class of 
effective acute antimigraine drugs, potentially, without cardiovascular side effects 
(Cohen & Schenck, 1999).    
Serotonin 5-HT7 receptor 
The 5-HT7 receptor is the most recently identified member of 5-HT receptor family 
and now fully characterised on the basis of structure, operational and expression 
studies (Vanhoenacker et al., 2000).  Earlier, the cDNA encoding for this receptor has 
been isolated from different species by either PCR amplification with degenerate 
primers or by screening the libraries with probes derived from sequence from other 
species (Bard et al., 1993; Lovenberg et al., 1993; To et al., 1995).  Previously, this 
receptor was known as a member of 5-HT1-like receptor family, but under the 
category of ‘orphan’ receptor (Hoyer et al., 1994; Saxena et al., 1998).  Interestingly, 
while 5-HT7 receptors show high affinity for 5-HT, these receptors are insensitive to 
sumatriptan.  It has been demonstrated that activation of 5-HT7 receptors produces 
smooth muscle relaxation, e.g. in the canine carotid circulation (Villalón et al., 1997; 
2001); however, also other physiological effects in mammalian brain and periphery 
have been proposed (Vanhoenacker et al., 2000). 
Molecular aspects of 5-HT7 receptor 
Initially, the 5-HT7 receptor was identified in the rat and mouse brain cDNA library 
by using degenerate oligonucleotide primers present in the conserve region of the 
5-HT receptor (Plassat et al., 1993; Ruat et al., 1993).  The full-length sequence of the 
rat and mouse cDNA encodes a protein of 448 amino acids, showing less than 50% 
homology with other 5-HT receptors.  Later, the guinea pig 5-HT7 receptor was also 
reported from the hippocampal library (Tsou et al., 1994).  The molecular structure of 
human 5-HT7 receptor cDNA contains an open reading frame of 1335 bp and encodes 
for a predicted protein of 445 amino acids (Bard et al., 1993).  The human and rat 
5-HT7 receptor gene consist of two introns interrupting the coding sequences; the first 
between transmembrane domain 3 and domain 4, while the second is located near the 
end of C terminal region.  Four isoforms of 5-HT7 receptor gene has been identified 
by alternate splicing near the C terminal intron in both recombinant human and rat 
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5-HT7 receptor (Heidmann et al., 1997; Heidmann et al., 1998).  The alternate 
receptor isoforms differ in their predicted C-terminal intracellular tails and may 
contribute to the diversity in physiological actions mediated by 5-HT7 receptors.  
Interestingly and similar to the above-mentioned 5-HT1 receptor subtypes, the 
molecular structure of 5-HT7 receptor shows seven transmembrane domains. The 
presence of two putative N-linked glycosylation sites as well as one putative 
recognition site for protein kinase C were observed in the amino terminal region and 
may be important for cAMP dependent protein kinase and calmodulin dependent 
protein kinase at the C terminal region (Bard et al., 1993; Lovenberg et al., 1993; 
Plassat et al., 1993; Ruat et al., 1993; Shen et al., 1993; Tsou et al., 1994).  The major 
gene structural differences between the 5-HT1 and 5-HT7 receptors are that the latter 
consist of two introns, while the former family of receptors is intronless.  
Binding profile of 5-HT7 receptor ligands 
For a long period of time, several compounds (see Table 1.5) were used to 
pharmacologically characterise 5-HT7 receptors, mainly based on their rank-order of 
potencies.  Recently, selective 5-HT7 receptor antagonists (e.g. SB 258719) have been 
developed, showing at least 100-fold more selectivity for 5-HT7 receptor as compared 
to other 5-HT receptor subtypes in recombinant human 5-HT7 receptor cell lines 
(Forbes et al., 1998; Thomas et al., 1998).  Suitable, but rather non-selective, 
radiolabelled agonists ([3H]5-HT and [3H]5-CT) and antagonists ([3H]risperidone or 
[125I]D-lysergic acid diethylamide [125I]LSD) were used in receptor binding assays 
(Adham et al., 1998; Jasper et al., 1997).  The pharmacological profile in affinity for 
various 5-HT receptor ligands showed the following rank of potency as 5-CT > 5-HT 
> methiothepin > metergoline > 8-hydroxy-2-(di-n-propylamino)tetralin 
(8-OH-DPAT) > sumatriptan > ketanserin. This unambiguous unique 
pharmacological profile for 5-HT7 receptors was observed to be similar across several 
species (Eglen et al., 1997).   
Signal transduction mechanisms of 5-HT7 receptor 
5-HT7 receptors are positively coupled to adenylate cyclase activity via Gs proteins 
(Adham et al., 1998), as observed for recombinant human (Bard et al., 1993), rat 
(Ruat et al., 1993) and guinea pig (Tsou et al., 1994) receptor.  For this reason, the 
major signal transduction mechanism for 5-HT7 receptors is the opposite of that  
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Table  1.5.  Affinities (pKi) of 5-HT receptor ligands for recombinant 5-HT7 receptor 
from different species 
 
Ligand Humana Guinea pigb Ratc Moused 
 
Agonists 
    
5-HT 8.09 9.00 8.74f 8.30 
5-CT 9.03 9.40 9.92 9.00 
5-MeOT 8.30 9.00 8.75f 8.20 
Sumatriptan 6.02 6.60 6.30 5.70 
8-OH-DPAT 6.33 7.30 7.28 6.60 
 
Antagonists 
    
Spiperone 6.96 7.00 7.70 7.20 
Ergotamine - - 7.76g 7.30 
Clozapine - - 7.87f 7.40 
Ketanserin 5.87 6.20e 5.12 6.40 
Metergoline 8.19 8.16e 8.69f 7.50 
Methiothepin 8.43 8.00 8.99f 8.20 
Mesulergine 7.74 7.81e 8.15f 7.60 
Methysergide 7.08 7.40 7.90f 7.90 
Ritanserin 7.35 7.34e - - 
Cyproheptadine 6.91 6.90e 7.11 - 
Data are the means from radioligand displacement experiments using recombinant 
receptors expressed in mammalian cell lines.  Data from: a, (Bard et al., 1993); b, (Tsou 
et al., 1994); c, (Ruat et al., 1993); d, (Plassat et al., 1993); e, (To et al., 1995); f, (Shen et 
al., 1993); g, (Lovenberg et al., 1993). 
 
observed for the 5-HT1 receptor family (Lovenberg et al., 1993; Plassat et al., 1993; 
Tsou et al., 1994).  Interestingly, it has been demonstrated that different splice 
variants of the human 5-HT7 receptor display different coupling to adenylyl cyclase 
(Krobert et al., 2001).  However, no inhibition of adenylate activity or coupling to 
phospholipase C has been reported for the 5-HT7 receptor.   
 
 
Chapter 1 Introduction 
37 
Tissue distribution of 5-HT7 receptor 
The tissue distribution of 5-HT7 receptors has been investigated using RT-PCR, 
Northern blot and in situ hybridisation studies in both central and peripheral tissues 
(Bard et al., 1993; Lovenberg et al., 1993; Ruat et al., 1993; Shen et al., 1993).  In 
guinea pig brain tissue, the receptor has predominantly been observed in the 
pyramidal and granular cell layers of the hippocampus, periventricular thalamus and 
superficial cortex (Tsou et al., 1994).  Moreover, Northern blot analysis of different 
brain tissues of rat and guinea pig showed two mRNAs of approximately 3.9 and 3.1 
kb size (in rat) and 3.8 and 3.1 kb (in guinea pig) (Ruat et al., 1993).  In the same 
study, in situ hybridisation analyses showed the expression of 5-HT7 receptor mRNA 
in discrete areas of brain areas (pyramidal hippocampus cells, tenia tecta, amygdaloid 
or mammillary nucelei), indicating that 5-HT7 receptor may be involved in the 
regulation of mood, learning, neuroendocrine, vegetative behaviours (Ruat et al., 
1993) and in circadian phase shifts (Meyerhof et al., 1993).  Bard et al. (1993) have 
shown that 5-HT7 receptor mRNA signals were also found in peripheral human 
isolated tissues, such as coronary artery and the gastrointestinal tract.  Interestingly, a 
major role of 5-HT7 receptor has been proposed in the regulation of vascular tone in a 
variety of blood vessels (Ullmer et al., 1995).  In this sense, a detailed study on tissue 
distribution of 5-HT7 receptor has been performed in rat (aorta, renal artery, vena 
cava, portal vein, femoral vein and jugular vein) and porcine (pulmonary, coronary, 
cerebral arteries and cerebral vein) blood vessels, which showed the expression of this 
receptor in all the blood vessel except in rat jugular vein (Ullmer et al., 1995).  On the 
other hand, using Northern blot analysis in peripheral tissues, 5-HT7 receptor signals 
were not detected in most (except spleen) rat tissues, including lung, liver, kidney, 
gut, skeleton muscle, ovary, testis, pituitary, prostate and retina (Shen et al., 1993). 
Physiological function of 5-HT7 receptor 
It has been shown that 5-HT7 receptors are present in both the brain and peripheral 
tissues.  In the central nervous system, the role of 5-HT7 receptor was reported in 
circadian rhythm and depression.  Earlier, it has been shown that the suprachiasmatic 
nuclei of the hypothalamus are the primary sites involved in the regulation of phase 
shift circadian rhythms produced by serotonin in mammals (Lovenberg et al., 1993).  
Both the presence of 5-HT7 receptor mRNA in the suprachiasmatic nuclei of the 
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hypothalamus as well as the changes in the photic responses to 5-HT7 receptor 
agonists in this structure of hamsters, provides the evidence for its role in this 
physiological response (Duncan et al., 1999; Lovenberg et al., 1993).  Furthermore, 
different studies have demonstrated that activation of 5-HT7 receptors produces direct 
smooth muscle relaxation, as observed for example in rabbit pulmonary artery 
(Morecroft & MacLean, 1998), dog basilar artery (Terrón & Falcón-Neri, 1999), 
monkey jugular artery (Leung et al., 1996), dog coronary artery (Terrón, 1996), 
canine carotid circulation (Villalón et al., 1999) and guinea pig ileum (Carter et al., 
1995).  The regulatory role of 5-HT7 receptors in these blood vessels and tissues may 
hopefully open novel therapeutic application of this new class of 5-HT receptors, e.g. 
in hypertension or bowel syndrome.  Also, since dilatation of cranial blood vessels has 
been proposed to play an important role in the pathogenesis of a migraine attack 
(De Vries et al., 1999; Saxena & Tfelt-Hansen, 2000), it may be possible that 
selective 5-HT7 receptor antagonists are efficacious in prophylactic migraine therapy. 
Porcine model to study antimigraine drugs 
The pathophysiology of migraine headache is still not clear.  However, on the basis of 
the neurovascular hypothesis several animal models are proposed for migraine.  
According to the vascular hypothesis, the alterations in the cranial extracerebral 
vascular beds may be the primary cause of the migraine.  Earlier, Wolff (1963) has 
proposed that the vasodilatation of extracranial arteries supplied by the external 
carotid artery is the primary cause of the migraine headache.  Heyck, (1969) 
performed preliminary experiments in migraine patients and suggested that arterial 
blood is being shunted to the venous blood flow due to dilatation of the cephalic 
arteriovenous anastomoses (AVA; see Figure 1.4) during migraine.  Under 
physiological conditions, carotid AVAs are under a sympathetic constrictor tone, 
shunting only <5% of arterial blood back to the right side of the heart; resulting in a 
difference in oxygen saturation at the arterial and venous side (AVSO2 difference).  
However, in migraine patients it was shown that this AVSO2 difference was lower 
(Heyck, 1969).   
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Figure 1.4.  Schematic representation of an 
arteriovenous anastomosis (AVA) shunt model 
In recent years, several animal models (for example pig, dog and cat) have been 
developed and used to study the 
clinical efficacy and possible 
mechanisms of action of current and 
novel antimigraine agents (De Vries 
et al., 1999).   
 In recent years we have 
shown that several acute 
antimigraine drugs, including the 
triptans and ergots, decrease total 
carotid blood flow in anaesthetised 
pigs, without producing major 
systemic haemodynamic changes 
(De Vries et al., 1999).  Using the microsphere method (Saxena, 1995), it was shown 
that this response was exclusively caused by constriction of carotid AVAs.  
Additionally, consistent with the closure of carotid AVAs, all these agents increased 
AVSO2 difference in these animals.   
In summary, the cranial extracerebral vasodilatation may be an integral part of the 
pathophysiology of migraine and acute antimigraine drugs (e.g. sumatriptan and 
second generation of triptans) primarily constrict the dilated blood vessels to abort 
migraine attacks. 
Aims of the thesis 
1. To clone porcine 5-HT1B, 5-HT1D, 5-ht1F and 5-HT7 receptors. 
2. To express the porcine 5-HT1B, 5-HT1D and 5-ht1F receptors in cell-lines for 
pharmacological characterisation. 
3. To identify the tissue-distribution of porcine 5-HT1B, 5-ht1F and 5-HT7 receptors. 
4. To characterise 5-HT1B and 5-HT1D receptor in human blood vessels, functional 
assays and in situ hybridisation were performed. 
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Chapter 2 
Molecular cloning, pharmacological properties and tissue 
distribution of the porcine 5-HT1B receptor 
Summary    Using a combination of RT-PCR and inverse-PCR 
techniques, we amplified, cloned and sequenced a full-length porcine 
5-HT1B receptor cDNA derived from porcine cerebral cortex.  Sequence 
analysis revealed 1170 bp encoding an open reading frame of 390 amino 
acids showing a 95% similarity with the human 5-HT1B receptor.  The 
recombinant porcine 5-HT1B cDNA was expressed in monkey Cos-7 cells 
and its pharmacological profile was determined by radioligand binding 
assay using [3H]GR125743.  The affinities of several agonists (L694247 
> ergotamine ≥ 5-carboxamidotryptamine = dihydroergotamine = 5-HT > 
CP122638 = zolmitriptan > sumatriptan) and putative antagonists 
(GR127935 > methiothepin > SB224289 >> ritanserin > ketanserin ≥ 
BRL15572) correlated highly with those described for the recombinant 
human 5-HT1B receptor.  In membranes obtained from cells 
co-expressing the porcine 5-HT1B receptor and a mutant GαoCys351Ile 
protein, 5-HT and zolmitriptan increased, while the 5-HT1B receptor 
antagonist SB224289 decreased basal [35S]GTPγS binding, thus showing 
inverse agonism.  The potency of zolmitriptan in the [35S]GTPγS binding 
assay (pEC50: 7.64±0.04) agreed with its affinity in displacing the 
antagonist [3H]GR125743 (pKi: 7.36±0.07).  The 5-HT1B receptor 
mRNA was observed by RT-PCR in several blood vessels, cerebral 
cortex, cerebellum and trigeminal ganglion.  In situ hybridisation 
performed in frontal cerebral cortex sections revealed the expression of 
5-HT1B receptor mRNA in pyramidal cells.  In conclusion, we have 
cloned and established the amino acid sequence, ligand binding profile 
and location of the porcine 5-HT1B receptor.  This information may be 
useful in exploring the role of 5-HT1B receptor in pathophysiological 
processes relevant for novel drug discovery in diseases such as migraine. 
 
 
 
 
 
 
 
 
Based on: Bhalla, P., Sharma, H.S., Ma, X., Wurch, T., Pauwels, P.J. & Saxena, P.R. (2001). 
Molecular cloning, pharmacological properties and tissue distribution of the porcine 5-HT1B 
receptor.  Br. J. Pharmacol., 133(6), 891-901 
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Introduction 
Over a decade and a half ago, Bradley et al. (1986) provided a general framework for 
the classification and nomenclature of 5-hydroxytryptamine (5-HT; serotonin) 
receptors recognising three main types: ‘5-HT1-like’, 5-HT2 and 5-HT3 receptors.  The 
term ‘5-HT1-like’ represented a heterogeneous group of receptors mediating a variety 
of responses, including the contraction of cranial blood vessels, prejunctional 
inhibition of neuronal transmitter release, smooth muscle relaxation and tachycardia 
in the cat.  The antimigraine drug sumatriptan was described as a selective and potent 
agonist at 5-HT1-like receptors (Humphrey et al., 1988; Humphrey et al., 1989).  
However, subsequent studies showed that sumatriptan had a poor affinity for 
receptors mediating smooth muscle relaxation and tachycardia in the cat (now called 
5-HT7 receptors, Villalón et al., 1997; Saxena et al., 1998; De Vries et al., 1999a), but 
possessed a high affinity for 5-HT1D recognition sites (Waeber et al., 1989; Hoyer et 
al., 1990).  Molecular biological studies revealed that 5-HT1D recognition sites 
consisted of two distinct receptors, 5-HT1Dα and 5-HT1Dβ (Weinshank et al., 1992) 
that, on alignment with the human genome, were renamed 5-HT1D and 5-HT1B 
receptors, respectively (Hartig et al., 1996).  Interestingly, the pharmacology of the 
human 5-HT1B and 5-HT1D receptors is much closer than that of the human and rat 
5-HT1B receptors; the difference in the pharmacological profile of the two 5-HT1B 
receptors is due to just one amino acid in the seventh transmembrane domain (T355N, 
Metcalf et al., 1992; Oksenberg et al., 1992; Hoyer et al., 1994).  In particular, some 
β-adrenoceptor antagonists are more potent, while sumatriptan is less potent at the 
rodent than at the human 5-HT1B receptor (Hoyer et al., 1994). 
Sumatriptan as well as other triptans inhibit dural plasma protein extravasation, 
suppress action potentials in trigeminal nucleus caudalis, constrict isolated cranial 
blood vessels and decrease carotid arteriovenous anastomotic blood flow in 
anaesthetised animals (Moskowitz, 1992; Goadsby & Knight, 1997; 
Saxena & Tfelt-Hansen, 2000).   Although the trigeminal neural effects of triptans, 
mediated mainly by the 5-HT1D receptor, may be involved to some extent in their 
antimigraine action (De Vries et al., 1999b; Hargreaves & Shepheard, 1999), the 
efficacy of triptans is primarily attributed to the 5-HT1B receptor-mediated cranial 
vasoconstriction (De Vries et al., 1999b; Saxena & Tfelt-Hansen, 2000).  Previous 
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investigations from our laboratory have established that constriction of carotid 
arteriovenous anastomoses in the anaesthetised pig can serve as a predictive model for 
the antimigraine efficacy of 5-HT-based drugs (Saxena, 1995; De Vries et al., 1999b).  
To gain further insight into the mechanisms involved in drug actions as well as the 
disease, it is important to study the trigeminal neural control of porcine arteriovenous 
anastomoses and its potential modification by 5-HT receptor ligands.  However, one 
of the difficulties in undertaking such studies is the limited knowledge of the 
molecular biology of porcine 5-HT receptors.  We recently cloned the porcine 5-HT1D 
receptor and found that its amino acid sequence and ligand binding profile were very 
similar to that of the human 5-HT1D receptor, but a striking exception was the low 
affinity of BRL15572 ([1-(3-chlorophenyl)-4-[3,3-diphenyl (2-(S,R) 
hydroxypropanyl)piperazine] hydrochloride) at the porcine (Bhalla et al., 2000) 
compared to human (Price et al., 1997; Schlicker et al., 1997) receptor. 
In the present investigation, we describe the molecular cloning and 
characterisation of the porcine 5-HT1B receptor (receptor code: 2.1.5HT.01B).  Using 
the total RNA isolated from the pig cerebral cortex, a full-length cDNA encoding 
5-HT1B receptor was PCR-amplified and the deduced amino acid sequence was 
compared with that in other species.  The ligand binding profile of the porcine 5-HT1B 
receptor was evaluated after transient transfection in Cos-7 cells and its distribution in 
the porcine tissues was explored using reverse transcription polymerase chain reaction 
(RT-PCR) and in situ hybridisation. 
Methods 
RNA isolation and RT-PCR 
As described in detail previously (Bhalla et al., 2000), total RNA was extracted from 
a pig (Yorkshire x Landrace, female, 12 kg) cerebral cortex (Chomczynski & Sacchi, 
1987; Sharma et al., 1996) and processed for the purification of poly(A+) mRNA 
using an Oligotex mRNA purification Kit (Qiagen GmbH, Hilden, Germany).  
Poly(A+) mRNA (0.5 µg) was denatured at 65 °C and the first strand of cDNA was 
synthesised in a reaction volume of 20 µl by adding sequentially the following 
reagents: reverse transcription buffer (25 mM Tris-HCl, pH 8.3; 50 mM KCl; 5.0 mM 
MgCl2, 2.0 mM DTT), 1.0 mM dNTPs, ribonuclease inhibitor (1 U µl-1), random 
hexamer (150 ng µg-1 mRNA) and, finally, AMV reverse transcriptase (14 U µg-1 of 
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mRNA; Pharmacia-LKB, Uppsala, Sweden).  A parallel control without AMV reverse 
transcriptase was prepared to check the genomic contamination.  The reactions were 
carried out for 90 min at 42 °C, extended for another 10 min at 75 °C and then cooled 
to 4 °C.  The cDNA thus synthesised was diluted to 50 µl and stored at -20°C until 
used as a PCR template.  The quality of cDNA was checked by PCR amplification of 
porcine β-actin using human specific oligonucleotide primers (Ponte et al., 1984). 
 
Figure 2.1.  Strategy for cloning full-length porcine 5-HT1B receptor and position of 
various primers used for PCR amplification.  A. Unknown full-length porcine 5-HT1B 
receptor cDNA with primers derived from porcine (1) and human (2) nucleotide 
sequences.  B. The amplified partial sequence of porcine 5-HT1B receptor cDNA was 
used to design inverse porcine-specific primers (3) and (4).  C. The inverse-PCR 
amplified partial genomic sequence enabled us to design full-length porcine specific 
primers (5) and (6).  D. The full-length amplified product of porcine 5-HT1B receptor 
cDNA.  Arrows and black rectangles denote the direction of the primers and amplified 
products, respectively. 
 
Porcine specific 5-HT1B receptor cDNA was amplified using a combination of 
RT-PCR and inverse-PCR techniques.  Initially, we attempted to obtain the full-length 
5-HT1B receptor cDNA employing 5’ and 3’ end oligonucleotide primers designed 
Primer 1 Primer 2ATG
TGA
5’ 3’
Primer 3 Primer 4
ATG
TGA
5’ 3’
ATG TGA
5’ 3’
TGA
ATG
Primer 5 Primer 6
5’ 3’
A. Unknown p5-HT1B receptor cDNA
B. Partial p5-HT1B receptor cDNA
C. Partial ligated genomic p5-HT1B receptor
D. Full-length p5-HT1B receptor cDNA
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from the consensus sequences of other species (Demchyshyn et al., 1992; 
Maroteaux et al., 1992; Weinshank et al., 1992; Harwood et al., 1995; Zgombick et 
al., 1997).  Unlike the cloning of porcine 5-HT1D receptor (Bhalla et al., 2000), we 
were unsuccessful in this case and, therefore, an alternative strategy, as depicted in 
Figure 2.1, was employed. New forward (5’-CCTGCCCTGGAAAGTAGTAC-3’; 
nucleotides 4-23; GenBank accession number Z47984) and reverse 
(5’-TCAACTTGTGCACTTAAAAC-3’; nucleotides 1772-1791; GenBank accession 
number M75128) oligonucleotide primers (Figure 2.1A, 1 and 2) were designed from 
the porcine (partial) and human 5-HT1B receptor sequence, respectively.  For PCR 
amplification, a 20 µl reaction mixture containing the following components was 
prepared: 250 µM of each dNTP, 1.5 mM MgCl2, PCR buffer (1xPCR buffer: 10 mM 
Tris-HCl, pH 8.3, 50 mM KCl), Ampli Taq GoldTM enzyme (0.5 U), 0.5 µM each of 
the forward and reverse primer and 5 µl of cDNA template.  After brief 
centrifugation, the enzyme was first activated for 10 min at 94 °C in a PCR 
thermocycler (model PTC-100TM, M.J. Research Inc, Watertown, USA).  The timing 
of PCR was 1 min at 94 °C, 30 s at 55 °C and 90 s at 72 °C with total of 36 cycles.  
Finally, the reaction was extended for additional 10 min at 72 °C.  The PCR amplified 
product of expected size was purified using a PCR purification kit (Promega Benelux 
b.v., Leiden, The Netherlands) and ligated into a pCR™ II vector using TA cloning kit 
(Invitrogen BV., Groningen, The Netherlands).  The ligated vector was transformed 
into competent TOP10 cells and grown overnight on LB agar plates containing 
kanamycin (50 µg ml-1) with IPTG and X-gal at 37 °C.  White over blue colonies 
were selected to identify positive clones containing the DNA insert of expected size.  
Three insert positive clones (namely, pHTB-2, pHTB-4, pHTB-19) were further 
processed for the plasmid DNA isolation (mini-prep, Promega Benelux b.v., Leiden, 
The Netherlands) and sequenced by the dideoxy nucleotide chain termination method 
using an automated fluorescence based DNA sequencer (ABI PrismTM 310 Genetic 
analyser, Perkin Elmer Applied Biosystem Benelux, Nieuwerkerk a/d IJssel, The 
Netherlands).  The nucleotide sequences were compared and a consensus sequence 
was derived (DNAMAN sequence analysis program, Version 3.2, Lynnon Biosoft© 
1994-1997).  The final partial cDNA sequence (Figure 2.1B) was compared with 
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those in the GenBank (BLAST search at National Centre for Biotechnology 
Information, Bethesda, MD, USA). 
Analysis of 5’ and 3’ ends of porcine 5-HT1B receptor by Inverse-PCR  
Inverse-PCR was performed to establish the porcine specific sequence of 5’ and 3’ 
ends (Ochman et al., 1988).  Porcine genomic DNA was digested with Bgl II 
restriction enzyme, because the cloned human 5-HT1B receptor cDNA did not show 
any restriction site for this enzyme.  After purification, the restricted DNA was ligated 
overnight at 16 °C in the presence of T4-DNA ligase in order to obtain DNA circles.  
The ligated DNA circles were subjected to inverse-PCR using primers specific for 
porcine 5-HT1B receptor (5’-GAGGCGATCAGGTAGTTGGC-3’ for 5’ end and 
5’-GATGCCTGCTGGTTCCACC-3’ for 3’ end; Figure 2.1B, 3 and 4).  The 
amplified products were separated on a 1% agarose gel, purified, cloned and 
sequenced, as described above. 
Amplification and cloning of full-length porcine 5-HT1B receptor 
For the amplification of full-length porcine 5-HT1B receptor cDNA, forward and 
reverse oligonucleotide primers (5’-ATGGAGGAAGCGGGCGCTCAG-3’ and 
5’-TCAGCTTGTGCACTTAAAGCG-3’) were designed from the sequences 
generated from inverse-PCR (Figure 2.1C, 5 and 6).   After PCR amplification (see 
above), a product of expected size was purified, ligated into the pGEMT-Easy vector 
(Promega Benelux b.v., Leiden, The Netherlands), transformed into competent 
JM 109 cells and plasmid DNA was isolated.  Four insert positive clones (pHTB-11, 
pHTB-12, pHTB-14, pHTB-17) were further processed for the plasmid DNA 
purification and sequencing. The full-length cDNA sequence of porcine 5-HT1B 
receptor was derived from two independent PCR amplified products and further 
verified by multiple partial sequences derived from cDNA (RT-PCR) as well as 
genomic DNA (inverse-PCR) amplified products.  In sporadic cases showing 
nucleotide discrepancy in the sequence, the nucleotide having a clear majority in 
clones was preferred for establishing the final full-length cDNA sequence, using the 
DNAMAN sequence analysis program (Version 3.2, Lynnon Biosoft© 1994-1997).  
The final sequence (Figure 2.1D) was translated as a peptide sequence and compared 
with those in the GenBank (BLAST search at National Centre for Biotechnology 
Information, Bethesda, MD, USA).  The hydrophobic regions (indicating putative 
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transmembrane domains) and sequence homology with known 5-HT1B receptors from 
other species were established. 
Transient transfection and radioligand binding assay 
The purified full-length 5-HT1B receptor cDNA insert was subcloned into 
dephosphorylated eukaryotic expression vector, pcDNA3 and transformed into 
TOP10 competent cells.  The plasmid DNA was purified according to maxi prep 
protocol using a commercially available kit (Qiagen SA, Courtaboeuf, France).  
Monkey Cos-7 cells were transiently transfected with the plasmid using a gene pulser 
transfection apparatus (Bio-Rad S.A., Ivry Sur Seine, France), as described earlier by 
Pauwels et al. (1996).  After transfection, the cells were incubated for 48 h in 
Dulbecco modified Eagle’s medium (DMEM) containing 10% heat-inactivated foetal 
calf serum and antibiotics at 37 °C in a humidified chamber containing 5% CO2. 
The transfected cells were washed twice with phosphate buffer saline 
(2.7 mM KCl, 1.5 mM KH2PO4, 140 mM NaCl, 8 mM Na2HPO4; pH 7.2) and kept at 
-80 °C for 10 min.  The cells were scrapped from the petri-dish in ice-cold Tris-buffer 
(pH: 7.7) and homogenised.  The homogenate was centrifuged at 1,000 rpm for 5 min 
at 4 °C and the supernatant was collected and centrifuged again at 13,000 rpm for 
20 min.  The membrane pellet was resuspended into 50 mM Tris-HCl buffer (pH: 7.7) 
containing 4 mM CaCl2, 10 µM pargyline and 0.1 % ascorbic acid, as described 
before (Pauwels & Colpaert, 1996).  The membrane protein concentration was 
measured by dye binding assay (Bradford, 1976) using the Bio-Rad Kit and bovine 
serum albumin was used as a standard.  
Binding assays to membranes obtained from transfected Cos-7 cells were 
performed using 1.0 nM [3H]GR125743 ([3H]N-[4-methoxy-3-(4-methylpiperazin-
1-yl)phenyl]-3-methyl-4-(4-pyridyl) benzamide) as radioligand.  Incubation mixtures 
consisted of 0.4 ml of cell membrane preparation (30-50 µg of protein), 0.05 ml of the 
radioligand and 0.05 ml of compounds for inhibition or 10 µM 5-HT to determine 
non-specific binding.  The reaction was terminated by filtration with ice-cold 
Tris-buffer and radioactivity on the filter paper was measured by using a liquid 
scintillation counter (Pauwels et al., 1996; Wurch et al., 1997).  The filtration was 
performed over 0.2% polyethyleneimine-treated Whatman (Clifton, NJ, USA) GF/B 
glass fibre filters.  Data were analysed graphically with inhibition curves, and IC50 
Chapter 2 Recombinant porcine 5-HT1B receptor 
56 
values were derived.  Ki values were calculated according to the equation Ki = 
IC50/(1+C/KD), where C is the concentration and KD is the equilibrium dissociation 
constant of the radioligand.  Ligand saturation binding curves were analysed by the 
nonlinear least square curve-fitting programme to determine Kd and Bmax values 
(Munson & Rodbard, 1980).  Control binding experiments were run with 
nontransfected cells and they did not display specific [3H]GR125743 binding. 
[35S]GTPγS binding response 
CHO-K1 cells transiently co-expressing the cloned porcine 5-HT1B receptor and a 
mutant GαoCys351Ile protein (Dupuis et al., 1999) were collected in 
phosphate-buffered-saline (pH 7.4) and centrifuged for 20 min at 48,000 g and the 
pellet containing the membrane fraction was stored at -80 °C.  [35S]GTPγS binding 
was measured using the method previously described by Pauwels et al. (1997).  
Briefly, the pellet was thawed and diluted in 20 mM HEPES buffer (pH 7.4) 
containing 30 µM GDP, 100 mM NaCl, 3 mM MgCl2 and 0.2 mM ascorbic acid.  
Incubation mixtures were prepared in glass tubes and consisted of 0.4 ml of 
membrane preparation (containing 5 µg protein) with 5-HT (10 µM), SB224289 
(2,3,6,7-tetrahydro-1’-methyl-5-[2’-methyl-4’(5-methyl-1,2,4-oxadiazol-3 
-yl) biphenyl 4-carbonyl] furo [2,3-f] indole-3-spiro-4`-piperidine hydrochloride; 
1 µM) or zolmitriptan (0.1 nM -10 µM) in a volume of 0.05 ml.  After an incubation 
period of 30 min at 25 °C, 0.05 ml [35S]GTPγS (0.5 nM) was added for an additional 
period of 30 min.  The reaction was stopped by adding 3 ml of ice-cold 20 mM 
HEPES (pH 7.4) containing 3 mM MgCl2 and rapid filtration over Whatmann GF/B 
glass fibre filters with a Brandel harvester.  The filters were rinsed three additional 
times with 3 ml HEPES buffer, placed in scintillation vials and the radioactivity was 
extracted in 4 ml of Emulsifier-Safe.  Maximal stimulation of [35S]GTPγS binding 
was defined in the presence of 10 µM 5-HT.  Emax values were expressed as a 
percentage of the maximal response obtained with 10 µM 5-HT.  EC50 values were 
defined as the concentration of compound at which 50% of its own maximal 
stimulation was obtained. 
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Detection of 5-HT1B receptor mRNA by RT-PCR 
RT-PCR was used to detect 5-HT1B receptor mRNA in the following tissues obtained 
from pigs (Yorkshire x Landrace, female, 12-15 kg): brain cortex, cerebellum, 
trigeminal ganglion, left cardiac ventricle, left anterior descending coronary, 
pulmonary, common carotid, superior mesenteric and femoral arteries and saphenous 
vein.  The tissue samples were dissected and cleaned and the total RNA was isolated 
as described above.  The residual DNA contamination was removed by treatment with 
RNase-free DNase (10 U 6 µg-1 RNA) for 25 min at 37 °C as per instruction 
(Promega Benelux b.v., Leiden, The Netherlands).  The purified total RNA samples 
were reverse transcribed into cDNA in presence of reverse transcriptase enzyme. A 
control reaction was always prepared in absence of reverse transcriptase to monitor 
the DNA contamination.  For the PCR amplification of porcine 5-HT1B receptor, 
porcine specific sense (5’-CCTGCCCTGGAAAGTAGTAC-3’; nucleotides 135-154) 
and antisense (5’-TGATGGGCATCACCAGGATG-3’; nucleotides 297-316) primers 
were used along with other components of PCR exactly as described earlier, except 
that the annealing temperature was kept at 60 °C instead of 55 °C.  The PCR 
amplified products  (12 µl each) were separated on 3% agarose gel by electrophoretic 
separation and photographed. 
Localisation of 5-HT1B receptor mRNA by in situ hybridisation 
A piece of frontal cerebral cortex, obtained from a pig (Yorkshire x Landrace, female, 
14 kg), was fixed using phosphate buffer saline containing 4% paraformaldehyde.  
After dehydration and embedding in paraffin, 5 µm thick sections were cut 
(Microtome, Microm Type HM325, Walldorf, Germany) and layered on 
superfrost plus® glass slides (Menzel-Glaser, Braunschweig, Germany).  For in situ 
hybridisation, a digoxigenin-labelled cRNA probe was prepared from recombinant 
porcine 5-HT1B receptor cDNA containing 470 bp (nucleotides 135-695).  The cloned 
plasmid DNA was linearised with either Bam HΙ or Xba Ι, purified and transcribed to 
synthesise sense and antisense cRNA probes, using T7 or SP6 RNA polymerase. The 
cRNA probes were quantified by dot blotting as per protocol described for DIG RNA 
labelling kit (Roche Diagnostics Nederland B.V., Almere, The Netherlands).  In situ 
hybridisation was performed following the method described by de Boer et al. (1998).  
The purple coloured hybrids representing the 5-HT1B receptor mRNA in the tissue 
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sections was visualised under a light microscope (Leica DM RBE, GmbH, Wetzlar, 
Germany).  
Drugs and other chemicals 
All chemicals used in this study were of molecular biology and/or culture grade.  The 
oligonucleotide primers were commercially procured from Life Technologies b.v. 
(Breda, The Netherlands) and the sources of the kits used have been identified in the 
text. 
The compounds used in pharmacological assays were: 5-HT creatinine sulphate 
(Sigma Chemicals, St. Louis, MO, USA), BRL15572 (gift: Dr. A.A. Parsons, 
SmithKline Beecham Pharmaceuticals, Harlow, Essex, UK), 
5-carboxamidotryptamine, CP122638 (N-methyl-3-[pyrrolidin-2(R)-ylmethyl]-
1H-indol-5-ylmethyl sulphonamide), [3H]GR125743 (83.0 Ci mmol-1; Amersham, 
Les Ulis, France), GR127935 ((N-[4-methoxy-3-(4-methyl-1-piperazinyl) 
phenyl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl) [1,1-biphenyl]-4-carboxamide 
hydrochloride, [35S]GTPγS (1000 Ci mmol-1; Amersham, Les Ulis, France), 
ketanserin (Sigma Chemicals, St. Louis, MO, USA), L694247 
(2-[5-[3-(4-methylsulphonylamino) benzyl-1,2,4-oxadiazol-5-yl]-1H-indole-3-yl] 
ethylamine; Tocris Cookson, Bristol, UK), methiothepin, ritanserin, sumatriptan, 
SB224289 and zolmitriptan.  Except those specified above, all other compounds were 
synthesised at Centre de Recherche Pierre Fabre (Castres, France). 
Results 
Cloning of 5-HT1B receptor cDNA derived from porcine cerebral cortex  
As described in the Methods section (Figure 2.1), using RT-PCR technique, we 
amplified a partial fragment (1038 bp) from porcine brain cortex cDNA.  Upon 
sequencing, this fragment revealed a high homology with the human 5-HT1B receptor 
(data not shown).  On the basis of this porcine specific partial sequence of 5-HT1B 
receptor, inverse primers were designed and used on porcine ligated genomic DNA to 
establish the sequence of 5’ and 3’ ends of the porcine 5-HT1B receptor (Figure 2.2). 
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Inverse-PCR (5’end)
Inverse-PCR (3’end)
      5’end
1     ATGGAGGAACCGGGTGCTCAGTGCGCTCCACCGCCGCCCGCGGGCTCCGAGACCTGGGTT
      ||||||||| |||| ||||||||||| || |||| ||||||| ||||| ||||| || ||
142   ATGGAGGAAGCGGGCGCTCAGTGCGCCCCGCCGCTGCCCGCGAGCTCCCAGACCCGGCTT
61    CCTCAAGCCAACTTATCCTCTGCTCCCTCCCAAAACTGCAGCGCCAAGGACTACATTTAC
       ||||||||||| | ||| | |||||||||||||||||||||||| ||| ||||||||||
202   TCTCAAGCCAACCTCTCCGCGGCTCCCTCCCAAAACTGCAGCGCCGAGGGCTACATTTAC
121   CAGGACTCCATCTCCCTACCCTGGAAAGTACTGCTGGTTATGCTATTGGCGCTCATCACC
      |||||||||||| |||| |||||||||||| | ||||| || ||  |||| ||| |||||
262   CAGGACTCCATCGCCCTGCCCTGGAAAGTAGTACTGGTCATTCTGCTGGCTCTCTTCACC
181   TTGGCCACCACGCTCTCCAATGCCTTTGTGATTGCCACAGTGTACCGGACCCGGAAACTG
      ||||||||||||||||||||||| |||||||| ||||| ||||||||||| ||||| ||
322   TTGGCCACCACGCTCTCCAATGCGTTTGTGATCGCCACTGTGTACCGGACGCGGAAGCTC
241   CACACCCCGGCTAACTACCTGATCGCCTC
      || ||||| || |||||||||||| ||||  3’end
382 CATACCCCCGCCAACTACCTGATCTCCTC
    5’End
1024  GATGCCTGCTGGTTCCACCTAGCCATCTTTGACTTCTTCACATGGCTGGGCTATCTCAAC
      |||||||||||||||||||| |||||||||||||||||||| ||||| || |||||||||
1     GATGCCTGCTGGTTCCACCTGGCCATCTTTGACTTCTTCACGTGGCTAGGTTATCTCAAC
1084  TCCCTCATCAACCCCATAATCTATACCATGTCCAATGAGGACTTTAAACAAGCATTCCAT
      ||||||||||||||||| ||||||||||||| |||||||||||| |||||||| ||||||
61    TCCCTCATCAACCCCATCATCTATACCATGTTCAATGAGGACTTCAAACAAGCGTTCCAT
1144  AAACTGATACGTTTTAAGTGCACAAGTTGA
      ||||||||||| |||||||||||||| |||  3’end
121   AAACTGATACGCTTTAAGTGCACAAGCTGA
 
Figure 2.2.  Sequence of inverse-PCR amplified product from porcine genomic DNA 
circles (in bold letters) showing high homology with the sequence of human 5-HT1B 
receptor (in normal letters).  The deduced 5’ (N) and 3’ (C) terminal sequences of 
porcine 5-HT1B receptor are shown double underlined in boxes, while the inverse-PCR 
primers are thick underlined. 
 
To amplify the full-length porcine 5-HT1B receptor, the cDNA template derived 
from poly(A+) mRNA of porcine brain cortex was used with porcine specific 5’ and 
3’ end primers.  Agarose gel electrophoresis of RT-PCR products (Figure 2.3) shows 
amplification of the porcine β-actin cDNA (625 bp), which ensures that the quality of 
cDNA samples was adequate for amplification of other products.  The presence of 
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genomic DNA contamination was excluded by performing a parallel reaction in the 
absence of reverse transcriptase.  The expected band (~1200 bp) of porcine cDNA, 
observed in presence of porcine specific primers, was cloned (Figure 2.3). 
 
1353 bp →
603 bp →
310 bp →
RT-PCR product Plasmid DNA
M 1 2 3 M 4 5
M: Marker
1: β-actin control
2: Negative control
3: 1200 bp product
4: Uncut plasmid
5: Plasmid + insert
 
Figure 2.3.  Agarose gel electrophoresis of RT-PCR products of cDNA synthesised 
from porcine cerebral cortex (left panel) and recombinant plasmid with insert cDNA 
(right panel).  The different lanes marked on top denote: φx174 DNA/Hae III marker 
(M), positive control showing RT-PCR product of 625 bp using β-actin primers (1), 
negative control, i.e. a sample without reverse transcriptase to monitor genomic and/or 
PCR contamination (2), RT-PCR product of approximately 1200 bp obtained using 
forward and reverse primers of porcine specific 5-HT1B receptor (3), recombinant 
uncut plasmid DNA vector (4) and plasmid DNA vector restricted with EcoR1 
enzyme and showing a DNA insert of approximately 1200 bp (5).  The size of 3 
marker bands is indicated in the left margin. 
 
Sequence analysis of cloned porcine cDNA 
Sequencing of the recombinant plasmid revealed 1170 bp, starting with ATG codon 
and ending with TGA codon.  DNAMAN analysis showed that this full-length porcine 
cDNA encoded a 390 amino acid protein exhibiting features of a typical G-protein 
coupled receptor with predicted seven transmembrane domains and putative 
N-glycosylation and phosphorylation sites (Figure 2.4).  A BLAST search at GenBank 
of the 1170 bp nucleotide sequence revealed resemblance with the sequence of 
5-HT1B receptors from other species. 
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TM 1
TM 2
TM 3
TM 5
TM 4
TM 6
TM 7
+ +
z
z 

1    ATG GAG GAA GCG GGC GCT CAG TGC GCC CCG CCG CTG CCC GCG AGC TCC CAG ACC CGG CTT
1    MET Glu Glu Ala Gly Ala Gln Cys Ala Pro Pro Leu Pro Ala Ser Ser Gln Thr Arg Leu
                               
61   TCT CAA GCC AAC CTC TCC GCG GCT CCC TCC CAA AAC TGC AGC GCC GAG GGC TAC ATT TAC
21   Ser Gln Ala Asn Leu Ser Ala Ala Pro Ser Gln Asn Cys Ser Ala Glu Gly Tyr Ile Tyr
121  CAG GAC TCC ATC GCC CTG CCC TGG AAA GTA GTA CTG GTC ATT CTG CTG GCT CTC TTC ACC
41   Gln Asp Ser Ile Ala Leu Pro Trp Lys Val Val Leu Val Ile Leu Leu Ala Leu Phe Thr
181  TTG GCC ACC ACG CTC TCC AAT GCG TTT GTG ATC GCC ACT GTG TAC CGG ACG CGG AAG CTC
61   Leu Ala Thr Thr Leu Ser Asn Ala Phe Val Ile Ala Thr Val Tyr Arg Thr Arg Lys Leu
241  CAT ACC CCC GCC AAC TAC CTG ATC GCC TCC TTG GCG GTC ACC GAC CTG CTG GTA TCC ATC
81   His Thr Pro Ala Asn Tyr Leu Ile Ala Ser Leu Ala Val Thr Asp Leu Leu Val Ser Ile
301  CTG GTG ATG CCC ATC AGC ACC ATG TAC ACG GTC ACC GGC CGC TGG ACG CTA GGC CAG GTG
101  Leu Val Met Pro Ile Ser Thr Met Tyr Thr Val Thr Gly Arg Trp Thr Leu Gly Gln Val
361  GTC TGC GAC TTC TGG CTG TCG TCG GAC ATC ACC TGT TGC ACT GCT TCC ATC TTG CAC CTC
121  Val Cys Asp Phe Trp Leu Ser Ser Asp Ile Thr Cys Cys Thr Ala Ser Ile Leu His Leu
421  TGT GTC ATC GCT TTG GAC CGC TAC TGG GCC ATC ACG GAC GCC GTG GAG TAC TCG GCT AAA
141  Cys Val Ile Ala Leu Asp Arg Tyr Trp Ala Ile Thr Asp Ala Val Glu Tyr Ser Ala Lys
481  AGG ACT CCC AAG AGG GCG GCC GTC ATG ATC GCG CTG GTG TGG GTC TTC TCC ATT TCC ATC
161  Arg Thr Pro Lys Arg Ala Ala Val Met Ile Ala Leu Val Trp Val Phe Ser Ile Ser Ile
541  TCG CTG CCG CCC TTC TTC TGG CGT CAG GCC AAA GCC GAG GAG GAG GTG TCG GAC TGC GTG
181  Ser Leu Pro Pro Phe Phe Trp Arg Gln Ala Lys Ala Glu Glu Glu Val Ser Asp Cys Val
601  GTG AAC ACG GAC CAC ATC CTC TAC ACT GTC TAC TCC ACG GTG GGC GCT TTC TAC TTC CCC
201  Val Asn Thr Asp His Ile Leu Tyr Thr Val Tyr Ser Thr Val Gly Ala Phe Tyr Phe Pro
661  ACC CTG CTC CTC ATC GCC CTC TAT GGC CGC ATC TAT GTG GAA GCC CGC TCC CGG ATT TTG
221  Thr Leu Leu Leu Ile Ala Leu Tyr Gly Arg Ile Tyr Val Glu Ala Arg Ser Arg Ile Leu
                      
721  AAA CAG ACA CCT AAC AGA ACT GGC AAG CGC CTG ACC CGA GCC CAA CTG ATA ACT GAC TCC
241  Lys Gln Thr Pro Asn Arg Thr Gly Lys Arg Leu Thr Arg Ala Gln Leu Ile Thr Asp Ser
781  CCC GGG TCC ACA TCT TCG GTC ACC TCC ATT AAC TCA CGA GCT CCA GAC TTA CCC AGC GAG
261  Pro Gly Ser Thr Ser Ser Val Thr Ser Ile Asn Ser Arg Ala Pro Asp Leu Pro Ser Glu
841  TCA GGA TCT CCT GTG TAC GTG AAT CAA GTC AAA GTG CGA GTC TCA GAC GCC CTG CTG GAG
281  Ser Gly Ser Pro Val Tyr Val Asn Gln Val Lys Val Arg Val Ser Asp Ala Leu Leu Glu
901  AAG AAG AAA CTC ATG GCC GCT AGG GAG CGC AAA GCG ACA AAG ACC CTG GGG ATC ATT TTG
301  Lys Lys Lys Leu Met Ala Ala Arg Glu Arg Lys Ala Thr Lys Thr Leu Gly Ile Ile Leu
961  GGA GCA TTT ATT GTG TGT TGG CTG CCC TTC TTC ATC ATT TCT CTG GCC ATG CCT ATC TGC
321  Gly Ala Phe Ile Val Cys Trp Leu Pro Phe Phe Ile Ile Ser Leu Ala Met Pro Ile Cys
1021 AAG GAT GCC TGC TGG TTC CAC CTG GCC ATC TTT GAC TTC TTC.ACG TGG CTA GGT TAT CTC
341  Lys Asp Ala Cys Trp Phe His Leu Ala Ile Phe Asp Phe Phe Thr Trp Leu Gly Tyr Leu
1081 AAC TCC CTC ATC AAC CCC ATC ATC TAT ACC ATG TTC AAT GAG GAC TTC AAA CAA GCG TTC
361  Asn Ser Leu Ile Asn Pro Ile Ile Tyr Thr Met Phe Asn Glu Asp Phe Lys Gln Ala Phe
1141 CAT AAA CTG ATA CGC TTT AAG TGC ACA AGC TGA
381  His Lys Leu Ile Arg Phe Lys Cys Thr Ser ***
z PKA-phosphorylation;+ N-glycosylation;  PKC-phosphorylation
 
Figure 2.4.  Nucleotide and deduced amino acid (in bold) sequences of the 
recombinant cDNA derived from porcine cerebral cortex.  Numbering of nucleotide 
and amino acids is shown on the left.  Computer analysis (software DNAMAN, 
version 3.2, Lynnon Biosoft©) predicted a typical G-protein coupled receptor with 
transmembrane (TM) 1-7 domains (underlined) as well as the putative N-glycosylation 
and protein kinase A (PKA) and protein kinase C (PKC) phosphorylation sites. 
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Figure 2.5.  Comparison of amino acid sequences of the pig 5-HT1B receptor 
(Genbank accession number: AF188626) with the human (Swissprot accession 
number P28222), rabbit (P49144), mouse (P28334), rat (P28564) and guinea pig 
(O08892) 5-HT1B receptor.  The areas shaded black show identity across the different 
species. 
 
Figure 2.5 compares the amino acid sequence of the porcine 5-HT1B receptor 
with those of other mammalian species (human, rabbit, mouse, rat and guinea pig).  
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Across the species, there was an 88-95% similarity in the overall sequence and the 
transmembrane domains 2-5 in porcine and human receptors were identical.  
However, it may be noted that some amino acids were unique to the porcine 5-HT1B 
receptor: Ala4, Ser15,21 and Arg19 towards the N-terminal end, Val51 and Ile54 in the 
first transmembrane domain, Leu277 in the third intracellular loop, Ala336 in the sixth 
transmembrane domain as well as Phe372 in the seventh transmembrane domain. 
Pharmacological characterisation of recombinant porcine 5-HT1B receptor 
Membrane preparations from COS-7 cells transfected with porcine 5-HT1B receptor 
showed a high affinity for [3H]GR125743.  The equilibrium dissociation constant (Kd) 
and total number of binding sites (Bmax) for [3H]GR125743 were found to be 
0.66±0.05 nM and 2.70±0.36 pmol mg-1 protein (n=3 each), respectively. 
The affinity constants (pKi values) of 14 serotonergic compounds (8 agonists 
and 6 putative antagonists) for the displacement of [3H]GR125743 from membranes 
obtained from COS-7 cells expressing porcine 5-HT1B receptor are shown in 
Table 2.1. 
 
Table 2.1  Inhibition by serotonergic compounds of [3H]GR125743 (1 nM) binding to 
membranes derived from Cos-7 cells transiently expressing the pig 5-HT1B receptor cDNA 
Agonists pKi Putative antagonists pKi 
L694247 9.07 ± 0.02 GR127935 8.50 ± 0.03 
Ergotamine  8.06 ± 0.00 Methiothepin 8.29 ± 0.04 
5-Carboxamidotryptamine  8.06 ± 0.18 SB224289 7.88 ± 0.07 
Dihydroergotamine  8.00 ± 0.10 Ritanserin 6.67 ± 0.01 
5-HT  7.84 ± 0.07 Ketanserin 5.78 ± 0.12 
CP122638 7.37 ± 0.05 BRL15572 5.58 ± 0.07 
Zolmitriptan 7.36 ± 0.07   
Sumatriptan 7.25 ± 0.15   
Data are mean ± s.e.mean (n=3). 
 
The rank order of potency of agonists was L694247 > ergotamine ≥ 
5-carboxamidotryptamine = dihydroergotamine = 5-HT > CP122638 = zolmitriptan > 
sumatriptan, while that of the putative antagonists was GR127935 > methiothepin > 
SB224289 >> ritanserin > ketanserin ≥ BRL15572. 
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Figure 2.6.  Regression analysis of pKi values (affinity constants) of 5-HT receptor 
ligands obtained with the cloned pig 5-HT1B receptor (see Table 2.1) with those 
reported with cloned 5-HT1B (human and rat; upper panels) and 5-HT1D (pig and 
human; lower panels) receptors (for references, see text).  In each case [3H]GR125743 
was used as radioligand, except for the rat 5-HT1B receptor, where [3H]5-HT was used 
and pKi values of some compounds included in Table 2.1 (ergotamine, CP122638, 
SB224289, ritanserin and BRL15572) were not available.  The Spearman correlation 
coefficient (rS) and the corresponding values of the slope (b), calculated with 
SlideWrite plus for Windows© (Advanced Graphics Software, Encinitas, CA, USA), 
are listed in each panel. 
 
In Figure 2.6, pKi values of the above compounds obtained in the present experiments 
with membranes from cells expressing the cloned pig 5-HT1B receptor (Table 2.1) 
have been plotted against pKi values obtained earlier with the same compounds using 
membranes from cells expressing the cloned human (Wurch et al., 1998 and 
unpublished) or rat (Beer et al., 1998) 5-HT1B receptor as well as the cloned porcine 
(Bhalla et al., 2000) or human (Wurch et al., 1998 and unpublished) 5-HT1D receptor. 
The affinity constants at the porcine 5-HT1B receptor showed the highest correlation 
with those at the human 5-HT1B receptor (rs=0.988; b=0.985).This was closely 
followed by that at the rat 5-HT1B receptor (rs=0.808), although the slope (b=0.455) 
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was conspicuously lower.  The correlation at the porcine (rs=0.656) or human 
(rs=0.455) 5-HT1D receptors was much weaker.  It may be noted that the selective 
5-HT1B receptor antagonist SB224289 (Schlicker et al., 1997; Gaster et al., 1998; 
Selkirk et al., 1998) showed a high affinity (pKi: 7.88±0.07, Table 2.1), while the 
selective 5-HT1D receptor antagonist BRL15572 (Schlicker et al., 1997; Gaster et al., 
1998) a low affinity (pKi: 5.58±0.07; Table 2.1) at the porcine 5-HT1B receptor. 
[35S]GTPγS binding response 
The basal [35S]GTPγS binding to membranes obtained from CHO-K1 cells transiently 
co-expressing the cloned porcine 5-HT1B receptor and a mutant GαoCys351Ile protein 
was 181±34 fmol [35S]GTPγS mg-1 protein (n=5). 
 
Figure 2.7.  Increase in [35S]GTPγS binding, as percentage of the response to 
10 µM 5-HT, by zolmitriptan in CHO-K1 cells transiently co-expressing the cloned 
pig 5-HT1B receptor and a mutant GαoCys351Ile protein (pEC50 zolmitriptan: 
7.64±0.04).  Data are mean±s.e.mean (n=5); s.e.mean values fall within the symbol. 
The basal 35S]GTPγS binding (181±34 fmol mg-1 protein; n=5) was increased by 
10 µM 5-HT to 390±62 fmol mg-1 protein (123±10% of the basal value; n=5) and 
decreased by 1 µM  SB224289 to 136±29 fmol mg-1 protein (-27±4% of the basal 
value; n=5). 
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5-HT (10 µM) increased [35S]GTPγS binding by 123±10% (n=5) over the basal 
level; no effect was observed in membranes from cells transfected with empty 
plasmid.  Zolmitriptan caused a concentration-dependent increase in [35S]GTPγS 
binding and elicited a full agonist response at the receptor (100±2% increase as 
compared to 10 µM 5-HT; Figure 2.7).  The potency (pEC50 value) of zolmitriptan 
was 7.64±0.04 nM (n=5), which is close to its binding affinity at the porcine 5-HT1B 
receptor (pKi: 7.36±0.07 nM, n=3; Table 2.1).  The selective 5-HT1B receptor 
antagonist SB224289 (1 µM) decreased basal [35S]GTPγS binding by -27±4% (n=5), 
showing that SB224289 exhibits a  negative efficacy (inverse agonism). 
5-HT1B receptor mRNA expression in various porcine tissues 
RT-PCR technique was used to assess the expression of 5-HT1B receptor in various 
porcine tissues.  As shown in Figure 2.8, a fragment of expected size (approximately 
180 bp), representing porcine 5-HT1B receptor mRNA, was detected in the brain 
(cortex and cerebellum), trigeminal ganglion, heart (left ventricle) and blood vessels 
(left anterior descending coronary, pulmonary, common carotid, superior mesenteric 
and femoral arteries and saphenous vein).   
   M1  1   2  3   4   5   6  7   8   9 10 11 12 M1 M2
2645 bp → ← 1353 bp
676 bp →
179 bp →
← 603 bp
← 194 bp
M1: pGEM marker
1: Brain cortex
2: Cerebellum
3. Trigeminal ganglion
4: Left ventricle
5: LAD coronary artery
6: Pulmonary artery
7: Carotid artery
8: Mesenteric artery
9: Femoral artery
10:  Saphenous vein
11:  Brain cortex without RT
12:  Autoclaved water
M2: φx174 DNA/Hae III
        marker
 
Figure 2.8.  Agarose gel electophoresis of PCR amplified products derived from 
cDNA obtained from a number of porcine tissues.  The size of marker bands is 
indicated in margins.  LAD, left anterior descending; RT, reverse transcriptase.  No 
such fragment was found in the negative controls (autoclaved water or brain cortex in 
the absence of reverse transcriptase step) run simultaneously during PCR, thus ruling 
out the possibility of genomic DNA and/or PCR contamination. 
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In situ hybridisation 
In situ hybridisation technique was used to localise the expression pattern of 5-HT1B 
receptor mRNA in porcine frontal cerebral cortex.   
 
Figure 2.9.  Localisation of 5-HT1B receptor mRNA in the frontal part of porcine 
cerebral cortex by in situ hybridisation. Left panel: photomicrograph showing the 
expression of 5-HT1B receptor mRNA with the antisense DIG-labelled cRNA probe 
(dark spots).  Right panel: photomicrograph showing no hybridisation signals with the 
sense probe.  M, Molecular layer; P, pyramidal layer.  Scale bar = 50 µm. 
 
Using the antisense DIG-labelled cRNA probe, the 5-HT1B receptor mRNA was 
clearly visualised in the pyramidal cells and weak signals were also observed in the 
outer molecular layer (Figure 2.9, left panel).  The specificity of the mRNA signals 
was confirmed with the sense probe, which did not show any signal in the cerebral 
cortex (Figure 2.9, right panel). 
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Discussion 
Sequence analysis of porcine 5-HT1B receptor 
The specific primer sequences of the full-length porcine 5-HT1B receptor were 
identified by inverse PCR on ligated genomic DNA and used for amplification of the 
full-length porcine 5-HT1B receptor cDNA from cerebral cortex.  The nucleotide 
sequence of porcine 5-HT1B receptor cDNA, which completely matched with a partial 
sequence submitted to GenBank by T. Wurch and colleagues (accession number: 
Y11867), revealed 1170 bp encoding an open reading frame of 390 amino acid 
peptide.  This peptide showed a high homology (88-95%) with the sequence of 
5-HT1B receptors in other species (Hamblin et al., 1992; Harwood et al., 1995; Jin et 
al., 1992; Maroteaux et al., 1992; Voigt et al., 1991; Zgombick et al., 1997).  The 
homology between the cloned porcine and human 5-HT1B receptors (Hamblin et al., 
1992; Jin et al., 1992) was the highest (95%) and there was a total identity in 
transmembrane domains 2-5.  It is to be noted that the presence of the amino acid 
threonine at position 355 within the seventh transmembrane domain of the porcine 
5-HT1B receptor, rather than asparagine at the corresponding position 351 in the 
mouse (Maroteaux et al., 1992) and rat (Voigt et al., 1991), was identical to the 
human (Hamblin et al., 1992; Jin et al., 1992), rabbit (Harwood et al., 1995) and 
guinea pig (Zgombick et al., 1997) 5-HT1B receptors.  Furthermore, the presence of 
putative asparagine-linked glycosylation and protein kinase A and C phoshorylation 
sites were consistent with the previously cloned receptors from other species 
(Harwood et al., 1995; Jin et al., 1992). 
As observed in the porcine 5-HT1D receptor (Bhalla et al., 2000), with which 
there was an overall 61% amino acid identity, the porcine 5-HT1B receptor showed 
some unique amino acids (Ala4, Ser15,21 and Arg19 towards the N-terminal end, Val51 
and Ile54 in the first transmembrane domain, Leu277 in the third intracellular loop, 
Ala336 in the sixth transmembrane domain as well as Phe372 in the seventh 
transmembrane domain). These divergent amino acids were reconfirmed in the 
inverse PCR sequence derived from genomic DNA.  Furthermore, it was most likely 
the presence of Ala4 that interfered with the amplification of full-length porcine 
5-HT1B receptor cDNA based on primers designed from other species and necessitated 
the alternative cloning strategy used here (see Methods section). 
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Ligand binding properties of porcine 5-HT1B receptor 
It is well known that the pharmacological profile of the rodent and human 5-HT1B 
receptor differs substantially (Hoyer et al., 1994; Metcalf et al., 1992; Oksenberg et 
al., 1992).  Our recent investigation also revealed that BRL15572, a selective 
antagonist at human 5-HT1D receptor (Price et al., 1997; Schlicker et al., 1997), 
unexpectedly exhibited a low affinity at the recombinant porcine 5-HT1D receptor 
(Bhalla et al., 2000).  Thus, for a pathophysiological animal model to be of value in 
the evaluation of new drugs it is imperative that the pharmacology of the candidate 
receptor in the specific animal species must be comparable to that of the human 
receptor homologue. 
Membranes prepared from COS-7 cells transfected with the porcine 5-HT1B 
receptor showed a high affinity and saturable binding for the 5-HT1B/1D receptor 
radioligand [3H]GR125743.  Ligand displacement studies established that the 
pharmacological profile of the porcine 5-HT1B receptor and the affinity rank order for 
agonists (L694247 > ergotamine ≥ 5-carboxamidotryptamine = dihydroergotamine = 
5-HT > CP122638 = zolmitriptan > sumatriptan) and putative antagonists (GR127935 
> methiothepin > SB224289 >> ritanserin > ketanserin ≥ BRL15572) were close to 
those described for the recombinant human 5-HT1B receptor (Pauwels et al., 1996a).  
It may be emphasised that, unlike the low affinity of BRL15572 at the porcine 5-HT1D 
receptor (Bhalla et al., 2000), the selective 5-HT1B receptor antagonist SB224289 
(Gaster et al., 1998; Hagan et al., 1997; Selkirk et al., 1998) did have a high affinity at 
the recombinant porcine 5-HT1B receptor.  As expected, BRL15572 showed a low 
affinity for the porcine 5-HT1B receptor, but this compound cannot be used to 
differentiate between porcine 5-HT1B and 5-HT1D receptor subtypes.  In addition, 
ketanserin differentiated between porcine 5-HT1B (pKi: 5.78±0.12) and 5-HT1D (pKi: 
7.42±0.04) receptors showing a 40-fold selectivity for the 5-HT1D over 5-HT1B 
receptor (present results, Bhalla et al., 2000).  It is known that ketanserin 
differentiates between recombinant human, guinea pig, rabbit and rat 5-HT1B and 
5-HT1D receptor subtypes (Bard et al., 1996; Beer et al., 1998; Harwood et al., 1995; 
Kaumann et al., 1994; Zgombick et al., 1997), but not the canine receptors (Wurch et 
al., 2000; Zgombick et al., 1991). 
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The correlation between the affinity constants (as well as the associated slope) 
for the porcine and human 5-HT1B receptors was higher than for the porcine and rat 
5-HT1B receptors (Figure 2.5).  Although we recognise that the affinity constants for 
the rat 5-HT1B receptor were obtained using [3H]5-HT (not  [3H]GR125743 as in pig) 
and β-adrenoceptor antagonists were not evaluated, its molecular basis may be the 
presence of threonine at position 355 in the seventh transmembrane domain of porcine 
and human 5-HT1B receptors, rather than asparagine at the corresponding position in 
rodent receptors (Oksenberg et al., 1992).  The correlation between the porcine 
5-HT1B and 5-HT1D receptors for binding affinity of ligands was not so high, as 
observed earlier for the cloned human and guinea pig receptors (Weinshank et al., 
1992; Zgombick et al., 1997). 
Functional characterisation of porcine 5-HT1B receptor 
Functional properties of recombinant 5-HT1B receptors have been established using 
predominantly cellular responses employing cAMP and [35S]GTPγS binding assays 
(Pauwels et al., 1996b; Pauwels et al., 1997).  Using membranes from cells transiently 
co-expressing the porcine 5-HT1B receptor and a mutant GαoCys351Ile protein, we 
showed that 5-HT (10 µM) increased basal [35S]GTPγS binding by 123% over the 
basal levels and that zolmitriptan behaved as a near full agonist in this respect.  This 
result is in agreement with earlier observations in the recombinant human 5-HT1B 
receptor (Pauwels et al., 1997).  Moreover, as can be expected, the potency of 
zolmitriptan in the [35S]GTPγS binding assay (pEC50: 7.64±0.04; Figure 2.7) closely 
agreed with its affinity in the ligand binding assay (pKi: 7.36±0.07; Table 2.1).  
Finally, the 5-HT1B receptor antagonist SB224289 (Gaster et al., 1998; Hagan et al., 
1997; Selkirk et al., 1998) inhibited basal [35S]GTPγS binding, thus exhibiting a 
negative efficacy (inverse agonism), as noticed earlier using the recombinant human 
5-HT1B receptor (Selkirk et al., 1998). 
Localisation of porcine 5-HT1B receptor 
Ullmer (1995) has previously reported that the 5-HT1B receptor mRNA is expressed in 
all blood vessels examined, both in the rat (aorta, renal, artery, vena cava and portal, 
femoral and jugular veins) and pig (coronary, cerebral and pulmonary arteries and 
cerebral vein).  The present study also shows the ubiquitous presence of the 5-HT1B 
receptor mRNA in various porcine blood vessels.  The presence of 5-HT1B receptor 
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mRNA indicates that the vasoconstrictor property of 5-HT1B receptor ligands, such as 
the triptans, is mediated by the 5-HT1B receptor.  Indeed, sumatriptan-induced 
constriction of porcine carotid arteriovenous anastomoses is antagonised by the 
selective 5-HT1B receptor antagonist SB224289 (De Vries et al., 1999).  However, it 
may be pointed out that despite the expression of 5-HT1B receptor mRNA, 
sumatriptan fails to contract the porcine coronary artery (Humphrey et al., 1988; 
Humphrey et al., 1990).  Interestingly, sumatriptan can reduce coronary blood flow in 
pigs fed a high cholesterol diet (Saxena, unpublished observations).  It is therefore 
possible that that hypercholesterolaemia either increases the density of 5-HT1B 
receptors or improves their coupling with G-proteins. 
The 5-HT1B receptor mRNA was also observed in porcine trigeminal ganglion, 
as is the case in the human trigeminal ganglion (Bouchelet et al., 1996; Bruinvels et 
al., 1992).  Since no studies exploring neural effects of triptans have been performed 
in the pig, we do not know whether or not the neural effects of triptans (Goadsby et 
al., 1997; Saxena et al., 2000) are mediated by this receptor.  Porcine frontal cortex 
and cerebellum also showed the presence of the 5-HT1B receptor mRNA and in situ 
hybridisation studies revealed mRNA expression mainly in the pyramidal neurones of 
the frontal cerebral cortex.  The 5-HT1B receptor is widely distributed in the brain and 
it may serve as an autoreceptor inhibiting transmitter release (Bonaventure et al., 
1998; Marcoli et al., 1999).   
 
In conclusion, we have established the cDNA sequence of recombinant porcine 
5-HT1B receptor, which shows a high homology with other species homologues.  The 
pharmacological profile of the recombinant porcine 5-HT1B receptor is quite similar to 
that of the human 5-HT1B receptor.  The cloned porcine 5-HT1B receptor is also 
functionally active as observed by [35S]GTPγS binding and is ubiquitously expressed 
in blood vessels and brain tissues. 
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Chapter 3 
Molecular cloning, sequence analysis and pharmacological properties 
of the porcine 5-HT1D receptor 
Summary A cDNA encoding the full-length 5-HT1D receptor derived 
from porcine cerebral cortex was amplified, cloned and sequenced, using 
guinea pig 5-HT1D receptor coding sequence oliginucleotide primers in 
reverse transcription-polymerase chain reaction (RT-PCR).  The 5’ and 
3’ ends of the porcine 5-HT1D receptor cDNA were verified by inverse 
PCR.  Sequence analysis of porcine 5-HT1D receptor cDNA revealed an 
open reading frame of 1134 nucleotides encoding a polypeptide of 377 
amino acids having 92% homology with the human 5-HT1D receptor and 
88-90% homology with other species homologues.  The porcine 5-HT1D 
receptor cDNA was further subcloned into a mammalian expression 
vector pcDNA3 and expressed in monkey Cos-7 cells.  Radioligand 
binding assays using either [3H]5-CT or [3H]GR125743 on Cos-7 cell 
membranes showed that pKi values of 14 serotonin ligands were highly 
correlated with those obtained with the human 5-HT1D receptor.  
Nonetheless, a selective antagonist at the human 5-HT1D receptor, 
BRL15572, only poorly recognised the porcine homologue.  Using 
membranes from cells co-expressing the porcine 5-HT1D receptor and rat 
Gαi1Cys351Ile protein, it was shown that 5-HT and zolmitriptan increased, 
while ketanserin decreased basal [35S]GTPγS binding.  The potency of 
zolmitriptan in the [35S]GTPγS binding assay (pEC50: 8.46±0.08) agreed 
with its affinity in displacing the ligands [3H]5-CT and [3H]GR125743 
(pKi: 8.38±0.15 and 8.67±0.08, respectively).  In conclusion, we have 
established the cDNA sequence and pharmacology of the cloned porcine 
5-HT1D receptor.  This information would be useful in exploring the role 
of divergent amino acid residues in the receptor-ligand interaction as well 
as the role of 5-HT1D receptor in pathophysiological processes relevant 
for novel drug discovery in diseases such as migraine. 
 
 
 
 
 
 
Based on: Bhalla, P., Sharma, H.S., Wurch, T., Pauwels, P.J. & Saxena, P.R. (2000). 
Molecular cloning, sequence analysis and pharmacological properties of the porcine 5-HT1D 
receptor.  Br. J. Pharmacol., 131, 949-957 
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Introduction 
5-Hydroxytryptamine (5-HT; serotonin) has long been suspected to be involved in the 
pathophysiology of migraine, but the exact nature of its role is even today not clear 
(Hamel et al., 2000).  Nevertheless, pharmacological characterisation of 5-HT 
receptors was instrumental in the design of the antimigraine drug sumatriptan 
(Humphrey et al., 1988; Humphrey et al., 1990; Saxena et al., 1992), an agonist at a 
novel, but heterogeneous group of 5-HT receptors, then called “5-HT1-like” (Bradley 
et al., 1986).  The term “5-HT1-like” has since become redundant (Saxena et al., 
1998), because this group has been shown to comprise of receptors where sumatriptan 
has either a high (5-HT1B, 5-HT1D and 5-ht1F) or low (5-HT7) affinity (Hoyer et al., 
1994; Peroutka et al., 1989; Waeber et al., 1990). 
Sumatriptan as well as the second-generation triptans potently constrict isolated 
cranial blood vessels and decrease arteriovenous anastomotic fraction of carotid blood 
flow in anaesthetised animals.  These drugs also inhibit dural plasma protein 
extravasation and action potentials in trigeminal nucleus caudalis following 
stimulation of the trigeminal ganglion and superior sagittal sinus, respectively 
(Edvinsson et al., 1998; Moskowitz, 1992; Saxena et al., 2000).  Molecular and 
pharmacological studies have convincingly shown that the vasoconstrictor effect of 
triptans is mediated via 5-HT1B, but not 5-HT1D or 5-ht1F receptors (Bouchelet et al., 
2000; Bouchelet et al., 1996; Cohen et al., 1999; De Vries et al., 1998; De Vries et 
al., 1999b; Nilsson et al., 1999; Verheggen et al., 1998).  On the other hand, the 
trigeminal neural effects of triptans seem to involve primarily the 5-HT1D receptor, 
although 5-HT1B and 5-ht1F receptors have also been implicated (De Vries et al., 
1999a; Hargreaves et al., 1999; Hoyer et al., 1990; Longmore et al., 1997; McCall, 
1997; Mitsikostas et al., 1999; Wainscott et al., 1998).  The antimigraine efficacy of 
triptans has, therefore, been attributed to their ability to constrict large intracranial 
arteries and arteriovenous anastomoses via the 5-HT1B receptor and to the inhibition 
of peripheral trigeminal sensory nerve terminals in the meninges and central terminals 
in brain stem sensory nuclei via the 5-HT1D receptor (Hargreaves et al., 1999; Saxena 
et al., 2000). 
Previous investigations from our laboratory have established that constriction of 
carotid arteriovenous anastomoses in the anaesthetised pig can serve as a predictive 
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model for the antimigraine efficacy of 5-HT-based drugs (De Vries et al., 1999a; De 
Vries et al., 1999c; Saxena, 1995).  To gain further insight into the mechanisms 
involved in drug actions as well as the disease, it is important to study the trigeminal 
neural control of porcine arteriovenous anastomoses and its potential modification by 
5-HT1D receptor ligands.  However, one of the difficulties in undertaking such studies 
is the lack of knowledge of molecular biology of porcine 5-HT1B and 5-HT1D 
receptors.  Although we (De Vries et al., 1999b) have employed SB224289 
(2,3,6,7-tetrahydro-1’-methyl-5-[2’-methyl-4’(5-methyl-1,2,4-oxadiazol-3-yl) 
biphenyl-4-carbonyl] furo [2,3-f] indole-3-spiro-4`-piperidine hydrochloride) and 
BRL15572 ([1-(3-chlorophenyl)-4-[3,3-diphenyl (2-(S,R) hydroxypropanyl) 
piperazine] hydrochloride), that have been shown to be selective antagonists for the 
human 5-HT1B and 5-HT1D receptors (Gaster et al., 1998; Price et al., 1997; Schlicker 
et al., 1997; Selkirk et al., 1998), respectively, it is difficult to be sure that these 
compounds also have a high and selective affinity at the respective porcine receptor. 
In the present investigation, we describe the molecular cloning and 
characterisation of the porcine 5-HT1D receptor (R.C.: 2.1.5HT.01D).  Using the total 
RNA derived from the pig cerebral cortex, a full-length cDNA encoding 5-HT1D 
receptor was amplified and the deduced amino acid sequence was compared with 
those in the other species.  The pharmacological profile of the porcine 5-HT1D 
receptor was evaluated after transient transfection in Cos-7 cells and compared with 
that of the recombinant human 5-HT1D receptor.  A part of these results has been 
presented to the British Pharmacological Society (Bhalla et al., 2000). 
Methods 
mRNA isolation and cDNA synthesis 
Brain cortex obtained from a pig (Yorkshire x Landrace, female, 12 kg) killed after an 
acute haemodynamic experiment was snap frozen in liquid nitrogen and stored at 
-80°C.  The frozen tissue was transferred to guanidium thiocyanate buffer, 
homogenised (Ultra-Turrax homogeniser, model T8, Janke & Kunkel GmbH, Staufen, 
Germany) and the total RNA was extracted as described earlier (Chomczynski et al., 
1987; Sharma et al., 1996).  The RNA concentration was measured by UV absorbance 
at 260 nm using a Gene Quant RNA/DNA calculator (Pharmacia-LKB, Biochrom, 
England) and the quality of RNA was assessed by OD260/OD280 ratio of >1.8 as well 
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as by formaldehyde-agarose gel electrophoresis.  Subsequently, poly(A+) mRNA was 
purified from the total RNA using an Oligotex mRNA purification Kit (Qiagen 
GmbH, Hilden, Germany).  Poly(A+) mRNA (0.5 µg) was denatured at 65 °C and the 
first strand of cDNA was synthesised in a reaction volume of 20 µl by adding 
sequentially the following reagents: reverse transcription buffer (25 mM Tris-HCl, 
pH 8.3; 50 mM KCl; 5.0 mM MgCl2, 2.0mM DTT), 1.0 mM dNTPs, ribonuclease 
inhibitor (1 U µl-1), random hexamer (150 ng µg-1 mRNA) and, finally, AMV reverse 
transcriptase (14 U µg-1 mRNA).  A control was similarly prepared, except that the 
AMV reverse transcriptase was omitted.  The reactions were carried out for 90 min at 
42 °C, extended for another 10 min at 75 °C and then cooled to 4°C.  The cDNA thus 
synthesised was diluted to 50 µl and stored at –20°C until used as a PCR template.  
The quality of cDNA was checked by PCR amplification of β-actin using specific 
oligonucleotide primers (Ponte et al., 1984). 
PCR amplification and cloning of 5-HT1D receptor cDNA 
Oligonucleotide primers were designed according to the start and stop codon regions 
of the guinea pig 5-HT1D receptor gene (Wurch et al., 1997; Zgombick et al., 1997).  
The forward and reverse primers were 5’-ATGTCCCCGCCAAACCAGTC-3’ and 
5’-CTAGGAGGCTTTCCGGAAATG-3’, respectively.  The following components 
were added in a reaction volume of 20 µl: 250 µM of each dATP, dTTP, dGTP and 
dCTP, 1.5 mM MgCl2, PCR buffer (1xPCR buffer: 10mM Tris-HCl, pH 8.3, 50 mM 
KCl), Ampli Taq GoldTM (0.5 U), 0.5  µM each of the forward and reverse primer and 
5 µl of cDNA template.  After brief centrifugation, the enzyme was first activated for 
10 min at 94 °C in a PCR thermocycler (model PTC-100TM, M.J. Research Inc, 
Watertown, USA).  cDNA was denatured for 1 min at 94 °C and annealed to the 
primers for 30 s at 60 °C with the reaction extended for 90 s at 72 °C and this 
procedure was repeated for 36 cycles.  Finally, the reaction was extended for 
additional 10 min at 72 °C.  Several independent PCR reactions were performed to 
exclude possible misincorporation of nucleotides by Ampli Taq for sequence analysis. 
The amplified PCR products were separated on 1% agarose gel in TBE buffer 
(90 mM Tris-HCl, pH 8.0, 90 mM boric acid, 2 mM EDTA) containing ethidium 
bromide (0.5 µg ml-1), visualised under UV light and photographed.  Subsequently, 
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the PCR product of expected size was purified using a PCR purification kit (Promega 
Benelux b.v., Leiden, The Netherlands) and the amount of DNA was measured 
spectrophotometrically.  An aliquot of purified PCR product was ligated into the 
pGEMT-Easy vector (Promega Benelux b.v., Leiden, The Netherlands).  The ligated 
vector was transformed into competent JM 109 cells and grown on 
IPTG/X-gal-treated ampicillin resistant LB-Agar plates at 37 °C.  White over blue 
colonies were selected to identify positive clones, which were further characterised by 
the presence of an expected size insert in them.  Four insert positive clones (namely, 
pHTD-11, pHTD-13, pHTD-25, pHTD-27) were further processed for the plasmid 
DNA isolation and sequencing. 
Plasmid purification and sequencing 
Bacterial colonies harbouring recombinant plasmids were grown overnight at 37 °C in 
LB medium containing ampicillin (100 µg ml-1).  Bacteria were harvested by 
centrifugation and the plasmid DNA was isolated using a commercially available 
midi-prep plasmid isolation kit (Promega Benelux b.v., Leiden, The Netherlands).  
Purified plasmid DNA from all four clones (pHTD-11, pHTD-13, pHTD-25, 
pHTD-27) was sequenced by the dideoxy nucleotide chain termination method, using 
universal forward and reverse sequencing primers.  Sequencing reactions were loaded 
on an automated fluorescence based DNA sequencer (ABI PrismTM 310 Genetic 
analyser, Perkin Elmer Applied Biosystem Benelux, Nieuwerkerk a/d Ijssel, The 
Netherlands) and the raw sequence data were processed and analysed.  The nucleotide 
sequences thus obtained were compared and a consensus sequence was derived using 
the DNAMAN sequence analysis program (version 3.2, Lynnon Biosoft© 1994-1997).  
The final sequence was translated as a peptide sequence and compared with those in 
the GenBank (BLAST search at National Centre for Biotechnology Information, 
Bethesda, MD, USA; web site: http://www.ncbi.nlm.nih.gov/BLAST/).  The 
hydrophobic regions indicating putative transmembrane domains and sequence 
homology with known 5-HT1D receptors from other species were established. 
Inverse PCR 
Since the forward and reverse oligonucleotide primers used in RT-PCR were designed 
from the guinea pig 5-HT1D receptor sequence, we identified the 5’ and 3’ ends of our 
cloned porcine cDNA by inverse PCR (Ochman et al., 1988).  Porcine genomic DNA 
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was digested with EcoR1 restriction enzyme, as the cloned 5-HT1D receptor cDNA 
did not show any restriction site for EcoR1.  After purification, the restricted DNA 
was ligated overnight at 16 °C in the presence of T4-DNA ligase in order to obtain 
DNA circles.  Using porcine specific inverse primers, the ligated DNA fragments, as 
circles of different sizes in various dilutions, were subjected to PCR amplification.  
The internal oligonucleotide inverse primers, designed on the basis of porcine 5-HT1D 
receptor cDNA sequence, were 5’-GCATTGGAAAGGACAGTGGC-3’ (for 5’ end) 
and 5’-TCATCTGCTGGTTGCCCTTC-3’ (for 3’ end).  The PCR products were 
separated on a 1% agarose gel, purified, cloned and sequenced as described above. 
Transient transfection and ligand receptor binding assay 
The purified full-length pig 5-HT1D receptor cDNA insert was subcloned into 
dephosphorylated eukaryotic expression vector, pcDNA3 (Invitrogen, San Diego, Ca, 
USA) and transformed into TOP10 competent cells.  The clones containing the insert 
were selected and screened with restriction enzyme (HindΙΙΙ and EcoR1) for 
appropriate orientation.  The plasmid DNA was purified according to maxi prep 
protocol using a commercially available kit (Qiagen SA, Courtaboeuf, France).  
Monkey Cos-7 cells were transiently transfected with the plasmid using a gene pulser 
transfection apparatus (Bio-Rad S.A., Ivry Sur Seine, France), as described earlier by 
Pauwels et al. (1996).  After transfection, the cells were incubated for 48 h in 
Dulbecco modified Eagle’s medium (DMEM) containing 10% heat-inactivated foetal 
bovine serum and antibiotics at 37 °C in a humidified chamber containing 5% CO2. 
The transfected cells were washed twice with phosphate buffer saline 
(2.7 mM KCl, 1.5 mM KH2PO4, 140 mM NaCl, 8 mM Na2HPO4; pH 7.2) and kept at 
-80 °C for 10 min.  The cells were scrapped from the petri-dish in ice-cold 50 nM 
Tris-HCl buffer (pH: 7.7) and homogenised.  The homogenate was centrifuged at 
1,000 rpm for 5 min at 4 °C and the supernatant was collected and centrifuged again 
at 13,000 rpm for 20 min.  The membrane pellet was resuspended into 50 mM 
Tris-HCl buffer (pH: 7.7) containing 4 mM CaCl2, 10 µM pargyline and 0.1 % 
ascorbic acid, as described before (Pauwels et al., 1996).  The membrane protein 
concentration was measured by dye binding assay (Bradford, 1976) using a Bio-Rad 
Kit and bovine serum albumin as a standard. 
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Binding assays to membranes obtained from transfected Cos-7 cells were 
performed using either 3.0 nM [3H]GR125743 ([3H]N-[4-methoxy-3-(4-methyl 
piperazin-1-yl)phenyl]-3-methyl-4-(4-pyridyl) benzamide) or 1.0 nM 
[3H]5-carboxamidotryptamine ([3H]5-CT) as radioligands.  Incubation mixtures 
consisted of 0.40 ml of cell membrane preparation (30-50 µg of protein), 0.05 ml of 
one of the radioligands and 0.05 ml of compounds for inhibition or 10 µM 5-HT to 
determine non-specific binding.  The reaction was terminated by filtration with 
ice-cold Tris-buffer and radioactivity on the filter paper was measured by using a 
liquid scintillation counter (Pauwels et al., 1996; Wurch et al., 1997).  In case of 
[3H]GR125743, the filtration was performed over 0.2% polyethyleneimine-treated 
Whatman (Clifton, NJ, USA) GF/B glass fibre filters.  Data were analysed graphically 
with inhibition curves, and IC50 values were derived.  Ki values were calculated 
according to the equation Ki = IC50/(1+C/KD), where C is the concentration and KD is 
the equilibrium dissociation constant of the radioligand.  Ligand saturation binding 
curves were analysed by the nonlinear least square curve-fitting programme to 
determine Kd and Bmax values (Munson et al., 1980).  Control binding experiments 
were run with nontransfected cells and did not display specific [3H]5-CT or 
[3H]GR125743 binding. 
[35S]GTPγS binding 
CHO-K1 cells co-expressing the porcine 5-HT1D receptor and mutant Gαi1Cys351Ile 
protein (Dupuis et al., 1999) were collected in phosphate-buffered-saline (pH 7.4) and 
centrifuged for 20 min at 48,000 g and the pellet containing the membrane fraction 
was stored at -80 °C.  [35S]GTPγS binding was measured using the method previously 
described by Pauwels et al. (1997).  Briefly, the pellet was thawed and diluted in 
20 mM HEPES buffer (pH 7.4) containing 30 µM GDP, 100 mM NaCl, 3 mM MgCl2 
and 0.2 mM ascorbic acid.  Incubation mixtures were prepared in glass tubes and 
consisted of 0.4 ml of membrane preparation (containing 5 µg protein) with 5-HT 
(10 µM), ketanserin (10 µM) or zolmitriptan (0.1-10 µM) in a volume of 0.05 ml.  
After an incubation period of 30 min at 25 °C, 0.05 ml [35S]GTPγS (0.5 nM) was 
added for an additional period of 30 min.  The reaction was stopped by adding 3 ml of 
ice-cold 20 mM HEPES (pH 7.4) containing 3 mM MgCl2 and rapid filtration over 
Whatmann GF/B glass fibre filters with a Brandel harvester.  The filters were rinsed 
Chapter 3  Recombinant porcine 5-HT1D receptor 
82 
three additional times with 3 ml HEPES buffer, placed in scintillation vials and the 
radioactivity was extracted in 4 ml of Emulsifier-Safe.  Non-specific binding was 
determined in the presence of 10 µM unlabelled GTPγS.  Maximal stimulation of 
[35S]GTPγS binding was defined in the presence of 10 µM 5-HT.  Emax values were 
expressed as a percentage of the maximal response obtained with 10 µM 5-HT.  EC50 
values were defined as the concentration of compound at which 50% of its own 
maximal stimulation was obtained. 
Materials 
All oligonucleotide primers were commercially procured from Life Technologies b.v. 
(Breda, The Netherlands).  pGEMT-Easy vector system, Wizard® PCR prep and 
mini-prep DNA purification systems were purchased from Promega Benelux b.v. 
(Leiden, The Netherlands).  AmpliTaqGold and dye terminator/cycle sequencing 
ready reaction kit were procured from Perkin Elmer Applied Biosystem Benelux 
(Nieuwerkerk a/d Ijssel, The Netherlands).  Oligotex mRNA purification kit was 
purchased from Qiagen GmbH (Hilden, Germany).  Guanidinium thiocyanate was 
purchased from U.S. Biochemicals (Cleveland, OH, USA).  AMV-Reverse 
transcriptase enzyme was obtained from Pharmacia-LKB (Uppsala, Sweden).  All 
other chemicals used in this study were of molecular biology and/or tissue culture grade.  
The compounds used in pharmacological assays were: 5-HT creatinine sulphate 
(Sigma Chemicals, St. Louis, MO, USA), [3H]5-CT (56.5 Ci mmol-1, New England 
Nuclear, Les Ulis, France), BRL15572, CP122638 
(N-methyl-3-[pyrrolidin-2(R)-yl-methyl]-1H-indol-5-ylmethyl sulphonamide), 
[3H]GR125743 (83.0  Ci mmol-1; Amersham, Les Ulis, France), GR127935 
((N-[4-methoxy-3-(4-methyl-1-piperazinyl) phenyl]-2'-methyl-4'-(5-methyl-1,2,4-
oxadiazol-3-yl) [1,1-biphenyl]-4-carboxamide hydrochloride, ketanserin (Sigma 
Chemicals, St. Louis, MO, USA), L694247 (2-[5-[3-(4-methylsulphonylamino) 
benzyl-1,2,4-oxadiazol-5-yl]-1H-indole-3-yl] ethylamine), methiothepin, ritanserin, 
sumatriptan, SB224289 and zolmitriptan.  Except BRL15572 (gift: Dr. A.A. Parsons 
(SmithKline Beecham Pharmaceuticals, Harlow, Essex, UK) and L694247 (Tocris 
Cookson, Bristol, UK), all compounds were synthesised at Centre de Recherche 
Pierre Fabre (Castres, France). 
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Results 
Cloning of 5-HT1D receptor cDNA 
Figure 3.1 shows the gel electrophoresis of RT-PCR products of cDNA prepared from 
the poly(A+) mRNA of porcine brain cortex used for the amplification of 5-HT1D 
receptor.  The quality of cDNA was established by detecting a DNA fragment of 
expected size (625 bp) encoding β-actin cDNA.   
M 1 2 M 1 2
1353-
603 -
310 -
 
Figure 3.1. Left panel.  Agarose gel electrophoresis of RT-PCR products of cDNA 
synthesised from porcine brain cortex (see Methods).  M, φx174 DNA/Hae III marker; 
Lanes 1, RT-PCR product of 625 bp using β-actin primers; Lane 2, RT-PCR product 
of approximately 1200 bp obtained using forward and reverse primers of 
5-HT1D receptors. A control without template cDNA (in absence of reverse 
transcriptase) did not show any signal (not included in the figure).  Right panel.  
Agarose gel electrophoresis of recombinant plasmid with 5-HT1D receptor cDNA.  
M, φx174 DNA/Hae III marker; Lane 1, recombinant plasmid DNA restricted with 
EcoR1 enzyme and showing a DNA insert of approximately 1200 bp; 
Lane 2, non-digested recombinant plasmid DNA.  The size (bp) of 3 markers is 
indicated in the left margin. 
 
Employing this cDNA as a template and oligonucleotide primers designed from the 
known guinea pig 5-HT1D receptor cDNA sequence (Wurch et al., 1997; Zgombick et 
al., 1997), a DNA fragment of expected size (~1140 bp) was amplified by PCR (left 
panel).  The PCR amplified product was cloned and the presence of the insert checked 
with EcoR1 (right panel). 
Sequence analysis of 5-HT1D receptor 
The full-length band disclosed a nucleotide sequence of 1134 bp encoding a 377 
amino acid long protein.  A BLAST search at the GenBank revealed that the identified 
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sequence most closely matched with the sequence of 5-HT1D receptor and the 
software DNAMAN analysis predicted seven hydrophobic transmembrane domains 
(Figure 3.2).  Since porcine 5-HT1D receptor cDNA was amplified using primers 
based on 5’ and 3’ ends of guinea pig 5-HT1D receptor sequence (Wurch et al., 1997; 
Zgombick et al., 1997), the 5’ and 3’ terminals of the porcine cDNA were confirmed 
by inverse PCR.   
1    ATG TCC CCG CCA AAC CAG TCA GTG GAA GAC CTT CTG CAG GGG ACT TCC AAC AGA TCC CTG
1  M   S   P   P   N   Q   S   V   E   D   L   L   Q   G   T   S   N   R   S   L
61   AAT GCC ACA GAA ACT CCA AAA GCT TGG GAT CCA GGG ACC CTC CAA GTC CTC AAA ATT TCT
21    N   A   T   E   T   P   K   A   W   D   P   G   T   L   Q   V   L   K   I   S
121  CTC GCT GTG GTC CTC TCC ATC ATC ACA CTG GCC ACT GTC CTT TCC AAT GCC TTT GTA CTC
41    L   A   V   V   L   S   I   I   T   L   A   T   V   L   S   N   A   F   V   L
181  ACT ACC ATC TTC CTG ACC AGG AAG CTC CAC ACT CCA GCC AAC TAT CTC ATT GGC TCC CTG
61    T   T   I   F   L   T   R   K   L   H   T   P   A   N   Y   L   I   G   S   L
241  GCC ATG ACA GAC CTC TTA GTT TCC ATC TTG GTC ATG CCC ATC AGC ATC CCA TAT ACC ATC
81    A   M   T   D   L   L   V   S   I   L   V   M   P   I   S   I   P   Y   T   I
301  ACC CAA ACC TGG AGC TTT GGC CAA CTC CTG TGT GAC ATC TGG CTG TCT TCT GAC ATC ACA
101   T   Q   T   W   S   F   G   Q   L   L   C   D   I   W   L   S   S   D   I   T
361  TGC TGC ACG GCC TCC ATC CTG CAT CTC TGT GTC ATT GCT CTG GAC AGG TAC TGG GCC ATC
121   C   C   T   A   S   I   L   H   L   C   V   I   A   L   D   R   Y   W   A   I
421  ACG GAT GCC CTG GAG TAT AGT AAA CGC CGG ACA GCG GGC CAC GCG GCT GCC ATG ATT GCC
141   T   D   A   L   E   Y   S   K   R   R   T   A   G   H   A   A   A   M   I   A
481  ATT GTC TGG GCC ATC TCC ATC TGC ATC TCC ATC CCA CCA CTC TTT TGG CGG CAG GCC AGG
161   I   V   W   A   I   S   I   C   I   S   I   P   P   L   F   W   R   Q   A   R
541  GCT CAT GAA GAG ATA TCA GAC TGC CTG GTG AAC ACT TCT CAG ATC TCC TAC ACC ATC TAC
181   A   H   E   E   I   S   D   C   L   V   N   T   S   Q   I   S   Y   T   I   Y
601  TCC ACC TGT GGG GCC TTC TAC ATC CCA TCT CTG TTG CTC ATC ATC CTC TAT GGC CGG ATC
201   S   T   C   G   A   F   Y   I   P   S   L   L   L   I   I   L   Y   G   R   I
661  TAC AGG GCC GCC CGG AAC CGC ATC TTG AAT CCA CCG TCA CTC TAC GGG AAG CGC TTC ACC
221   Y   R   A   A   R   N   R   I   L   N   P   P   S   L   Y   G   K   R   F   T
721  ACA GCC CAT CTC ATC ACA GGC TCT GCA GGC TCC TCG CTG TGC TCG CTC AAC CCC AGC CTT
241   T   A   H   L   I   T   G   S   A   G   S   S   L   C   S   L   N   P   S   L
781  CAT GAG GAG CAC GCT CAT TCA GCC GGT TCC CCT CTC TTT TTC AAC CAC GTG AAA ATC AAG
261   H   E   E   H   A   H   S   A   G   S   P   L   F   F   N   H   V   K   I   K
841  CTT GCC GAT AGT GTC CTA GAG CGC AAG AGG ATT TCC GCT GCC CGA GAG AGG AAA GCC ACT
281   L   A   D   S   V   L   E   R   K   R   I   S   A   A   R   E   R   K   A   T
901  AAA ACC CTG GGG ATC ATT CTG GGG GCT TTT ATC ATC TGC TGG TTG CCC TTC TTT GTT GCA
301   K   T   L   G   I   I   L   G   A   F   I   I   C   W   L   P   F   F   V   A
961  TCT CTG GTC CTC CCC ATC TGC CGG GAC TCC TGC TGG ATC CAC CCA GCC CTT TTT GAC TTT
321   S   L   V   L   P   I   C   R   D   S   C   W   I   H   P   A   L   F   D   F
1021 TTC ACT TGG CTA GGC TAC TTA AAC TCC CTC ATC AAT CCA ATA ATC TAT ACT GTG TTT AAT
341   F   T   W   L   G   Y   L   N   S   L   I   N   P   I   I   Y   T   V   F  N
1081 GAA GAG TTT CGG CAA GCG TTT CAG AAA GTT GTC CAT TTC CGG AAA GCC TCC TAG
361   E   E   F   R   Q   A   F   Q   K   V   V   H   F   R   K   A   S  ***
I
II
III
IV
V
VI
VII
 
Figure 3.2. Nucleotide and deduced amino acid (in bold) sequences of the pig 5-HT1D 
receptor (GenBank accession number: AF 117655).  The computer predicted (software 
DNAMAN, version 3.2, Lynnon Biosoft©) transmembrane domains I-VII (underlined) 
and putative N-glycosylation (★), protein kinase A phoshorylation (■) and protein 
kinase C phosphorylation (●) sites are indicated in the sequence. 
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Inverse-PCR (5’ end)
1    ATGTCCCCGCCAAACCAGTCAGTGGAAGACCTTCTGCAGGGGACTTCCAACAGATCCCTG
     ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
21   ATGTCCCCGCCAAACCAGTCAGTGGAAGACCTTCTGCAGGGGACTTCCAACAGATCCCTG
61   AATGCCACAGAAACTCCAAAAGCTTGGGATCCAGGGACCCTCCAAGTCCTCAAAATTTCT
     ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
81   AATGCCACAGAAACTCCAAAAGCTTGGGATCCAGGGACCCTCCAAGTCCTCAAAATTTCT
121  CTCGCTGTGGTCCTCTCCATCATCACACTGGCCACTGTCCTTTCCAATGC
     ||||||||||||||||||||||||||||||||||||||||||||||||||
141  CTCGCTGTGGTCCTCTCCATCATCACACTGGCCACTGTCCTTTCCAATGC
932  TCATCTGCTGGTTGCCCTTCTTTGTTGCATCTCTGGTCCTCCCCATCTGCCGGGACTCCT
     ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1    TCATCTGCTGGTTGCCCTTCTTTGTTGCATCTCTGGTCCTCCCCATCTGCCGGGACTCCT
992  GCTGGATCCACCCAGCCCTTTTTGACTTTTTCACTTGGCTAGGCTACTTAAACTCCCTCA
     ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
61   GCTGGATCCACCCAGCCCTTTTTGACTTTTTCACTTGGCTAGGCTACTTAAACTCCCTCA
1052 TCAATCCAATAATCTATACTGTGTTTAACGAAGAGTTTCGGCAAGCGTTTCAGAAAGTTG
     ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
121  TCAATCCAATAATCTATACTGTGTTTAATGAAGAGTTTCGGCAAGCGTTTCAGAAAGTTG
1112 TCCATTTCCGGAAAGCCTCCTAG
     |||||||||||||||||||||||
181  TCCATTTCCGGAAAGCCTCCTAG
Inverse-PCR (3’ end)
5’ end
5’ end
3’ end
3’ end
 
Figure 3.3. Sequence of inverse-PCR amplified products (in bold letters) showing a 
100% homology at both 5’ and 3’ ends with the sequence of the cDNA identified from 
the pig brain cortex (in normal letters).  The 5’ and 3’ terminal sequences are 
identified in shaded boxes, while the inverse PCR primers are underlined. 
 
Using a set of porcine specific internal inverse primers (based on the derived 
sequence) and the porcine ligated genomic DNA fragments, a PCR product of 
approximately 400 bp was amplified, cloned and sequenced.  Sequence analysis 
revealed that, compared to the derived porcine 5-HT1D receptor cDNA, there was a 
100% identity with 170 nucleotides from the 5’ end (Figure 3.3, upper panel) and 203 
nucleotides from the 3’ end (Figure 3.3, lower panel).  The 5’ (N) and 3’ (C) terminals 
were identical to those obtained by cDNA sequencing (Figure 3.3, shaded boxes).    
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    65PIG
    65HUMAN
    65RABBIT
    65GUINEAPIG
    62MOUSE
    62RAT
    65DOG
MSPPNQSVEDLLQGTSNRSLNATETPKAWDPGTLQVLKISLAVVLSIITLATVLSNAFVLTTIFL
MSPLNQSAEGLPQEASNRSLNATETSEAWDPRTLQALKISLAVVLSVITLATVLSNAFVLTTILL
MSPSNQSAEGLPQEAANRSLNATGTPEAWDPGTLQALKISLAVVLSIITVATVLSNTFVLTTILL
MSPPNQSEEGLPQEASNRSLNATETPGDWDPGLLQALKVSLVVVLSIITLATVLSNAFVLTTILL
MSLPNQSLEGLPQEASNRSLNAT...GAWDPEVLQALRISLVVVLSVITLATVLSNAFVLTTILL
MSLPNQSLEGLPQEASNRSLNAT...GAWDPEVLQALRISLVVVLSIITLATVLSNAFVLTTILL
MSPPNQSLEGLLQEASNRSLNATETPEAWGPETLQALKISLALLLSIITMATALSNAFVLTTIFL
   130PIG
   130HUMAN
   130RABBIT
   130GUINEAPIG
   127MOUSE
   127RAT
   130DOG
TRKLHTPANYLIGSLAMTDLLVSILVMPISIPYTITQTWSFGQLLCDIWLSSDITCCTASILHLC
TRKLHTPANYLIGSLATTDLLVSILVMPISIAYTITHTWNFGQILCDIWLSSDITCCTASILHLC
TRKLHTPANYLIGSLATTDLLVSILVMPISIAYTITHTWNFGQVLCDIWVSSDITCCTASILHLC
TRKLHTPANYLIGSLATTDLLVSILVMPISIAYTTTRTWNFGQILCDIWVSSDITCCTASILHLC
TKKLHTPANYLIGSLATTDLLVSILVMPISIAYTTTRTWNFGQILCDIWVSSDITCCTASILHLC
TKKLHTPANYLIGSLATTDLLVSILVMPISIAYTTTRTWNFGQILCDIWVSSDITCCTASILHLC
TRKLHTPANYLIGSLAMTDLLVSILVMPISIAYTTTRTWSFGQILCDIWLSSDITCCTASILHLC
   195PIG
   195HUMAN
   195RABBIT
   195GUINEAPIG
   192MOUSE
   192RAT
   195DOG
VIALDRYWAITDALEYSKRRTAGHAAAMIAIVWAISICISIPPLFWRQARAHEEISDCLVNTSQI
VIALDRYWAITDALEYSKRRTAGHAATMIAIVWAISICISIPPLFWRQAKAQEEMSDCLVNTSQI
VIALDRYWAITDALEYSKRRTAGHAAAMIAVVWAISICISIPPLFWRQAKAHEEVSDCLVNTSQI
VIALDRYWAITDALEYSKRRTAGHAGAMIAAVWVISICISIPPLFWRQAQAQEEMSDCLVNTSQI
VIALDRYWAITDALEYSKRRTAGHAAAMIAAVWIISICISIPPLFWRQATAHEEMSDCLVNTSQI
VIALDRYWAITDALEYSKRRTAGHAAAMIAAVWAISICISIPPLFWRQATAHEEMSDCLVNTSQI
VIALDRYWAITDALEYSKRRTAGRAAVMIATVWVISICISIPPLFWRQAKAQEDMSDCQVNTSQI
   260PIG
   260HUMAN
   260RABBIT
   260GUINEAPIG
   257MOUSE
   257RAT
   260DOG
SYTIYSTCGAFYIPSLLLIILYGRIYRAARNRILNPPSLYGKRFTTAHLITGSAGSSLCSLNPSL
SYTIYSTCGAFYIPSVLLIILYGRIYRAARNRILNPPSLYGKRFTTAHLITGSAGSSLCSLNSSL
SYTIYSTCGAFYIPSVLLIVLYGRIYMAARNRILNPPSLYGKRFTTAHLITGSAGSSLCSLSPSL
SYTIYSTCGAFYIPSVLLIILYSRIYRAARSRILNPPSLSGKRFTTAHLITGSAGSSLCSLNPSL
SYTIYSTCGAFYIPSILLIILYGRIYVAARSRILNPPSLYGKRFTTAQLITGSAGSSLCSLNPSL
SYTIYSTCGAFYIPSILLIILYGRIYVAARSRILNPPSLYGKRFTTAQLITGSAGSSLCSLNPSL
SYTIYSTCGAFYIPSVLLIILYGRIYVAARNRILNPPSLYGKRFTTAQLITGSAGSSLCSLSPSL
   324PIG
   324HUMAN
   324RABBIT
   323GUINEAPIG
   321MOUSE
   321RAT
   324DOG
HEEHAHSA.GSPLFFNHVKIKLADSVLERKRISAARERKATKTLGIILGAFIICWLPFFVASLVL
HEGHSHSA.GSPLFFNHVKIKLADSALERKRISAARERKATKILGIILGAFIICWLPFFVVSLVL
GEGHSHSA.GSPLFFNPVRIKLADSVLERKRISAARERKATKTLGIILGAFIGCWLPFFVASLVL
HEGHMHP..GSPLFFNHVRIKLADSVLERKRISAARERKATKTLGIILGAFIVCWLPFFVVSLVL
HESHTHT.VGSPLFFNQVKIKLADSILERKRISAARERKATKTLGIILGAFIICWLPFFVVSLVL
HESHTHT.VGSPLFFNQVKIKLADSILERKRISAARERKATKTLGIILGAFIICWLPFFVVSLVL
QEERSHAA.GPPLFFNHVQVKLAEGVLERKRISAARERKATKTLGIILGAFIVCWLPFFVASLVL
   377PIG
   377HUMAN
   377RABBIT
   376GUINEAPIG
   374MOUSE
   374RAT
   377DOG
PICRDSCWIHPALFDFFTWLGYLNSLINPIIYTVFNEEFRQAFQKVVHFRKAS
PICRDSCWIHPALFDFFTWLGYLNSLINPIIYTVFNEEFRQAFQKIVPFRKAS
PICRDSCWMPPGLFDFFTWLGYLNSLINPIIYTVFNEDFRQAFQRVIHFRKAF
PICRDSCWIHPALFDFFTWLGYLNSLINPIIYTVFNEDFRQAFQKVVHFRKAS
PICRDSCWIHPALFDFFTWLGYLNSLINPVIYTVFNEDFRQAFQKVVHFRKAS
PICRDSCWIHPALFDFFTWLGYLNSLINPVIYTVFNEDFRQAFQRVVHFRKAS
PICRASCWLHPALFDFFTWLGYLNSLINPIIYTVFNEEFRQAFQRVVHVRKAS
  
 
Figure 3.4. Comparison of amino acid sequences of the pig 5-HT1D receptor with 
human (GenBank accession number M89955), rabbit (Z50162), guinea pig (X94436), 
mouse (X94908), rat (M89953) and dog (X14049) 5-HT1D receptors (software 
DNAMAN, version 3.2, Lynnon Biosoft©).  The arrows drawn across the amino acid 
sequence indicate the seven transmembrane regions.  Shaded boxes show identity 
across the different species. 
 
In the intervening portion (not shown in the figure), there were only 
20 nucleotidesderived from the porcine genomic DNA, where the EcoR1 site was 
present 5 nucleotides away from 3’ end and 15 nucleotides before 5’ end. 
Figure 3.4 compares the amino acid sequence of porcine 5-HT1D receptor with 
those of other mammalian species.  It should be noted that towards the N-terminal of 
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porcine 5-HT1D receptor a number of amino acids (Val8,36, Asp10, Gly14, Thr15, Lys27, 
Pro97 and Glu102) were different from those in the other species.  However, there was a 
high homology in the overall sequence of the receptor across the species (from 88% in 
dog to 92% in humans).  Between the pig and human, the transmembrane-3 and 
transmembrane-7 regions showed an identical sequence while the remaining 
transmembrane regions showed a 92-96% homology. 
Binding properties of recombinant porcine 5-HT1D Receptor 
Membrane preparations from COS-7 cells transfected with porcine 5-HT1D receptor 
showed high affinity for the agonist [3H]5-CT as well as the antagonist 
[3H]GR125743.  The equilibrium dissociation constant (Kd) of [3H]5-CT and 
[3H]GR125743 for the porcine 5-HT1D receptor was, respectively, 1.08±0.04 nM and 
1.47±0.13  nM (both n=3).  The Bmax of [3H]GR125743 binding 
(2.70±0.59 pmol mg-1 protein; n=3) was about one and a half times as high as that of 
[3H]5-CT binding (1.74±0.04 pmol mg-1 protein; n=3), suggesting that part of the 
5-HT1D receptor population was in the high affinity state. 
Table 3.1 shows pKi values of a number of 5-HT receptor agonists and 
antagonists for the displacement of [3H]5-CT and [3H]GR125743 from membranes 
obtained from COS-7 cells expressing the cloned porcine 5-HT1D receptor.  There was 
an excellent correlation (rS=0.984; p≤0.05) between values obtained with the two 
radioligands.  The rank order of affinity of agonists was L694247 > 5-CT > 
zolmitriptan > 5-HT > sumatriptan = CP122638 = ergotamine > dihydroergotamine, 
while that of the antagonists was methiothepin > GR127935 > ketanserin > ritanserin 
>> SB224289 ≥ BRL 15572. 
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Table 3.1.  pKi values for a series of serotonergic compounds for the inhibition of  [3H]5-CT 
and [3H]GR125743 binding to cloned pig 5-HT1D receptor expressed in Cos-7 cells 
 
Compound [3H]5-CT  [3H]GR125743 
Agonists   
L694247 9.29±0.01 9.50±0.03 
5-CT 8.79±0.06 9.00±0.05 
Zolmitriptan 8.38±0.15 8.67±0.08 
5-HT 8.22±0.12 8.40±0.09 
Sumatriptan 7.97±0.04 8.06±0.04 
CP122638 7.84±0.11 8.67±0.08 
Ergotamine 8.00±0.04 7.89±0.03 
Dihydroergotamine 7.87±0.12 7.73±0.24 
Antagonists   
Methiothepin 8.74±0.06 8.81±0.14 
GR127935 7.92±0.18 7.98±0.17 
Ketanserin 7.17±0.06 7.42±0.04 
Ritanserin 6.80±0.13 7.26±0.18 
SB224289 6.15±0.22 6.39±0.08 
BRL15572 5.94±0.09 5.93±0.09 
Data are mean±s.e.mean (n=3-7).  The pKi values obtained with the two ligands correlated 
significantly (Spearman correlation coefficient rS=0.984; p≤0.05, SlideWrite plus for 
Windows, Advanced Graphics Software, Encinitas, CA, USA). 
 
In Figure 3.5, the affinity constants of the 14 compounds (8 agonists and 6 
antagonists; see Table 3.1) investigated in the present experiments with the cloned pig 
5-HT1D receptor have been plotted against values obtained earlier with the same 
compounds using membranes from cells expressing the human 5-HT1B or 5-HT1D 
receptor (Pauwels et al., 1996).  The correlation between the affinity constants at the 
cloned porcine 5-HT1D receptor, particularly using [3H]GR125743 as ligand, was 
clearly higher with the cloned human 5-HT1D than with  5-HT1B receptor (rs=0.903 
and 0.608, respectively; Figure 3.5, right panels).  Admittedly, this difference was not 
as great using [3H]5-CT as ligand (rs=0.724 and 0.716, respectively; Figure 3.5, left 
panels).   
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Figure 3.5. Regression analysis of pKi values (affinity constants) of 5-HT receptor 
ligands for the cloned pig 5-HT1D receptor (see Table 3.1 for ligands and data) against 
the cloned human 5-HT1D (upper panels) and 5-HT1B (lower panels) receptors (data 
from Pauwels et al., 1996; Wurch et al., 1998), using either [3H]5-CT (left panels) 
or [3H]GR125743 (right panels).  The Spearman correlation coefficient rS, calculated 
by using SlideWrite plus for Windows (Advanced Graphics Software, Encinitas, CA, 
USA), is listed in each panel.  The compounds clearly falling outside the regression 
line (BRL15572 and SB224289) are identified in the graphs. 
 
However, it is interesting to point out that the selective antagonist at the human 
5-HT1D receptor, BRL15572 (Price et al., 1997; Schlicker et al., 1997), displayed 
much less affinity at the pig 5-HT1D receptor (Figure 3.5, upper panels).  As can be 
expected, the selective antagonist at the human 5-HT1B receptor, SB224289 (Gaster et 
al., 1998; Selkirk et al., 1998), did not show a high affinity at the pig 5-HT1D receptor 
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(Figure 3.5, lower panels).  When BRL15572 was excluded from analysis, the 
correlation between the pKi values at pig and human 5-HT1D receptors was increased 
(rs=0.798 and 0.957 using [3H]5-CT and [3H]GR125743, respectively), but that 
between pig 5-HT1D and human 5-HT1B receptors was decreased  (rs=0.602 and 0.386 
using [3H]5-CT and [3H]GR125743, respectively). 
[35S]GTPγS binding 
The basal [35S]GTPγS binding in membranes obtained from CHO-K1 cells 
co-expressing the cloned porcine 5-HT1D receptor and the rat Gαi1Cys351Ile protein 
was 277±37 fmol [35S]GTPγS mg-1 protein.   
 
 
Figure 3.6. Increase in [35S]GTPγS binding, as percentage of the response to 10 µM 
5-HT, by zolmitriptan in CHO-K1 cells co-transfected with the cloned pig 5-HT1D 
receptor and rat Gαi1Cys351Ile protein.  The basal [35S]GTPγS binding (277±37 
fmol mg-1 protein) was increased by 5-HT (10 µM)  to 399±77 fmol mg-1 protein 
(44%) and decreased by ketanserin (10 µM)  to 220±23 fmol mg-1 protein (-25%). 
 
5-HT (10 µM) elicited an increase of 44% over the basal level.  Zolmitriptan 
caused a concentration-dependent increase in [35S]GTPγS binding and elicited a near 
full agonist response at the receptor (83±6% increase as compared to 10 µM 5-HT; 
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Figure 3.6).  The potency of zolmitriptan (pEC50: 8.46±0.08) was found to be close to 
the binding affinity at the porcine 5-HT1D receptor (pKi 8.38 and 8.67, see Table 3.1).  
The putative 5-HT1D receptor antagonist, ketanserin (10 µM), decreased basal 
[35S]GTPγS binding by about 25%, thus exhibiting a negative efficacy. 
Discussion 
Sequence of Porcine 5-HT1D receptor 
Using primers based on the nucleotide sequence of the guinea pig 5-HT1D receptor 
gene (Wurch et al., 1997; Zgombick et al., 1997) and cDNA derived from porcine 
cerebral cortex, a band of expected fragment size (~1140 bp) was amplified, cloned 
and sequenced.  The BLAST search of the cloned porcine cDNA fragment revealed 
high resemblance with previously cloned 5-HT1D receptors.  The full-length 
nucleotide sequence containing 1137 bp encoded a 377 amino acid peptide, which 
showed a close (88-92%) similarity with the human (Hamblin et al., 1991; Weinshank 
et al., 1992), rabbit (Harwood et al., 1995), guinea pig (Wurch et al., 1997; Zgombick 
et al., 1997), mouse (Wurch et al., 1997), rat (Hamblin et al., 1991; Wurch et al., 
1997) and dog (Zgombick et al., 1991) 5-HT1D receptor.  The similarity with the 
human 5-HT1D receptor in the predicted seven transmembrane regions was even 
higher (92-100%).  Moreover, the full-length amino acid sequence completely 
matched the partial sequence of the porcine 5-HT1D receptor, previously submitted to 
the GenBank by T. Wurch and colleagues (accession number P79400).  Thus, the 
nucleotide sequence of the mRNA obtained from the porcine cerebral cortex encodes 
the 5-HT1D receptor. 
 The computer-predicted hydrophobicity showed seven transmembrane 
spanning regions as well as putative N-linked glycosylation sites also observed in 
5-HT1D receptors from the other species (Wurch et al., 1997).  However, the 
N-terminal of porcine 5-HT1D receptor  (see Figure 3.3) showed several unique amino 
acids not present in other species (Harwood et al., 1995; Wurch et al., 1997).  The 
divergent nucleotides within the 5’ (N) and 3’ (C) ends were confirmed by inverse 
PCR using primers based on the derived sequence of the porcine 5-HT1D receptor.  It 
may, however, be noted that the threonine residue, being the seventh amino acid in the 
transmembrane-7 region of thus far cloned 5-HT1D (Thr342) as well as non-rodent 
5-HT1B (Thr355) receptors (see Harwood et al., 1995; Pregenzer et al., 1997; Wurch et 
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al., 1997; Zgombick et al., 1997; Zgombick et al., 1991), was conserved.  The 
presence of threonine at this position seems to be important for the largely similar 
ligand binding properties of 5-HT1B and 5-HT1D receptors.  Interestingly, a single 
amino acid change at the seventh residue (from Thr354/355 in non-rodent species to 
Asp351 in the rat or mouse) in the 5-HT1B receptor is known to confer major 
pharmacological differences between the two groups of 5-HT1B receptors (Oksenberg 
et al., 1992; Zgombick et al., 1997). 
Ligand binding properties of porcine 5-HT1D receptor 
The cloned porcine 5-HT1D receptor expressed in COS-7 cells showed high affinity 
for the two 5-HT1B/D receptor radioligands ([3H]5-CT and [3H]GR125743) and the 
rank order of agonists (L694247 > 5-CT > zolmitriptan > 5-HT > sumatriptan = 
CP122638 = ergotamine > dihydroergotamine) as well as antagonists (methiothepin > 
GR127935 > ketanserin > ritanserin >> SB224289 ≥ BRL 15572) affinity was found 
to be the same using either radioligand.  The affinity constants of these 14 compounds 
obtained in the present experiments with the cloned porcine 5-HT1D receptor showed a 
high correlation with those previously reported with the cloned human 5-HT1D 
receptor (Figure 3.5, Pauwels et al., 1996).  However, the most salient finding in the 
present investigation was that BRL15572, which behaves as a selective antagonist at 
the human 5-HT1D receptor (Price et al., 1997; Schlicker et al., 1997), did not show 
high affinity at the porcine 5-HT1D receptor.  The profound implications of this 
finding are obvious; a ligand selectively recognising a particular receptor may fail at 
other species homologues.  Indeed, this is also the case with ketanserin, which has a 
moderate selectivity for the 5-HT1D over the 5-HT1B receptors in the human (Pauwels 
et al., 1996; Zgombick et al., 1995), rabbit (Bard et al., 1996; Harwood et al., 1995), 
rat (Bach et al., 1993; Weinshank et al., 1992) and guinea pig (Wurch et al., 1997), 
but not in the dog (Zgombick et al., 1991).  Similarly, certain isochroman derivatives 
show a differential pharmacology at the guinea pig and gorilla 5-HT1D receptors 
(Pregenzer et al., 1997).  Such species differences in the pharmacology of homologue 
receptors can be used to explore the role of divergent amino acid residues in the 
receptor-ligand interaction as well as the validation of animal models with respect to 
drug discovery for human diseases. 
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In view of the poor affinity of BRL15572 at the cloned porcine 5-HT1D receptor, 
we have to admit that the use of this compound by us to rule out the involvement of 
5-HT1D receptor in the sumatriptan-induced constriction of porcine carotid 
arteriovenous anastomoses (De Vries et al., 1999b) was not adequate.  However, the 
conclusions that the response to sumatriptan is mediated by 5-HT1B receptor still 
seems valid, since both selective (SB224289, Gaster et al., 1998; Selkirk et al., 1998) 
as well as non-selective (GR127935, Pauwels et al., 1996; Skingle et al., 1996) 
5-HT1B receptor antagonists potently antagonised the carotid arteriovenous 
anastomotic constriction by sumatriptan (De Vries et al., 1996; De Vries et al., 
1999c). 
Functional characterisation of porcine 5-HT1D receptor 
Functional properties of recombinant 5-HT1D receptors have been established using 
predominantly cellular responses employing cAMP and [35S]GTPγS binding assays 
(Pauwels et al., 1996; Pauwels et al., 1997; Thomas et al., 1995). Using membranes 
from cells co-expressing the porcine 5-HT1D receptor and rat Gαi1Cys351Ile protein, we 
showed that 5-HT (10 µM) increased basal [35S]GTPγS binding by 44% and that 
zolmitriptan behaved as a near full agonist in this respect.  This result is in agreement 
with earlier observations on recombinant human 5-HT1D receptor (Pauwels et al., 
1997).  Moreover, as can be expected, the potency of zolmitriptan in the [35S]GTPγS 
binding assay (pEC50: 8.46±0.08, see Figure 3.6) closely agreed with its affinity in the 
ligand binding assay (pKi 8.38 and 8.67, see Table 3.1).  Finally, the putative 5-HT1D 
receptor antagonist ketanserin (10 µM) inhibited basal [35S]GTPγS binding, thus 
exhibiting negative efficacy (inverse agonism) as noticed earlier using the 
recombinant human 5-HT1D receptor (Pauwels et al., 1997; Thomas et al., 1995). 
In conclusion, we have established the cDNA sequence of cloned porcine 5-HT1D 
receptor, which shows a similar ligand binding profile as the cloned human 5-HT1D 
receptor, except that BRL15572, a selective antagonist at the human 5-HT1D receptor, 
is not recognised by the porcine homologue.  As shown by the increase in [35S]GTPγS 
binding, the cloned porcine 5-HT1D receptor is also functionally active. 
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Chapter 4 
Molecular cloning and expression of the porcine trigeminal ganglion 
cDNA encoding a 5-ht1F receptor 
Summary Using a combination of reverse transcription polymerase 
chain reaction (RT-PCR) and inverse-PCR techniques, we amplified, 
cloned and sequenced a full-length porcine 5-hydroxytryptamine 1F 
(5-ht1F) receptor complementary DNA (cDNA) derived from porcine 
trigeminal ganglion.  Sequence analysis revealed 1101 base pairs (bp) 
encoding an open reading frame of 366 amino acids showing a high 
similarity (>90%) with the 5-ht1F receptor sequences from other species, 
including human.  The recombinant porcine 5-ht1F receptor was 
expressed in African green monkey kidney cell lines (COS-7 cells) and 
its ligand binding profile was determined using [3H]5-HT.  The affinities 
of several agonists (LY334370 (5-(4-fluorobenzoyl)amino-3-(1-
methylpiperidin-4-yl)-1H-indole fumarate) > CP122638 (N-methyl-3 
[pyrrolidin 2(R)-yl methyl]-1H-indol-5-ylmethyl sulphonamide) = 
naratriptan = 5-HT > eletriptan > sumatriptan > frovatriptan = avitriptan 
> dihydroergotamine > zolmitriptan > 5-carboxamidotryptamine > 
rizatriptan > alniditan = donitriptan > L694247 (2-[5-[3-
(4-methylsulphonylamino)benzyl-1,2,4-oxadiazol-5-yl]-1H-indole-3-yl] 
ethylamine) and putative antagonists (methiothepin > GR127935 
(N-[4-methoxy-3-(4-methyl-1-piperazinyl) phenyl]-2'-methyl 
4'-(5-methyl-1,2,4-oxadiazol-3-yl) [1,1-biphenyl]-4-carboxamide 
hydrochloride) > ritanserin > SB224289 (2,3,6,7-tetrahydro-1’-methyl-
5-[2’-methyl-4’(5-methyl-1,2,4-oxadiazol-3-yl) biphenyl-4-carbonyl] 
furo [2,3-f] indole-3-spiro-4`-piperidine hydrochloride) > BRL155572 
([1-(3-chlorophenyl)-4-[3,3-diphenyl (2-(S,R) hydroxypropanyl)-
piperazine] hydrochloride) > ketanserin = pindolol) correlated highly 
with those described for the recombinant human 5-ht1F receptor 
(Spearman correlation coefficient; rS=0.942).  Nevertheless, as compared 
to the human homologue, some triptans (i.e. sumatriptan, zolmitriptan 
and rizatriptan) displayed a 10- to 15-fold lower affinity for the porcine 
5-ht1F receptor.  Using RT-PCR technique, the expression of porcine 
5-ht1F receptor mRNA was observed in cerebral cortex, trigeminal 
ganglion and several blood vessels, but not in skeletal muscles.  In 
conclusion, we have cloned and established the amino acid sequence and 
ligand binding profile of the porcine 5-ht1F receptor as well as the 
distribution of its mRNA.  This information may be helpful in exploring 
the role of 5-ht1F receptor in physiological processes and diseases, such 
as migraine. 
 
Based on: Bhalla, P., Sharma, H.S., Wurch, T., Pauwels, P.J. & Saxena, P.R. (2001). 
Molecular cloning and expression of the porcine trigeminal ganglion cDNA encoding a 5-ht1F 
receptor.  Eur J Pharmacol: Submitted 
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Introduction 
The physiological actions of serotonin (5-hydroxytryptamine, 5-HT) are mediated by 
multiple types of serotonin receptors and the characterisation (molecular, 
pharmacological and operational) of these receptors helps to recognise their 
importance as therapeutic targets (Barnes & Sharp, 1999; Hoyer et al., 1994; Saxena, 
1995).  Since the acute antimigraine agents (ergot alkaloids and triptans) display high 
affinity at 5-HT1B, 5-HT1D and 5-ht1F receptors, it became apparent that these 
receptors may be important targets for antimigraine drugs (Adham et al., 1993; 
Johnson et al., 1997; Leysen et al., 1996; Saxena & Tfelt-Hansen, 2000).  An 
important feature of these antimigraine drugs is cranial vasoconstriction, which is 
mediated by the 5-HT1B, rather than the 5-HT1D or 5-ht1F,  receptor (Bouchelet et al., 
2000; De Vries et al., 1999; Razzaque et al., 1999).  On the other hand, 5-HT1D and 
5-ht1F receptors have been shown to be primarily involved in triptan-induced 
inhibition of neurogenic dural plasma protein extravasation (Goadsby, 1999; 
Humphrey, 1991; Moskowitz, 1992; Phebus et al., 1997).  The presence of 5-HT1D 
and 5-ht1F receptor have been shown in the trigeminal ganglion (Bruinvels et al., 
1994; Waeber & Moskowitz, 1995) and that agonists at these receptors, for example 
PNU109291 ([(S)-(-)-1-[2-[4-(4-methoxyphenyl)-1-piperazinyl]ethyl]-N-methyl-
isochroman-6-carboxamide]) and LY344864 ([(R)-(+)-N-[3-(N,N-dimethylamino)-
1,2,3,4-tetrahydrocarbazol-6-yl]-4-fluoro-benzamide]) respectively, inhibit 
neurogenic dural inflammation (Ennis et al., 1998; Johnson et al., 1997; Phebus et al., 
1997).  Moreover, some recent reports also showed the role of 5-ht1F receptor in 
modulating c-fos protein expression and glutamate release in trigeminal ganglion and 
trigeminal nucleus caudalis in rats (Ma, 2001; Mitsikostas et al., 1999).  Even though 
a direct role of the 5-ht1F receptor in vasoconstriction has recently been ruled out 
(Bouchelet et al., 2000; Razzaque et al., 1999; Villalón et al., 1999), it is conceivable 
that the 5-ht1F receptor may indirectly affect vasomotor activity via the 
trigeminovascular system. 
Recently, we have cloned and sequenced the recombinant porcine 5-HT1B 
(Bhalla et al., 2001) and 5-HT1D (Bhalla et al., 2000) receptors, which possess a 
pharmacological profile very similar to those described for their human homologues.  
A notable exception, however, was BRL15572, a selective antagonist at the human 
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5-HT1D receptor (Price et al., 1997); BRL15572 poorly recognised the recombinant 
porcine 5-HT1D receptor (Bhalla et al., 2000).  In the present study, we have cloned, 
sequenced the porcine 5-ht1F receptor (p5-ht1F; R.C.: 2.1.5HT.01F) and studied its 
ligand-binding profile and tissue distribution. 
Methods 
PCR amplification and cloning of 5-ht1F receptor cDNA 
Porcine specific 5-ht1F receptor cDNA was amplified using a combination of RT-PCR 
and inverse-PCR techniques; for details see Bhalla et al. (2000; 2001).  cDNA was 
synthesised from RNA extracted from trigeminal ganglia obtained from a pig 
(Yorkshire x Landrace, female, 12 kg).  The quality of RNA and cDNA preparations 
was checked by PCR amplification of β-actin (Ponte et al., 1984). 
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Figure 4.1. Diagrammatic representation showing the methodology for cloning of the 
full-length porcine 5-ht1F receptor and the positions of various primers used for PCR 
amplification.  A. Unknown full-length porcine 5-ht1F receptor cDNA with 5’ (a) and 
3’ (b) end primers designed from known sequence from other species.  B. The 
amplified full-length product containing a partial sequence of porcine 5-ht1F receptor 
and the 5’ and 3’ end sequences derived from other species (hatched rectangles).  The 
partial sequence of porcine 5-ht1F receptor was used to design porcine-specific inverse 
primers (c) and (d).  C. The inverse-PCR amplified partial genomic sequence was used 
to design porcine specific primers (e) and (f) for amplifying the full-length porcine 
5-ht1F receptor cDNA.  D. The full-length amplified product of porcine 5-ht1F receptor 
cDNA. 
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As depicted in Figure 4.1, a PCR product containing a partial sequence of 
porcine 5-ht1F receptor cDNA was amplified using a forward 
(5’-ATGGATTTCTTAAACTCATCT-3’, nucleotides 1-21) and a reverse 
(5’-CTAATATCGACATCGTACAAG-3; nucleotides 1081-1101) oligonucleotide 
primers (Figure 4.1A, a and b), designed on the basis of consensus sequence of 5-ht1F 
receptors from other species (Adham et al., 1997; Adham et al., 1993; Amlaiky et al., 
1992; Lovenberg et al., 1993).  The amplified PCR products were separated on 1% 
agarose gel in TBE (100mM Tris, 90mM boric acid and 1mM 
ethylenediaminetetraacetic acid (EDTA)) buffer containing ethidium bromide, 
visualised under UV light and photographed.  The purified PCR products were then 
ligated into the pGEMT-Easy vector and transformed into competent JM109 cells.  
Four insert positive clones were processed for isolation of the plasmid DNA and 
sequencing. 
Since the forward and reverse oligonucleotide primers used in RT-PCR for 
amplification were based on a consensus sequence derived from other species, we 
identified the 5’ and 3’ ends of recombinant porcine cDNA by inverse-PCR (Ochman 
et al., 1988).  Porcine genomic DNA was digested with BamH1 restriction enzyme, as 
the cloned 5-ht1F receptor cDNA did not show any restriction site for BamH1.  After 
purification, the restricted DNA was ligated overnight at 16 °C in the presence of 
T4-DNA ligase in order to obtain DNA circles.  Using inverse primers based on the 
derived porcine cDNA sequence (5’-GCAGCTTTCGGGTCACAATAA-3’ for 5’ end 
and 5’-TTGCCAAGGAGGAACTGAATG-3’ for 3’ end; Figure 4.1B, c and d), the 
ligated DNA fragments were subjected to PCR amplification.  The PCR products 
were separated on a 1% agarose gel, purified, cloned and sequenced.  Finally, porcine 
specific forward (5’-ATGGATTTCTCAAACTCATCT-3’) and reverse 
(5’-CTAACACCGACACATCGCACA-3’) oligonucleotide primers, designed from 
the sequences generated from inverse-PCR (Figure 4.1C, e and f), were used to 
amplify the full-length 5-ht1F receptor cDNA from the porcine trigeminal ganglion 
(Figure 4.1D). 
The full-length cDNA sequence of porcine 5-ht1F receptor was derived from at 
least two independent PCR amplified products and further verified by multiple partial 
sequences derived from genomic DNA amplified products (inverse-PCR).  In sporadic 
cases showing nucleotide discrepancy in the sequence, the nucleotide having a clear 
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majority in clones was preferred for establishing the final full-length cDNA sequence, 
using the DNAMAN sequence analysis program (Version 3.2, Lynnon Biosoft© 
1994-1997).  The final sequence was translated as a peptide sequence and compared 
with those in the GenBank (BLAST search at National Centre for Biotechnology 
Information, Bethesda, MD, USA; web site: http://www.ncbi.nlm.nih.gov/BLAST/).  
The hydrophobic regions indicating putative transmembrane domains and sequence 
homology with known 5-ht1F receptors from other species were established. 
Transient transfection and radioligand binding assay 
The purified full-length pig 5-ht1F receptor cDNA insert was subcloned into 
dephosphorylated eukaryotic expression vector, pcDNA3 (Invitrogen, San Diego, Ca, 
USA).  Monkey COS-7 cells were transiently transfected with the recombinant 
plasmid and membranes were prepared for radioligand binding assays using 
8.0 nM [3H]5-HT (Pauwels et al., 1996).  Incubation mixtures consisted of 0.40 ml of 
cell membrane preparation (30-50 µg of protein), 0.05 ml of [3H]5-HT and 0.05 ml of 
compounds for inhibition or 10 µM 5-HT to determine non-specific binding.  The 
reaction was terminated by filtration over a Whatman GF/B glass-fibre filter with 
ice-cold Tris-buffer and the radioactivity on the filter paper was measured by using a 
liquid scintillation counter.  Data were analysed graphically with inhibition curves and 
IC50 values were derived.  Binding affinity constants (Ki values) were calculated 
according to the equation Ki = IC50/(1+C/KD), where C is the concentration and KD is 
the equilibrium dissociation constant of the radioligand.  Radioligand saturation 
binding curves were analysed by a non-linear least square curve-fitting programme to 
determine equilibrium dissociation constant (KD) and maximum binding site density 
(Bmax) values (Munson & Rodbard, 1980).  Control binding experiments were run 
with non-transfected COS-7 cells and they did not display detectable specific 
[3H]5-HT binding. 
RT-PCR for 5-ht1F receptor mRNA detection  
The expression of 5-ht1F receptor mRNA was studied by RT-PCR technique in a 
number of porcine tissues (brain cortex, cerebellum, trigeminal ganglion, skeletal 
muscles, saphenous vein and mesenteric, coronary and pulmonary arteries) obtained 
from four pigs previously used in acute haemodynamic experiments, as described in 
detail earlier (Bhalla et al., 2001).  The purified total RNA samples from the tissues 
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were reverse transcribed into cDNA in the absence (control reaction to monitor DNA 
contamination) or presence of reverse transcriptase enzyme.  Porcine specific sense 
(5’-CCAAGCAGGCTGGCATTATG-3’, nucleotides 410 bp-429 bp) and antisense 
(5’-GCTTTGCGTTCTCTTGTGCC-3’, nucleotides 853 bp-872bp) primers were used 
for the amplification of partial porcine 5-ht1F receptor cDNA.  The PCR amplified 
products were separated on 2% agarose gel by electrophoretic separation, stained with 
ethidium bromide, visualised under UV light and photographed. 
Materials 
All oligonucleotide primers were commercially procured from Life Technologies b.v. 
(Breda, The Netherlands).  Various chemicals used in this study were of molecular 
biology and/or culture grade.  pGEMT-Easy vector system, Wizard® PCR prep and 
mini-prep DNA purification systems were purchased from Promega Benelux b.v. 
(Leiden, The Netherlands).  Oligotex mRNA purification kit was purchased from 
Qiagen GmbH (Hilden, Germany).  AmpliTaqGold and dye terminator/cycle 
sequencing ready reaction kit were procured from Perkin Elmer Applied Biosystem 
Benelux (Nieuwerkerk a/d Ijssel, The Netherlands). 
The compounds used in pharmacological assays were: alniditan, avitriptan, 
BRL15572 (gift: Dr. A.A. Parsons, GlaxoSmithKline, Harlow, Essex, UK), 
5-carboxamidotryptamine, CP122638 (N-methyl-3 [pyrrolidin 2(R)-yl 
methyl]-1H-indol-5-ylmethyl sulphonamide), dihydrergotamine, eletriptan, 
frovatriptan, GR127935 (N-[4-methoxy-3-(4-methyl-1-piperazinyl) phenyl]-2'-methyl 
4'-(5-methyl-1,2,4-oxadiazol-3-yl) [1,1-biphenyl]-4-carboxamide hydrochloride, 
[3H]5-HT (80-130 Ci mmol-1, Amersham, Les Ulis, France), 5-HT creatinine sulphate 
(Sigma Chemicals, St. Louis, MO, USA), ketanserin (Sigma Chemicals, St. Louis, 
MO, USA), L694247 2-[5-[3-(4-methylsulphonylamino)benzyl-1,2,4-
oxadiazol-5-yl]-1H-indole-3-yl] ethylamine, LY334370 (5-(4-fluorobenzoyl)amino-
3-(1-methylpiperidin-4-yl)-1H-indole fumarate), methiothepin, naratriptan, pindolol, 
ritanserin, SB224289 (2,3,6,7-tetrahydro-1’-methyl-5-[2’-methyl-
4’(5-methyl-1,2,4-oxadiazol-3-yl) biphenyl-4-carbonyl] furo [2,3-f] indole-3-spiro-
4`-piperidine hydrochloride, rizatriptan sumatriptan and zolmitriptan.  Except those 
specified above, all other compounds were synthesised at Centre de Recherche Pierre 
Fabre (Castres, France). 
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Results 
Cloning of porcine 5-ht1F receptor cDNA derived from trigeminal ganglion 
Using RT-PCR technique, the trigeminal ganglion cDNA yielded a full-length clone 
of approximately 1150 bp containing a partial sequence of porcine 5-ht1F receptor (see 
Figure 4.1B).   
CTTGTGCGATGTCGGTGTTAG
ATGGATTTCTCAAACTCATCT
      ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
3’end
3’end
Inverse-PCR (5’end)
1     ATGGATTTCTTAAACTCATCTTATCAAAACTCGACCTCGGAAGAACTGTTAAACAGAATG
      |||||||||| |||||||||||||||||||||||||||||||||||||||||||||||||
250   TATCAAAACTCGACCTCGGAAGAACTGTTAAACAGAATG
61    CCAGCCAAAATTCTGGTGTCCTTCATTCTCTCCGGGTTGGCACTGATGACAACGACCATC
      ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
310   CCAGCCAAAATTCTGGTGTCCTTCATTCTCTCCGGGTTGGCACTGATGACAACGACCATC
121   AACTCCCTTGTGATAGCTGCAATTATTGTGACCCGAAAGCTGC
      |||||||||||||||||||||||||||||||||||||||||||
370   AACTCCCTTGTGATAGCTGCAATTATTGTGACCCGAAAGCTGC
Inverse-PCR (3’end)
659   TTGCCAAGGAGGAACTGAATGGCCAAGTTCTTTTGGAGAGTGGTGAGAAAAGCAGTAGAC
      ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1     TTGCCAAGGAGGAACTGAATGGCCAAGTTCTTTTGGAGAGTGGTGAGAAAAGCAGTAGAC
719   TGGTCTCCACCCCATACATGCTAGAAAAGTCTTTATCTGACCCATCAACAGACTTTGATA
61    TGGTCTCCACCCCATACATGCTAGAAAAGTCTTTATCTGACCCATCAACAGACTTTGATA
779   AAATTCATAGCACAGTGAAAAGTCCCAGGTCTGAATTCAGGCATGAGAGATCTTGGAGAA
      ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
121   AAATTCATAGCACAGTGAAAAGTCCCAGGTCTGAATTCAGGCATGAGAGATCTTGGAGAA
839   GGCAAAAGATCTCAGGCACAAGAGAACGCAAAGCAGCCACTACCCTGGGTTTAATCTTGG
      ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||181   GGCAAAAGATCTCAGGCACAAGAGAACGCAAAGCAGCCACTACCCTGGGTTTAATCTTGG
899   GTGCATTTGTAATATGTTGGCTTCCTTTTTTTGTAAAAGAATTAGTTGTTAATGTCTGTG
      ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||241   GTGCATTTGTAATATGTTGGCTTCCTTTTTTTGTAAAAGAATTAGTTGTTAATGTCTGTG
959   AAAAGTGTAAAATTTCTGAAGAAATGTCAAATTTTTTGACATGGCTTGGATATCTCAATT
      ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||301   AAAAGTGTAAAATTTCTGAAGAAATGTCAAATTTTTTGACATGGCTTGGATATCTCAATT
1019  CCCTCATAAACCCGATGATTTATACAATCTTTAATGAAGACTTCAAGAAAGCATTCCAAA
      ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||361   CCCTCATAAACCCGATGATTTATACAATCTTTAATGAAGACTTCAAGAAAGCATTCCAAA
1079  AACTTGTACGATGTCGATATTAG
      ||||||| |||||||| | ||||
421    AA
5’end
5’end
 
Figure 4.2.  Sequence of inverse-PCR amplified products from porcine genomic DNA 
circles (in bold letters) showing a high homology with porcine cDNA sequence 
derived from trigeminal ganglion (in normal letters).  The deduced 5’ (N) and 3’ (C) 
terminal sequences of porcine 5-ht1F receptor are shown double underlined in boxes, 
while inverse-PCR primers are thick underlined.  Please note that, except for a single 
mismatch at the 5’ end and three mismatches at the 3’ end (identified by missing 
vertical bar), there was a complete identity between the porcine cDNA and genomic 
DNA sequences. 
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The nucleotide sequence showed a high homology with 5-ht1F receptors from other 
species (data not shown).  On the basis of this sequence, porcine specific inverse 
primers were designed and used on porcine genomic DNA circles to establish the 
sequence of 5’ and 3’ ends of the porcine 5-ht1F receptor by inverse-PCR (Figure 
4.1C).  A PCR product of approximately 1200 bp was amplified, cloned and 
sequenced.  Whereas sequence analysis revealed a single mismatch in the 5’ end and 
three mismatches in the 3’ end of the 5-ht1F receptor, there were no differences in the 
rest of the sequence derived from porcine 5-ht1F receptor cDNA and genomic DNA 
(Figure 4.2). 
The full-length porcine 5-ht1F receptor cDNA was finally amplified by using 
cDNA templates derived from poly(A+) mRNA of porcine trigeminal ganglion and 
porcine specific 5’ end (sense) and 3’ end (antisense) primers (Figure 4.1D) and 
agarose gel electrophoresis of RT-PCR products is shown in Figure 4.3.   
M 1 2 3 M 4 5 6
RT-PCR product Plasmid DNA
1353 bp →
603 bp →
310 bp →
M: Marker
1: β-actin control
2: Negative control
3: 1150 bp product
4: Uncut plasmid
5: Plasmid + insert
6: Plasmid + inserts
 
Figure 4.3. Agarose gel electrophoresis of RT-PCR products of cDNA synthesised 
from porcine trigeminal ganglion (left panel) and recombinant plasmid with insert 
cDNA (right panel).  The different lanes marked on the top denote: M, φx174 
DNA/Hae III marker; 1, Positive control showing a RT-PCR product of 625bp using 
β-actin primers; 2. Negative control, i.e. a sample without the reverse transcriptase 
enzyme to monitor genomic and/or PCR contamination; 3. A RT-PCR product of 
approximately 1150 bp obtained using porcine specific forward and reverse primers of 
5-ht1F receptor; 4. Non-digested recombinant plasmid DNA; 5. Recombinant plasmid 
DNA restricted with Not1 enzyme and showing a DNA insert of approximately 
1150 bp; 6. Recombinant plasmid DNA restricted with EcoR1 enzyme and showing 
two DNA fragments of approximately 800 bp and 300 bp.  The size of 3 marker bands 
is indicated in the left margin. 
The amplification of the porcine β-actin cDNA (approximately 625 bp) ensured 
that the quality of cDNA samples was adequate for amplification of other products, 
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while any genomic contamination was ruled out by the absence of any band in the 
RNA samples lacking reverse transcriptase.  The trigeminal ganglion cDNA showed a 
PCR product band of approximately 1150 bp, which was cloned into pGEMT Easy 
vector and sequenced.  When the recombinant plasmid was checked by restriction 
analysis, it yielded a full-length cloned product with Not1, whereas with EcoR1, used 
on the basis of a single restriction site in 5-ht1F receptors of other species (Adham et 
al., 1997; Adham et al., 1993; Amlaiky et al., 1992; Lovenberg et al., 1993), resulted 
into two bands of 800 bp and 300 bp. 
z PKA-phosphorylation;+ N-glycosylation;  PKC-phosphorylation
+ +
1    ATG GAT TTC TCA AAC TCA TCT TAT CAA AAC TCG ACC TCG GAA GAA CTG TTA AAC AGA ATG
1    MET Asp Phe Ser Asn Ser Ser Tyr Gln Asn Ser Thr Ser Glu Glu Leu Leu Asn Arg Met
61   CCA GCC AAA ATT CTG GTG TCC TTC ATT CTC TCC GGG TTG GCA CTG ATG ACA ACG ACC ATC
21   Pro Ala Lys Ile Leu Val Ser Phe Ile Leu Ser Gly Leu Ala Leu Met Thr Thr Thr Ile
121  AAC TCC CTT GTG ATA GCT GCA ATT ATT GTG ACC CGA AAG CTG CAC CAC CCA GCC AAC TAC
41   Asn Ser Leu Val Ile Ala Ala  Ile Ile Val Thr Arg Lys Leu His His Pro Ala Asn Tyr
181  TTA ATT TGC TCC CTT GCA GTC ACA GAC TTC CTT GTA GCT GTC CTG GTG ATG CCT TTC AGC
61   Leu Ile Cys Ser Leu Ala Val Thr Asp Phe Leu Val Ala Val Leu Val Met Pro Phe Ser
241  ATT GTG TAT ATT GTG AGA GAG AGT TGG ATT ATG GGA CAA GTG GTC TGC GAC ATT TGG CTG
81   Ile Val Tyr Ile  Val Arg Glu Ser Trp Ile Met Gly Gln Val Val Cys Asp Ile Trp Leu
301  AGT GTT GAC ATT ACA TGC TGC ACA TGC TCC ATC TTG CAT CTC TCT GCT ATA GCT TTG GAT
101  Ser Val Asp Ile Thr Cys Cys Thr Cys Ser Ile Leu His Leu Ser Ala Ile Ala Leu  Asp
                                                              
361  CGG TAC CGT GCA ATC ACA GAT GCT GTT GAG TAT GCC CAG AAA AGA ACT CCC AAG CAG GCT
121  Arg Tyr Arg Ala Ile Thr Asp Ala Val Glu Tyr Ala Gln Lys Arg Thr Pro Lys Gln Ala
421  GGC ATT ATG ATT ACC ATA GTA TGG ATT ATA TCT ATT TTT ATC TCT ATG CCT CCT CTA TTC
141  Gly Ile Met Ile Thr Ile Val Trp Ile Ile Ser Ile Phe Ile Ser Met Pro Pro Leu Phe
481  TGG AGG CAC CAA GGA ACT AGC CGA GAT GAT GAG TGC ATC ATC AAA CAC GAC CAC ATT GTT
161  Trp Arg  His Gln Gly Thr Ser Arg Asp Asp Glu Cys Ile Ile Lys His Asp His Ile Val
541  TCC ACT ATT TAC TCA ACA TTT GGA GCT TTC TAT ATC CCA TTA ACT TTA ATT TTG ATC CTC
181  Ser Thr Ile Tyr Ser Thr Phe Gly Ala Phe Tyr Ile Pro Leu Thr Leu Ile Leu Ile Leu
601  TAC TAC AAA ATA TAT AAA GCA GCA AAG ACA TTG TAT CAC AAG AGA CAA GCA AGT AGG ATT
201  Tyr Tyr  Lys Ile Tyr Lys Ala Ala Lys Thr Leu Tyr His Lys Arg Gln Ala Ser Arg Ile
661  GCC AAG GAG GAA CTG AAT GGC CAA GTT CTT TTG GAG AGT GGT GAG AAA AGC AGT AGA CTG
221  Ala Lys Glu Glu Leu Asn Gly Gln Val Leu Leu Glu Ser Gly Glu Lys Ser Ser Arg Leu
721  GTC TCC ACC CCA TAC ATG CTA GAA AAG TCT TTA TCT GAC CCA TCA ACA GAC TTT GAT AAA
241  Val Ser Thr Pro Tyr Met Leu Glu Lys Ser Leu Ser Asp Pro Ser Thr Asp Phe Asp Lys
                  
781  ATT CAT AGC ACA GTG AAA AGT CCC AGG TCT GAA TTC AGG CAT GAG AGA TCT TGG AGA AGG
261  Ile His Ser Thr Val Lys Ser Pro Arg Ser Glu Phe Arg His Glu Arg Ser Trp Arg Arg
841  CAA AAG ATC TCA GGC ACA AGA GAA CGC AAA GCA GCC ACT ACC CTG GGT TTA ATC TTG GGT
281  Gln Lys Ile Ser Gly Thr Arg Glu Arg Lys Ala Ala Thr Thr Leu Gly Leu Ile Leu Gly
901  GCA TTT GTA ATA TGT TGG CTT CCT TTT TTT GTA AAA GAA TTA GTT GTT AAT GTC TGT GAA
301  Ala Phe Val Ile Cys Trp Leu Pro Phe Phe Val Lys Glu Leu Val Val Asn Val Cys Glu
961  AAG TGT AAA ATT TCT GAA GAA ATG TCA AAT TTT TTG ACA TGG CTT GGA TAT CTC AAT TCC
321  Lys Cys Lys Ile Ser Glu Glu Met Ser Asn Phe Leu Thr Trp Leu Gly Tyr Leu Asn Ser
1021 CTC ATA AAC CCG ATG ATT TAT ACA ATC TTT AAT GAA GAC TTC AAG AAA GCA TTC CAA AAA
341  Leu Ile Asn Pro Met Ile Tyr Thr Ile Phe Asn Glu Asp Phe Lys Lys Ala Phe Gln Lys
1081 CTT GTG CGA TGT CGG TGT TAG
361  Leu Val Arg Cys Arg Cys ***
  I
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Figure 4.4. Nucleotide and deduced amino acid (in bold) sequences of recombinant 
porcine 5-ht1F receptor cDNA, derived from trigeminal ganglion (GenBank accession 
number: AF 255663).  Numbering of nucleotides and amino acids is shown on the left.  
Computer analysis (software DNAMAN, version 3.2, Lynnon Biosoft©) predicted a 
typical G-protein receptor structure with seven transmembrane domains I-VII 
(underlined) as well as putative N-glycosylation, protein kinase A phoshorylation and 
protein kinase C phoshorylation sites. 
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   120Human
   120Chimpanzee
   120Gorilla
   120Orangutan
   120Pig
   120Guineapig
   120Mouse
   120Rat
LICSLAVTDFLVAVLVMPFSIVYIVRESWIMGQVVCDIWLSVDITCCTCSILHLSAIALD
LICSLAVTDFLVAVLVMPFSIVYIVRESWIMGQVVCDIWLSVDITCCTCSILHLSAIALD
LICSLAVTDFLVAVLVMPFSIVYIVKESWIMGQVVCDIWLSVDITCCTCSILHLSAIALD
LICSLAVTDFLVAVLVMPFSIVYIVRESWIMGQVVCDIWLSVDITCCTCSILHLSAIALD
LICSLAVTDFLVAVLVMPFSIVYIVRESWIMGQVVCDIWLSVDITCCTCSILHLSAIALD
LICSLAVTDFLVAVLVMPFSIVYIVRESWIMGQVLCDIWLSVDIICCTCSILHLSAIALD
LICSLAVTDFLVAVLVMPFSIVYIVRESWIMGQVLCDIWLSVDIICCTCSILHLSAIALD
LICSLAVTDFLVAVLVMPFSIVYIVRESWIMGQGLCDLWLSVDIICCTCSILHLSAIALD
   180Human
   180Chimpanzee
   180Gorilla
   180Orangutan
   180Pig
   180Guineapig
   180Mouse
   180Rat
RYRAITDAVEYARKRTPKHAGIMITIVWIISVFISMPPLFWRHQGTSRDDECIIKHDHIV
RYRAITDAVEYARKRTPKHAGIMITIVWIISVFISMPPLFWRHQGTSRDDECIIKHXHIV
RYRAITDAVEYARKRTPKHAGIMITIVWIISVFISMPPLFWRHQGTSRDDECIIKHDHIV
RYRAITDAVEYARKRTPKHAGIMITIVWIISVFISMPPLFWRHQGTSRDDECIIKHDHIV
RYRAITDAVEYAQKRTPKQAGIMITIVWIISIFISMPPLFWRHQGTSRDDECIIKHDHIV
RYRAITDAVEYARKRTPKQAGIMITIVWIISVFISMPPLFWRHQGTSRDDECIIKHDHIV
RYRAITDAVEYARKRTPRHAGIMITIVWVISVFISMPPLFWRHQGTSRDDECVIKHDHIV
RYRAITDAVEYARKRTPRHAGITITTVWVISVFISVPPLFWRHQGNSRDDQCIIKHDHIV
   240Human
   240Chimpanzee
   240Gorilla
   240Orangutan
   240Pig
   240Guineapig
   240Mouse
   240Rat
STIYSTFGAFYIPLALILILYYKIYRAAKTLYHKRQASRIAKEEVNGQVLLESGEKSTKS
STIYSTFGAFYIPLALILILYYKIYRAAKTLYHKRQASRIAKEEVNGQVLLESGEKSTKS
STIYSTFGAFYIPLALILILYYKIYRAAKTLYHKRQASRIAKEEMNGQVLLESGEKSTKS
STIYSTFGAFYIPLALILILYYKIYRAAKTLYHKRQASRIAKEEVNGQVLLESGEKSTKS
STIYSTFGAFYIPLTLILILYYKIYKAAKTLYHKRQASRIAKEELNGQVLLESGEKSSRL
STIYSTFGAFYIPLVLILILYYKIYKAAKTLYHKRQASRIAKEELNGQVLLESGEKSIKM
STIYSTFGAFYIPLVLILILYYKIYRAARTLYHKRQASRMIKEELNGQVFLESGEKSIKL
STIYSTFGAFYIPLVLILILYYKIYRAARTLYHKRQASRMIKEELNGQVLLESGEKSIKL
   300Human
   300Chimpanzee
   300Gorilla
   300Orangutan
   300Pig
   300Guineapig
   300Mouse
   300Rat
VSTSYVLEKSLSDPSTDFDKIHSTVRSLRSEFKHEKSWRRQKISGTRERKAATTLGLILG
VSTSYVLEKSLSDPSTDFDKIHSTVRSLRSEFKHEKSWRRQKISGTRERKAATTLGLILG
VSTSYVLEKSLSDPSTDFDKIHSTVKSLRSEFKHEKSWRRQKISGTRERKAATTLGLILG
VSTPYVLEKSLSDPSTDFDKIHSTVRSLRSEFKHEKSWRRQKISGTRERKAATTLGLILG
VSTPYMLEKSLSDPSTDFDKIHSTVKSPRSEFRHERSWRRQKISGTRERKAATTLGLILG
VSTTYVPEKSLSDPSTDFDKIHNTVKSPRCKLRHEKSWRRQKISGTRERKAATTLGLILG
VSTSYMLEKSLSDPSTDFDRIHSTVKSPRSELKHEKSWRRQKISGTRERKAATTLGLILG
VSTSYMLEKSLSDPSTDFDRIHSTVKSPRSELKHEKSWRRQKISGTRERKAATTLGLILG
   360Human
   360Chimpanzee
   360Gorilla
   360Orangutan
   360Pig
   360Guineapig
   360Mouse
   360Rat
AFVICWLPFFVKELVVNVCDKCKISEEMSNFLAWLGYLNSLINPLIYTIFNEDFKKAFQK
AFVICWLPFFVKELVVNVCDKCKISEEMSNFLAWLGYLNSLINPLIYTIFNEDFKKAFQK
AFVICWLPFFVKELVVNVCDKCKISEEMSNFLAWLGYLNSLINPLIYTIFNEDFKKAFQK
AFVICWLPFFVKELVVNVCEKCKISEEMSNFLTWLGYLNSLINPLIYTIFNEDFKKAFQK
AFVICWLPFFVKELVVNVCEKCKISEEMSNFLTWLGYLNSLINPMIYTIFNEDFKKAFQK
AFVICWLPFFVKELVVNVCEKCKISEEMANFLAWLGYLNSLINPLIYTIFNEDFKKAFQK
AFVICWLPFFVKELVVNVCEKCKISEEMSNFLAWLGYLNSLINPLIYTIFNEDFKKAFQK
AFVICWLPFFVKELVVNICEKCKISEEMSNFLAWLGYLNSLINPLIYTIFNEDFKKAFQK
   366Human
   366Chimpanzee
   366Gorilla
   366Orangutan
   366Pig
   366Guineapig
   366Mouse
   366Rat
LVRCRC
LVRCRX
LVRCRX
LVRCRX
LVRCRC
LVRCQY
LVRCRY
LVRCRN
 
Figure 4.5. Comparison of amino acid sequences of the porcine 5-ht1F receptor 
(Swissprot accession number: AAG44634) with the human (P30939), chimpanzee 
(BAA90454), gorilla (BAA90455), orang-utan (BAA90456), guinea pig (O08890), 
mouse (Q02284) and rat (P30940) (software DNAMAN, version 3.2, Lynnon 
Biosoft©). Shaded boxes show identity across the different species. 
Sequencing of the recombinant plasmid revealed an open reading frame of 1101 bp 
(Figure 4.4).  DNAMAN analysis showed that this full-length porcine cDNA encoded 
a 366 amino acid protein (calculated molecular weight: 41.8 kDa) exhibiting features 
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of a typical G-protein-coupled receptor with predicted seven transmembrane domains 
and putative N-glycosylation and phosphorylation sites.  In Figure 4.5, the amino acid 
sequence of the porcine 5-ht1F receptor has been compared with those of the human, 
chimpanzee, gorilla, orang-utan, guinea pig, mouse and rat.  Across the species there 
was a 90% (rat) to 93% (human) similarity in the overall sequence.  Nevertheless, it 
may be noted that the porcine 5-ht1F receptor contains several amino acids that are 
unique: Ser4, 11, Tyr8, Ala22 (N’ terminal extracellular region), Phe28, Ile29 (first 
transmembrane domain), Gln133 (second intracellular loop), Thr195 (fifth 
transmembrane domain), Ser238, Arg239, 276 (third intracellular loop) and Met345 
(seventh transmembrane domain).  Further, it may be noted that Pro244 (third 
intracellular loop) and Thr333 (seventh transmembrane domain) were present only in 
the pig and orang-utan (Figure 4.5). 
Ligand binding profile of recombinant porcine 5-ht1F receptor 
Saturation binding studies and Scatchard analysis, performed over 10 concentrations 
of 5-HT, demonstrated that membranes obtained from monkey COS-7 cells 
transiently transfected with the porcine 5-ht1F receptor showed a single population of 
high affinity binding sites for [3H]5-HT.  The equilibrium dissociation constant (KD) 
and maximum receptor density (Bmax) for [3H]5-HT were, respectively, 20.8±1.9 nM 
and 7.12±1.85 pmol.mg-1 of protein (n=3 each).  No detectable specific [3H]5-HT 
binding was observed in non transfected cell membranes. 
The affinity constants (pKi values) of 22 serotonergic compounds (15 
putative agonists and 7 putative antagonists) for the displacement of [3H]5-HT from 
membranes obtained from Cos-7 cells expressing porcine (present results) and human 
(John et al., 1999 and Pauwels, unpublished; Pauwels et al., 1997) 5-ht1F receptor are 
shown in Table 4.1.  Amongst the compounds tested, the potent and selective 5-ht1F 
receptor agonist LY334370 (Phebus et al., 1997) showed the highest affinity.  The 
rank order of affinity of the putative agonists was LY334370 > CP122638 = 
naratriptan = 5-HT > eletriptan > sumatriptan > frovatriptan = avitriptan > 
dihydroergotamine > zolmitriptan > 5-carboxamidotryptamine > rizatriptan > 
alniditan = donitriptan > L694247, while that of putative antagonists was 
methiothepin > GR127935 > ritanserin > SB224289 > BRL15572 > ketanserin = 
pindolol. 
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Table 4.1.  Affinity constants (Ki, nM) of serotonergic ligands for inhibition of [3H]5-HT 
binding to membranes derived from monkey Cos-7 cells expressing recombinant porcine 
5-ht1F receptor.  Corresponding data for the human 5-ht1F receptor (John et al., 1999 and 
Pauwels, unpublished; Pauwels et al., 1997) is presented for comparison. 
Compound Porcine 5-ht1F Human 5-ht1F Ratio porcine vs. 
human 
 
Agonists 
   
LY334370 3.0±0.7 2.0±0.3 1.5 
CP122638 13.6±3.1 2.6±0.7 5.2 
Naratriptan 15.2±2.1 4.3±0.7 3.5 
5-HT 17.4±5.3 8.4±1.2 2.1 
Eletriptan 81.4±26.5 17.6±3.5 4.6 
Sumatriptan 199±37 17.3±3.1 11.5 
Frovatriptan 338±78 102±38 3.3 
Avitriptan 360±27 179±37 2.0 
Dihydroergotamine 431±64 330±38 0.96 
Zolmitriptan 524±93 34.4±4.6 15.2 
5-Carboxamidotryptamine 1555±49 738±85 2.1 
Rizatriptan 2100±221 135±21 15.6 
Alniditan 3321±477 933±89 3.6 
Donitriptan 4264±990 3755±1020 1.1 
L 694247 >10000 >10000  
 
Antagonists 
   
Methiothepin 136±23 102±33 1.3 
GR127935 250±17 46.9±6.2 5.3 
Ritanserin 2151±267 1178±14 1.8 
SB-224289 7050±528 >10000  
BRL 15572 9138±120 NA  
Ketanserin >10000 >10000  
Pindolol >10000 NA  
Data are means ± S.E.M. (n=3-6).  NA, Not available. 
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In Figure 4.6, pKi values of the above compounds obtained in the present 
experiments with membranes from cells expressing the cloned pig 5-ht1F receptor 
have been plotted against pKi values obtained earlier with the same compounds using 
membranes from cells expressing the cloned human 5-ht1F (John et al., 1999 and 
Pauwels, unpublished; Pauwels et al., 1997) as well as human (Wurch et al., 1998 and 
unpublished) or porcine (Bhalla et al., 2001; Bhalla et al., 2000) 5-HT1B and 5-HT1D 
receptors.    
 
Figure 4.6. Regression analysis of binding affinity constants (pKi values) of 5-HT 
receptor ligands at the cloned porcine 5-ht1F receptor (see Table 4.1) with those 
reported with cloned 5-ht1F (human; top panel), 5-HT1B (pig and human; middle 
panels) and 5-HT1D (pig and human; lower panels) receptors, using [3H]5-HT (5-ht1F) 
and [3H]GR125743 (5-HT1B and 5-HT1D) as ligands (for references, see text).  Please 
note that values for some compounds were not available for all receptors.  The 
Spearman correlation coefficient (rS) and the corresponding values of the slope (b), 
calculated with SlideWrite plus for Windows© (Advanced Graphics Software, 
Encinitas, CA, USA), are listed in each panel.  The compounds included in the graphs 
are 1. LY334370, 2. CP122638, 3. naratriptan, 4. 5-HT, 5. eletriptan, 6. sumatriptan, 
7. dihydroergotamine, 8. frovatriptan, 9. avitriptan, 10. zolmitriptan, 
11. 5-carboxamidotryptamine, 12. rizatriptan, 13. alniditan, 14. ketanserin, 
15. methiothepin, 16. GR127935, 17. ritanserin, 18. SB224289, 19. L694247, and 
20. BRL15572. 
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The affinity constants at the porcine 5-ht1F receptor showed the highest 
correlation with those at the human 5-ht1F receptor (rs=0.944; b=0.815).  In contrast, 
the correlation at the porcine or human 5-HT1B (rs=0.287 and 0.329, respectively) and 
5-HT1D (rs=0.424 and 0.318, respectively) receptors was much weaker.  However, it 
may be noted that, except dihydroergotamine, all compounds and, in particular, 
sumatriptan, zolmitriptan and rizatriptan, displayed 10- to 15-times less affinity at the 
porcine than at the human 5-ht1F receptors (see Table 4.1). 
Expression of 5-ht1F receptor mRNA in porcine tissues 
Based on the recombinant porcine specific 5-ht1F receptor sequence, two internal 
primers were designed and used on cDNA templates prepared from several porcine 
tissues.   
 M  1   2   3   4   5   6   7   8   9  10  M
2645 bp →
460 bp →
M: pGEM marker
  1: Brain cortex
  2: Cerebellum
  3: Trigeminal ganglion
  4: Skeletal muscles
  5: Mesenteric artery
  6: Coronary artery
  7: Pulmonary artery
  8: Saphenous vein
  9: Brain cortex without RT
10: Autoclaved water
 
Figure 4.7.  Agarose gel electrophoresis of PCR amplified products derived from 
cDNA obtained from a number of porcine tissue samples.  The size of marker bands is 
indicated in the left margin.  RT, Reverse transcriptase enzyme. 
 
As shown in Figure 4.7, a single band of PCR amplified product (approximately 
460 bp) representing the presence of 5-ht1F receptor mRNA was clearly detected in 
the brain cortex, trigeminal ganglion and saphenous vein.  Moderate signals were 
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observed in the coronary and pulmonary artery, while only weak or no signals were 
noticed in the cerebellum, mesenteric artery and skeletal muscles.  The possibility of 
genomic DNA and/or PCR contamination was ruled out on the basis of absence of 
any band in negative controls (autoclaved water and brain cortex RNA in the absence 
of reverse transcription). 
Discussion 
Cloning and sequence analysis 
Specific primer sequences of the full-length porcine 5-ht1F receptor were identified by 
inverse-PCR on genomic DNA and used for amplification of full-length 5-ht1F 
receptor cDNA prepared from the porcine trigeminal ganglion.  The nucleotide 
sequence of 1101 bp DNA fragment revealed an open reading frame of 366 amino 
acid protein of the porcine 5-ht1F receptor displaying a high homology (90-93%) with 
the human and several other mammalian species.  The computer analysis predicted 
seven transmembrane domains as well as putative N-glycosylation and 
phosphorylation sites, similar to those observed in other species (Adham et al., 1997; 
Adham et al., 1993; Amlaiky et al., 1992; Lovenberg et al., 1993). 
A comparison of porcine 5-ht1F receptor amino acid sequence with previously 
characterised recombinant porcine 5-HT1B (Bhalla et al., 2001) and 5-HT1D (Bhalla et 
al., 2000) receptors showed 48% and 49% homology, respectively.  Moreover, 
analogous to porcine 5-HT1B (Ala4, Ser15,21 and Arg19) and 5-HT1D (Val8,36, Asp10, 
Gly14, Thr15, Lys27, Pro97 and Glu102) receptors, the porcine 5ht1F receptor also showed 
some unique amino acids (Ser4,11,238, Tyr8, Phe28, Ile29, Gln133, Thr195, Arg239,276, 
Met345) as compared to other species.  Interestingly, Pro244 and Thr333 were common 
to the pig and orang-utan 5ht1F receptor.  The encoding divergent amino acids at the 5’ 
(Ser4,11, Tyr8, Phe28, Ile29) and 3’ (Ser238, Arg239,276, Met345) ends were also verified 
when the genomic DNA was used for inverse-PCR (see Figure 4.2), thus ruling out 
the possibility of sequencing error. 
Ligand binding profile 
Using [3H]5-HT as a radioligand, membranes from Cos-7 cells expressing the porcine 
5-ht1F receptor showed a KD value of 20.8±1.9 nM, which agreed with the Ki value of 
5-HT (17.4±5.3 nM; Table 1).  The present KD value is somewhat higher than that 
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obtained with the human 5-ht1F receptor (KD: 9.2±0.99 nM, Adham et al., 1993), but 
is not dissimilar to that obtained with the guinea pig 5-ht1F receptor (KD: 14±3 nM, 
Adham et al., 1997).  Although in both cases [3H]5-HT was used as radioligand, the 
guinea pig receptor was expressed, as in the present investigation, in Cos-7 cells, 
whereas the human receptor was expressed in LM(tK-) cells. 
Overall, the pharmacological profile of the porcine 5-ht1F receptor was similar to 
that of the human homologue and the affinity constants of serotonergic drugs at the 
two 5-ht1F receptors showed a very high correlation (Table 4.1 and Figure 4.6).  Also, 
LY334370 and CP122638, which are reasonably selective at the 5-ht1F receptor 
(Waeber & Moskowitz, 1995; Wainscott et al., 1998), were the two compounds with 
highest affinities at the porcine 5-ht1F receptor.  However, it should be pointed out that 
generally the compounds investigated were less potent at the porcine compared to the 
human receptor (Table 4.1).  This was most marked for sumatriptan, zolmitriptan and 
rizatriptan, which had over 10-fold lower affinity at the porcine receptor.  The lower 
affinity at the porcine 5-ht1F receptor may be due to a single or multiple amino acid 
differences in its transmembrane domains.  Indeed, as pointed out above, several 
amino acids in the porcine 5-ht1F receptor are unique (Phe28 and Ile29 in the first, 
Thr195 in the fifth and Met345 in the seventh transmembrane domain).  In any case, 
5-ht1F receptor agonism is not a requirement for antimigraine efficacy (Dahlöf & 
Saxena, 2000), since alniditan and rizatriptan, which do not have a particularly high 
affinity at the 5-ht1F receptor (Table 1), effectively abort migraine attacks (Adelman et 
al., 2001; Diener et al., 2001).  Moreover, it is still unclear if the efficacy of the 5-ht1F 
receptor agonist LY33470 in migraine (Goldstein et al., 2001) is due to a selective 
action on this receptor (Dahlöf & Saxena, 2000). 
Interestingly, like 5-HT1D (Thr342) (Harwood et al., 1995; Weinshank et al., 
1992; Wurch et al., 1997) and non-rodent 5-HT1B (Thr355) (Adham et al., 1994) 
receptors, the porcine (and orang-utan) 5-ht1F receptor has a polar threonine amino 
acid at the homologous position within the seventh transmembrane domain (Thr333) 
(see Figure 4.5).  This is strikingly different from the human, guinea pig, mouse and 
rat 5-ht1F receptors, which all have a non-polar alanine residue (Ala333) (Adham et al., 
1997; Adham et al., 1993; Amlaiky et al., 1992; Lovenberg et al., 1993) or from the 
rat and mouse 5-HT1B receptors, which have a polar asparagine residue (Asn355) 
(Oksenberg et al., 1992).  It is known that a single point mutation of either threonine 
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(5-HT1B, 5-HT1D and 5-ht1E) or alanine (5-ht1F) to asparagine considerably increases 
the affinity of these human receptors for β-adrenoceptors antagonists (Adham et al., 
1994; Oksenberg et al., 1992).  The presence of Thr333 in the porcine 5-ht1F receptor is 
in agreement with its low affinity for the β-adrenoceptors antagonist pindolol (Ki: 
>10,000 nM; Table 4.1).  However, despite Thr333, the ligand binding profile of the 
porcine 5-ht1F receptor resembles that of the human 5-ht1F receptor having an Ala333 
and not that of the 5-HT1B (Thr355) or 5-HT1D (Thr342) receptors.  Whether or not 
Thr333 in the porcine 5-ht1F receptor is responsible for the lower affinity of these drugs 
will be worth investigating. 
Tissue distribution of mRNA 
Expression of mRNA for 5-ht1F receptor in the porcine trigeminal ganglion supports 
the possible central role of these receptors in inhibiting dural plasma protein 
extravasation (Johnson et al., 1997; Phebus et al., 1997), presumably by a presynaptic 
action.  Furthermore, since the mRNA signals were found in other brain tissues 
(cortex, cerebellum), the 5-ht1F receptors may function as auto- and/or heteroreceptor 
(Barnes & Sharp, 1999; Hoyer et al., 1994).  Interestingly, despite the presence of the 
5-ht1F receptor mRNA in some blood vessels (Bouchelet et al., 2000 and present 
results; Nilsson et al., 1999), it is practically ruled out that this receptor mediates 
vasoconstriction (Bouchelet et al., 2000; Cohen & Schenck, 2000; Shepheard et al., 
1999).  In the case of porcine coronary artery, the mRNA signals of 5-ht1F receptor 
were detected.  Earlier reports in the human coronary artery, also employing the 
RT-PCR technique, have either denied (Ishida et al., 1999) or advocated (Nilsson et 
al., 1999) the presence of 5-ht1F receptor mRNA.  Even though, we do not have a 
clear explanation for the presence of mRNA signals in vascular beds, it may be that 
these receptors mediate some other (patho)physiological responses, for example 
plasma protein extravasation or mitosis leading to vascular remodelling. 
In conclusion, we have cloned the porcine 5-ht1F receptor cDNA from the 
trigeminal ganglion by RT-PCR technique.  The ligand binding profile of porcine 
5-ht1F receptor was consistent with the human 5-ht1F receptor, although some triptans 
exhibited a conspicuously lower affinity for the porcine receptor.  This information 
may be helpful in exploring the role of 5-ht1F receptor in physiological processes and 
diseases, such as migraine. 
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Chapter 5 
Molecular cloning and tissue distribution of mRNA encoding porcine 
5-HT7 receptor and its comparison with the structure of other species 
Summary  The effects of 5-hydroxytriptamine (5-HT, serotonin) are 
mediated via five main receptor types of which the 5-HT7 receptor is the 
most recently characterised member.  The 5-HT7 receptor has been 
shown to mediate cranial blood vessels dilatation that may result in 
migraine headache.  We report here the cDNA cloning, sequencing and 
tissue distribution of porcine 5-HT7 receptor and illustrate its comparison 
with corresponding receptor of known species.  Employing a 
combination of reverse transcriptase and inverse polymerase chain 
reaction we amplified and sequenced a full length cDNA from the 
porcine cerebral cortex.  The deduced amino acid sequence comparison 
confirmed that the cloned porcine receptor belongs to 5-HT7 receptor as 
described for human and other species and showing overall homology of 
92-96%.  The expression of 5-HT7 receptor mRNA was observed in 
porcine central (cerebral cortex, trigeminal ganglion and cerebellum) as 
well as in peripheral (pulmonary and  coronary arteries, superior vena 
cava and saphenous vein) tissues.  The established cDNA sequence and 
tissue distribution of porcine 5-HT7 receptor will be helpful in exploring 
the role of this receptor in pathophysiological processes and to predict as 
a potential therapeutic target for antimigraine drug development. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Based on: Bhalla, P., Saxena, P.R.  & Sharma, H.S. Molecular cloning, sequencing 
and tissue distribution of the porcine 5-HT7 receptor. Submitted 
S
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Introduction 
Devising a novel general framework featuring structural (peptide sequence), 
operational (ligands affinity rank-order and functional effects) and transductional 
(second messenger) criteria for receptor classification and nomenclature, Hoyer et al. 
(1994) recognised four main types 5-hydroxytryptamine (5-HT; serotonin) receptors 
(5-HT1-4) as well as several ‘orphan’ receptors awaiting characterisation.  One such 
‘orphan’ category, termed ‘5-HT1-like’, was shown to be a heterogeneous group 
comprising four receptor types, namely 5-HT1B, 5-HT1D, 5-ht1F and 5-HT7 (Saxena et 
al., 1998).  The 5-HT7 receptor (Receptor code: 2.1.5HT.07.000.00.00) is now 
recognised as a main class of 5-HT receptors mediating circadian phase shifts and 
gastrointestinal and vascular smooth muscle relaxation (Eglen et al., 1997; Martin, 
1998; Saxena et al., 1998; Vanhoenacker et al., 2000), including dilatation of cranial 
blood vessels (Terrón et al., 1999; Villalón et al., 1997a; Villalón et al., 2001).  The 
latter feature is a hallmark of migraine headache (Humphrey et al., 1991; Saxena, 
1995b; Tfelt-Hansen et al., 2000a), a trigeminovascular disorder (May et al., 2001) 
involving 5-HT (Hamel et al., 2000).  Moreover, prophylactic antimigraine drugs, 
particularly methysergide, behave as antagonists at the 5-HT7 receptor (Hoyer et al., 
1994; Tfelt-Hansen et al., 2000b), which is located not only on cerebral blood vessels 
(Shen et al., 1993) but also on trigeminal ganglion (Terrón et al., 2001). 
The 5-HT7 receptor is the recently identified member of 5-HT receptor family 
and has been characterised on the basis of structural, operational and transductional 
characteristics.  The 5-HT7 receptor has been cloned from human, rat, mouse and 
guinea pig, belonging to the G-protein-coupled receptor superfamily and is positively 
linked to adenylyl cyclase (Eglen et al., 1997; Vanhoenacker et al., 2000).  Genomic 
structure of the human 5-HT7 receptor showed two introns, first between the 3rd and 
4th transmembrane domains coding regions and second near the C terminal region 
(Ruat et al., 1993) and the entire gene is localised on chromosome 10q23.3-q24.4 
(Gelernter et al., 1995).  The splice variants of 5-HT7 receptor have been reported in 
rodents and human tissues (Heidmann et al., 1997).  Recently, the three splice variants 
in case of human 5-HT7 receptor were found to be indistinguishable both 
pharmacologically as well as coupling to adenylyl cyclase activity (Krobert et al., 
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2001).  However, these splice variants of 5-HT7 receptor showed altered pattern of 
tissue distribution (Heidmann et al., 1997; Heidmann et al., 1998; Krobert et al., 
2001).  
Previous investigations from our laboratory have established that constriction of 
carotid arteriovenous anastomoses in the anaesthetised pig can serve as a predictive 
model for the antimigraine efficacy of 5-HT-based drugs (De Vries et al., 1999; 
Saxena, 1995b).  To complement our continuing in vivo investigations, we set out to 
clone and sequence the porcine 5-HT7 receptor cDNA from cerebral cortex and 
investigated its distribution in various central and peripheral tissues. 
Materials and methods 
PCR amplification and cloning of 5-HT7 receptor cDNA 
Porcine 5-HT7 receptor cDNA was amplified using a combination of RT-PCR and 
inverse-PCR techniques; for details see Bhalla et al. (2001; 2000).  cDNA was 
synthesised from RNA extracted from cerebral cortex obtained from a pig (Yorkshire 
x Landrace, female, 12 kg).  The quality of RNA extraction and cDNA preparation 
was checked by PCR amplification of β-actin (Ponte et al., 1984). 
 
Table 5.1.  Primers used for RT-PCR and inverse PCR amplification of porcine 
5-HT7 receptor1 
Primers Amplified fragment 
No. Direction 
Sequence 
Nucleotides Amino 
acids 
a Forward 5’-GCAGTGGCGTTCTACATCCC-3’ 
b Reverse 5’-CAAGGTGGTGGCTGCTTTCT-3’ 739-993 247-331 
c Forward 5’-GAGGGAAGCCTGGGAACTTG-3’ 
d Reverse 5’-GGAGGAGTGTGCGAACCTTTC-3’ 
544-844; 
903-1302 
182-281; 
302-434 
e Forward ATGATGGGCGTTAACAGCAGC-3’ 
f Reverse 5’-GTGATGGAGGCGGAGAGAAG-3’ 1-648 1-216 
g Forward 5’-CCTTGGGATCACGAGGCCGC-3’ 
h Reverse 5’-CTCTCAGCAAGCTTCAGGGCC-3’ 549-1277 184-426 
i Forward 5’-GGAGGAGTGTGCGAACCTTTC-3’ 
j Reverse 5’-GGATCATGAATCATGACCTTT-3’ 903-1344 302-447 
1These primers were based either on PCR amplified sequences of porcine 5-HT7 receptor 
(primers a-d, f-i) or consensus sequences of known recombinant 5-HT7 receptors from 
other species (Bard et al., 1993; Plassat et al., 1993; Ruat et al., 1993; Tsou et al., 
1994) (primers e and j). 
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As shown in Figure 5.1, porcine 5-HT7 receptor was amplified using a 
combination of RT-PCR and inverse-PCR techniques (for details, see Bhalla et al., 
2001).  Based on the partial sequence of porcine 5-HT7 receptor (Ullmer et al., 1995, 
GenBank accession number Z48177), primers a and b were used to amplify a product 
of approximately 250 base pairs (bp), which was used to design porcine-specific 
inverse primers c and d (Figure 5.1A, B; Table 5.1).   
TGAATG c d
5’ 3’B
Partial p5-HT7 receptor
TGAATG
D
Full-length p5-HT7 receptor cDNA
ATG b
A
TGA
5’ 3’Unknown 5-HT7 receptor
a
TGAATG
5’ 3’
C Partial ligated genomic p5-HT7 receptor
f ie j
g h
 
Figure 5.1.  Strategy for cloning porcine 5-HT7 receptor and position of various 
primers (a-j, with directions given by the arrows) used for PCR amplification.   
Horizontal bars show the position of introns, black bars denote the amplified products, 
while crossed bars indicate the sequence of primers e and j.  A. Unknown full-length 
porcine 5-HT7 receptor with primers (a and b) derived from a partial sequence of 
porcine 5-HT7 receptor (GenBank accession number Z48177).  B. The amplified 
partial sequence of porcine 5-HT7 receptor cDNA was used to design inverse porcine 
specific primers (c and d).  C. The inverse-PCR amplified partial genomic sequence 
enabled us to design further porcine specific primers between the introns (f-i) and 
5’and 3’ ends primers designed from other species (e and j).  D. Three different sizes 
of amplified products showed the full-length sequence of porcine 5-HT7 receptor 
cDNA. 
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These inverse primers were used with genomic DNA circles prepared after 
digesting the porcine genomic DNA with Bgl ΙΙ restriction enzyme, selected on the 
basis of the absence of Bgl ΙΙ-sensitive restriction site in the cDNA sequence of 5-HT7 
receptor from other species (DNAMAN sequence analysis program, Version 3.2, 
Lynnon Biosoft©, 1994-1997).  The PCR amplified products were purified and ligated 
into pGEMT Easy vector (Promega Benelux b.v., Leiden, The Netherlands).  The 
ligated products were transformed into competent JM 109 cells and grown overnight 
on LB agar (containing ampicillin, IPTG and X-gal) plates at 37°C.  White over blue 
colonies were further processed for the plasmid DNA isolation (mini-prep, Promega 
Benelux b.v., Leiden, The Netherlands) and sequenced by the dideoxy nucleotide 
chain termination method using an automated fluorescence based DNA sequencer 
(ABI PrismTM 310 Genetic analyser, Perkin Elmer Applied Biosystem Benelux, 
Nieuwerkerk aan den IJssel, The Netherlands).  The nucleotide sequences were 
compared and a consensus sequence was derived using the DNAMAN sequence 
analysis program software.  The final partial genomic DNA sequence (Figure 5.1C) 
was compared with those in the GenBank (BLAST search at National Centre for 
Biotechnology Information, Bethesda, MD, USA). 
For the amplification of full-length porcine 5-HT7 receptor cDNA, three sets of 
primers (Figure 5.1C) were used with the cDNA template derived from porcine 
cerebral cortex: (i) primers e and f, (ii) primers g and h, and (iii) primers i and j 
(Figure 5.1C, D; Table 5.1).  These primers were designed based either on the inverse 
PCR amplified sequence (primers f-i) of porcine 5-HT7 receptor or consensus 
sequences (primers e and j) of recombinant 5-HT7 receptors from the human (Bard et 
al., 1993), rat (Ruat et al., 1993)  (now the 5-HT7(a) isoform in these two species 
(Vanhoenacker et al., 2000)), mouse (Plassat et al., 1993), and guinea pig (Tsou et al., 
1994).   Thus, the amplified three products were checked on a 1% agarose gel, 
purified, cloned and sequenced.  The nucleotide sequences obtained from the 
amplified products were aligned together to derive a final sequence of the porcine 
5-HT7 receptor, using the DNAMAN sequence analysis program (Version 3.2, 
Lynnon Biosoft©, 1994-1997).  The cDNA sequences of the cloned products were 
confirmed by at least two independent PCRs and further verified by genomic DNA 
(inverse-PCR) amplified products.  In sporadic cases showing nucleotide discrepancy 
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in the sequence, the nucleotide having a clear majority in clones was preferred for 
establishing the final full-length cDNA sequence. 
The final sequence (Figure 5.1D) was translated as a peptide sequence and 
compared with those in the GenBank (BLAST search at National Centre for 
Biotechnology Information, Bethesda, MD, USA).  The hydrophobic regions 
(indicating putative transmembrane domains) and sequence homology with known 
5-HT7 receptors from other species were identified. 
Tissue distribution of the 5-HT7 receptor mRNA 
As described in detail before (Bhalla et al., 2001; Bhalla et al., 2000), RT-PCR 
technique was used to detect 5-HT7 receptor mRNA in the following porcine tissues 
obtained from pigs (Yorkshire x Landrace, female, 12-15 kg): brain cortex, trigeminal 
ganglion, cerebellum, pulmonary and coronary arteries, left cardiac ventricle, superior 
vena cava and saphenous vein.  The tissue samples were dissected and cleaned and 
total RNA was isolated.  The purified total RNA samples were reverse transcribed 
into cDNA in the presence of reverse transcriptase enzyme. A control reaction was 
always prepared in the absence of reverse transcriptase to monitor possible DNA 
contamination.  The porcine 5-HT7 receptor was detected using porcine specific sense 
(5’-GCAGTGGCGTTCTACATCCC-3’; nucleotides 739-758) and antisense 
(5’-CAAGGTGGTGGCTGCTTTCT-3’; nucleotides 974-993) primers.  The PCR 
amplified products were separated on 1.5% agarose gel by electrophoretic separation 
and photographed. 
All oligonucleotide primers were commercially procured from Life 
Technologies b.v. (Breda, The Netherlands).  Various chemicals used in this study 
were of molecular biology and/or culture grade.  pGEMT-Easy vector system, 
Wizard® PCR prep and mini-prep DNA purification systems were purchased from 
Promega Benelux b.v. (Leiden, The Netherlands).  Oligotex mRNA purification kit 
was purchased from Qiagen GmbH (Hilden, Germany).  AmpliTaqGold and dye 
terminator/cycle sequencing ready reaction kit were procured from Perkin Elmer 
Applied Biosystem Benelux (Nieuwerkerk a/d Ijssel, The Netherlands).   
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Results 
Cloning and sequence analysis of porcine 5-HT7 receptor cDNA 
The various primers and the approximate length of products that were amplified using 
RT-PCR and inverse PCR are shown in Table 5.1. The first two primers (a and b) 
yielded a product of expected length from the porcine cDNA derived from brain 
cortex.  This product corresponded to a fragment of porcine 5-HT7 receptor cDNA 
reported earlier (Ullmer et al., 1995, GenBank accession number Z48177).  Based on 
this fragment, we designed two porcine-specific inverse primers (c and d) and 
obtained a product of approximately 1100 bp from ligated porcine genomic DNA.  
Upon sequencing, this fragment revealed a high homology (>90%) with the human 
5-HT7 receptor (data not shown) and represented a part of porcine 5-HT7 receptor 
between the two introns.  Subsequently, we amplified and cloned three fragments of 
expected sizes from the cDNA template derived from porcine cerebral cortex, used 
with specially designed primer sets (Table 5.1; Figure 5.2, lanes 2, 3 and 4).  
Sequencing of these cloned fragments revealed the specific partial sequences of 
porcine 5-HT7 receptor and these sequences were overlapped to obtain the full-length 
sequence of porcine 5-HT7 receptor cDNA (Figure 5.3).  It may, however, be pointed 
out that the 5’ and 3’ end primers were from different species (see Table 5.1). 
 
M     1      2      3      4
Recombinant Plasmids
 1353 bp →
   603 bp →
   310 bp →
 
Figure 5.2.  Agarose gel electrophoresis of recombinant plasmid with different sizes 
of insert cDNA (amplified from cDNA template of porcine cerebral cortex).  The 
different lanes marked on the top denote: φx174 DNA/Hae III marker (M), 
recombinant uncut plasmid DNA vector (1) and plasmid DNA vector restricted with 
EcoR1 enzyme and showing different DNA insert of approximately 650, 750 and 
450bp (2, 3 and 4).  The size (base pairs; bp) of 3 marker bands is indicated on the left 
margin. 
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1     ATG ATG GGC GTT AAC AGC AGC GGC CGC CCG GAC CTC TAC GGG CAT CTC CGT TCT ATC CTC
1     MET Met Gly Val Asn Ser Ser Gly Arg Pro Asp Leu Tyr Gly His Leu Arg Ser Ile Leu
61    TTG CCG GAG GTG GGG CGC GGG CTT CCC GAC TTG AGC TCC GAC GGC GCC GGC CCT GTC GCG
21    Leu Pro Glu Val Gly Arg Gly Leu Pro Asp Leu Ser Ser Asp Gly Ala Gly Pro Val Ala
121   GGC TCC TGG GCG CCG CAC CTG CTG CAC GGG GTC CCT GAG GTG ACG GCC AGC CCC GTG CCC
41    Gly Ser Trp Ala Pro His Leu Leu His Gly Val Pro Glu Val Thr Ala Ser Pro Val Pro
                                  ¹
181   ACC TGG GAC GCG CCC CGG GAC AAT GCC TCG GGC TGC GGG GAG CAG ATC AAC TAC GGC AGA
61    Thr Trp Asp Ala Pro Arg Asp Asn Ala Ser Gly Cys Gly Glu Gln Ile Asn Tyr Gly Arg
241   GCC GAG AAA GTT GTG ATC GGC TCC ATC CTG ACG CTC ATC ACG CTG CTG ACG ATC GCC GGC
81    Ala Glu Lys Val Val Ile Gly Ser Ile Leu Thr Leu Ile Thr Leu Leu Thr Ile Ala Gly
301   AAC TGC CTG GTG GTG ATT TCG GTC TGC TTC GTC AAG AAG CTC CGT CAG CCC TCC AAC TAC
101   Asn Cys Leu Val Val Ile Ser Val Cys Phe Val Lys Lys Leu Arg Gln Pro Ser Asn Tyr
361   CTG ATC GTG TCT CTG GCG CTG GCC GAC CTC TCG GTG GCC GTG GCG GTC ATG CCC TTC GTC
121   Leu Ile Val Ser Leu Ala Leu Ala Asp Leu Ser Val Ala Val Ala Val Met Pro Phe Val
421   AGC GTC ACT GAC CTT ATT GGG GGC AAG TGG ATC TTT GGC CAC TTC TTC TGC AAC GTC TTT
141   Ser Val Thr Asp Leu Ile Gly Gly Lys Trp Ile Phe Gly His Phe Phe Cys Asn Val Phe
481   ATC GCC ATG GAC GTC ATG TGC TGC ACG GCC TCG ATC ATG ACC CTG TGC GTG ATC AGT ATC
161 Ile Ala Met Asp Val Met Cys Cys Thr Ala Ser Ile Met Thr Leu Cys Val Ile Ser Ile
541   GAC AGG TAC CTT GGG ATC ACG AGG CCG CTG ACG TAC CCC GTC AGG CAG AAT GGC AAG TGC
181   Asp Arg Tyr Leu Gly Ile Thr Arg Pro Leu Thr Tyr Pro Val Arg Gln Asn Gly Lys Cys
601   ATG GCT AAG ATG ATC CTC TCT GTC TGG CTT CTC TCC GCC TCC ATC ACT TTG CCG CCG CTC
201 Met Ala Lys Met Ile Leu Ser Val Trp Leu Leu Ser Ala Ser Ile Thr Leu Pro Pro Leu
661   TTC GGC TGG GCG CAG AAC GTA AAT GAC GAC AAG GTG TGC TTG ATC AGC CAG GAT TTT GGC
221   Phe Gly Trp Ala Gln Asn Val Asn Asp Asp Lys Val Cys Leu Ile Ser Gln Asp Phe Gly
721   TAC ACG ATC TAC TCC ACG GCA GTG GCG TTC TAC ATC CCC ATG TCC GTC ATG CTT TTC ATG
241   Tyr Thr Ile Tyr Ser Thr Ala Val Ala Phe Tyr Ile Pro Met Ser Val Met Leu Phe Met
781   TAC TAC CAG ATT TAC AAG GCC GCC AGG AAG AGC GCC GCC AAA CAC AAG TTC CCA GGC TTC
261   Tyr Tyr Gln Ile Tyr Lys Ala Ala Arg Lys Ser Ala Ala Lys His Lys Phe Pro Gly Phe
841   CCT CGG GAG GAG CCC GAC AGC GTC ATT TCA CTG AAT GGC ATG GTG AAG CTC CAG AAG GAG
281   Pro Arg Glu Glu Pro Asp Ser Val Ile Ser Leu Asn Gly Met Val Lys Leu Gln Lys Glu
901   GTG GAG GAG TGT GCG AAC CTT TCG AGA CTC CTC AAA CAC GAG AGG AAA AAC ATC TCC ATC
301   Val Glu Glu Cys Ala Asn Leu Ser Arg Leu Leu Lys His Glu Arg Lys Asn Ile Ser Ile
961   TTT AAG AGG GAA CAG AAA GCA GCC ACC ACC TTG GGG ATC ATT GTC GGG GCC TTC ACC GTG
321   Phe Lys Arg Glu Gln Lys Ala Ala Thr Thr Leu Gly Ile Ile Val Gly Ala Phe Thr Val
1021  TGC TGG CTG CCG TTT TTC CTC CTC TCG ACG GCC AGA CCC TTC ATC TGT GGC ACT GCG TGC
341   Cys Trp Leu Pro Phe Phe Leu Leu Ser Thr Ala Arg Pro Phe Ile Cys Gly Thr Ala Cys
1081  AGC TGC ATC CCG CTG TGG GTG GAG AGG ACA TTT CTG TGG CTG GGC TAT GCA AAC TCT CTC
361   Ser Cys Ile Pro Leu Trp Val Glu Arg Thr Phe Leu Trp Leu Gly Tyr Ala Asn Ser Leu
                                                                  
1141  ATT AAC CCC TTT ATA TAT GCC TTC TTC AAC CGG GAC CTG AGG ACC ACC TAC CGC AGC CTG
381   Ile Asn Pro Phe Ile Tyr Ala Phe Phe Asn Arg Asp Leu Arg Thr Thr Tyr Arg Ser Leu
1201  CTC CAG TGC CAG TAC CGG AAT ATC AAC CGG AAG CTC TCG GCT GCA GGC ATG CAC GAG GCC
401   Leu Gln Cys Gln Tyr Arg Asn Ile Asn Arg Lys Leu Ser Ala Ala Gly Met His Glu Ala
1261  CTG AAG CTT GCT GAG AGG CCC GAG AGA CCT GAG CTT GTG CTA CAA AAG TCT GAC TAC TGT
421   Leu Lys Leu Ala Glu Arg Pro Glu Arg Pro Glu Leu Val Leu Gln Lys Ser Asp Tyr Cys
1321  AGG AAA AAA GGT CAT GAT TCA TGA
441   Arg Lys Lys Gly His Asp Ser ***
I
+
+
z

II
III
IV
V
VI
VII
z PKA-phosphorylation;+ N-glycosylation;  PKC-phosphorylation
 
Figure 5.3.  Nucleotide and deduced amino acid (in bold) sequences of the 
recombinant cDNA derived from porcine cerebral cortex.  Numbering of nucleotide 
and amino acids is shown on the left.  Computer analysis (software DNAMAN, 
version 3.2, Lynnon Biosoft©) predicted a typical G-protein coupled receptor with 
transmembrane domains I-VII (underlined) as well as the putative N-glycosylation, 
protein kinase A phoshorylation and protein kinase C phosphorylation sites. 
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    64PIG
    62Human
    65Mouse
    65Rat
    63Guinea-pig
MMGVNSSGRPDLYGHLRSILLPEVGRGLPDLSSDG.AGPVAGSWAPHLLHGVPEVTASPVPTWDA
MMDVNSSGRPDLYGHLRSFLLPEVGRGLPDLSPDGGADPVAGSWAPHLLS...EVTASPAPTWDA
MMDVNSSGRPDLYGHLRSLILPEVGRRLQDLSPDGGAHSVVSSWMPHLLSGFPEVTASPAPTWDA
MMDVNSSGRPDLYGHLRSLILPEVGRGLQDLSPDGGAHPVVSSWMPHLLSGFLEVTASPAPTWDA
MMGVNSSGRPDLYGHLHSILLP..GRGLPDWSPDGGADPGVSTWTPRLLSGVPEVAASPSPSWDG
   129PIG
   127Human
   130Mouse
   130Rat
   128Guinea-pig
PRDNASGCGEQINYGRAEKVVIGSILTLITLLTIAGNCLVVISVCFVKKLRQPSNYLIVSLALAD
PPDNASGCGEQINYGRVEKVVIGSILTLITLLTIAGNCLVVISVCFVKKLRQPSNYLIVSLALAD
PPDNVSGCGEQINYGRVEKVVIGSILTLITLLTIAGNCLVVISVCFVKNVRQPSNYLIVSLALAD
PPDNVSGCGEQINYGRVEKVVIGSILTLITLLTIAGNCLVVISVCFVKKLRQPSNYLIVSLALAD
TWDNVSGCGEQINYGRAEKVVIGSILTLITLLTIAGNCLVVISVCFVKKLRQPSNYLIVSLALAD
   194PIG
   192Human
   195Mouse
   195Rat
   193Guinea-pig
LSVAVAVMPFVSVTDLIGGKWIFGHFFCNVFIAMDVMCCTASIMTLCVISIDRYLGITRPLTYPV
LSVAVAVMPFVSVTDLIGGKWIFGHFFCNVFIAMDVMCCTASIMTLCVISIDRYLGITRPLTYPV
LSVAVAVMPFVSVTDLIGGKWIFGHFFCNVFIAMDVMCCTASIMTLCVISIDRYLGITRPLTYPV
LSVAVAVMPFVSVTDLIGGKWIFGHFFCNVFIAMDVMCCTASIMTLCVISIDRYLGITRPLTYPV
LSVAVAVIPFVSVTDLIGGKWIFGHFFCNVFIAMDVMCCTASIMTLCVISIDRYLGITRPLTYPV
   259PIG
   257Human
   260Mouse
   260Rat
   258Guinea-pig
RQNGKCMAKMILSVWLLSASITLPPLFGWAQNVNDDKVCLISQDFGYTIYSTAVAFYIPMSVMLF
RQNGKCMAKMILSVWLLSASITLPPLFGWAQNVNDDKVCLISQDFGYTIYSTAVAFYIPMSVMLF
RQNGKCMAKMILSVWPLSASITLPPLFGWAQNVNDDKVCLISQDFGYTIYSTAVAFYIPMSVMLF
RQNGKCMAKMILSVWLLSASITLPPLFGWAQNVNDDKVCLISQDFGYTIYSTAVAFYIPMSVMLF
RQNGKCMPKMILSVWLLSASITLPPLFGWAQNVNDDKVCLISQDFGYTIYSTAVAFYIPMSVMLF
   324PIG
   322Human
   325Mouse
   325Rat
   323Guinea-pig
MYYQIYKAARKSAAKHKFPGFPREEPDSVISLNGMVKLQKEVEECANLSRLLKHERKNISIFKRE
MYYQIYKAARKSAAKHKFPGFPRVEPDSVIALNGIVKLQKEVEECANLSRLLKHERKNISIFKRE
MYYQIYKAARKSAAKHKFSGFPRVQPESVISLNGVVKLQKEVEECANLSRLLKHERKNISSFKRE
MYYQIYKAARKSAAKHKFPGFPRVQPESVISLNGVVKLQKEVEECANLSRLLKHERKNISIFKRE
MYYRIYKAARKSAAKHKFPGFPRVQPESIISLNGMVKLQKEVEECANLSRLLKHERKNISIFKRE
   389PIG
   387Human
   390Mouse
   390Rat
   388Guinea-pig
QKAATTLGIIVGAFTVCWLPFFLLSTARPFICGTACSCIPLWVERTFLWLGYANSLINPFIYAFF
QKAATTLGIIVGAFTVCWLPFFLLSTARPFICGTSCSCIPLWVERTFLWLGYANSLINPFIYAFF
QKAATTLGIIVGAFTVCWLPFFLLSTARPFICGTSCSCIPLWVERTCLWLGYANSLINPFIYSFF
QKAATTLGIIVGAFTVCWLPFFLLSTARPFICGTSCSCIPLWVERTCLWLGYANSLINPFIYAFF
QKAATTLGIIVGAFTVCWLPFFLLSTARPFICGTACSCIPLWVERTCLWLGYANSLINPFIYAFF
   447PIG
   445Human
   448Mouse
   448Rat
   446Guinea-pig
NRDLRTTYRSLLQCQYRNINRKLSAAGMHEALKLAERPERPELVLQKSDYCRKKGHDS
NRDLRTTYRSLLQCQYRNINRKLSAAGMHEALKLAERPERPEFVLQNADYCRKKGHDS
NRDLRTTYRSLLQCQYRNINRKLSAAGMHEALKLAERPERSEFVLQNCDHCGKKGHDT
NRDLRTTYRSLLQCQYRNINRKLSAAGMHEALKLAERPERSEFVLQNSDHCGKKGHDT
NRDLRTTYRSLLQCQYRNINRKLSAAGMHEALKLAERPERPECVLQNSDYCRKKGHDS
 
Figure 5.4.  Comparison of amino acid sequences of the pig 5-HT7 receptor with those 
of human (Swissprot accession number AAC37538), mouse (CAA80654), rat 
(AAA40617) and guinea pig (AAA83015) 5-HT7 receptors.  The areas shaded black 
show identity across the species. 
 
The full-length porcine 5-HT7 receptor cDNA consisted of 1344 bp, starting 
with ATG codon and ending with TGA codon.  DNAMAN analysis showed that this 
porcine cDNA encoded an open reading frame of 447 amino acid peptide exhibiting 
features of a typical G-protein-coupled receptor with predicted seven transmembrane 
domains and putative N-glycosylation and phosphorylation sites (Figure 5.3).  A 
BLAST search at GenBank of the 1344 bp nucleotide sequence revealed high 
homology (>90%) with the sequence of the 5-HT7 receptor from other species. 
Figure 5.4 compares the amino acid sequence of porcine 5-HT7 receptors with 
that reported from other mammalian species (5-HT7(a) isoform in the case of human 
and rat).  The amino acid homology between the cloned porcine 5-HT7 and human 
5-HT7(a) receptors was the highest (96%) and there was a 100% identity in 
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transmembrane domains, except in the ΙV and V domains (96%).  Nevertheless, some 
unique amino acids were unique to the porcine 5-HT7 receptor sequence, namely: 
Ser33, Gly37, His49, Val59 and Arg66 (N-terminal extracellular region), Leu221 (IV 
transmembrane domain), Met248 (V transmembrane domain), Glu283 (III intracellular 
loop) and  Leu433 and Lys436 (C-terminal intracellular region). 
Tissue distribution of 5-HT7 receptor 
RT-PCR technique was used to assess the expression of 5-HT7 receptor in several 
porcine tissues.  As shown in Figure 5.5, a fragment of expected size (approximately 
300 bp), representing porcine 5-HT7 receptor mRNA, was detected in the brain cortex, 
trigeminal ganglion, cerebellum (weak signal), pulmonary and coronary arteries, 
superior vena cava and saphenous vein, but not in the left cardiac ventricle.   
 
Figure 5.5.  Agarose gel electophoresis of PCR amplified products derived from 
cDNA obtained from porcine tissues.  The lanes marked on top denote: pGEM marker 
(M), brain cortex (1), trigeminal ganglion (2), cerebellum (3), pulmonary artery (4), 
coronary artery (5), left cardiac ventricle (6), superior vena cava (7), saphenous vein 
(8), brain cortex without reverse transcriptase (9), autoclaved water (10) and pGEM 
marker (M).  The size of marker bands is indicated in the left margin. 
 
Possible genomic DNA and/or PCR contamination in the present experiments 
was ruled out because no amplification was found in the negative controls (autoclaved 
water or brain cortex in the absence of reverse transcriptase step). 
2645  bp   → 
676  bp   → 
350  bp   → 
M    1     2     3     4     5     6     7     8     9   10    M 
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Discussion 
Sequence analysis of porcine 5-HT7 receptor 
The primers derived from inverse PCR sequence of porcine genomic DNA as well as 
from consensus sequence of other species were used for the amplification of 
full-length porcine 5-HT7 receptor cDNA from the cerebral cortex.  The nucleotide 
sequence of porcine 5-HT7 receptor encoded an open reading frame of 447 amino acid 
peptide, which showed a high homology (92-96%) with the sequence of human (Bard 
et al., 1993), mouse (Plassat et al., 1993), rat (Lovenberg et al., 1993; Ruat et al., 
1993; Shen et al., 1993) and guinea pig (Tsou et al., 1994) homologues.  Additionally, 
the partial sequence of porcine 5-HT7 receptor, previously submitted to the GenBank 
by Ullmer et al. (1995) was identical to the amino acid sequence present in full-length 
porcine 5-HT7 receptor.  Thus, the nucleotide sequence of the mRNA obtained from 
porcine cerebral cortex encodes for the 5-HT7 receptor. 
It is important to point out that the porcine 5-HT7 receptor gene, as is the case in 
other species (Bard et al., 1993; Ruat et al., 1993) contains two introns, the first 
between the 3rd and 4th transmembrane domains and the second near the C terminal 
region (Bard et al., 1993; Ruat et al., 1993).  Three splice variants of the 5-HT7 
receptor have been reported in rats (5-HT7(a), 5-HT7(b) and 5-HT7(c) with 448, 435 and 
470 amino acids, respectively) as well as humans (5-HT7(a), 5-HT7(b) and 5-HT7(d) with 
445, 432 and 479 amino acids, respectively) (Heidmann et al., 1997).  Although these 
splice variants are pharmacologically indistinguishable and are all positively coupled 
to adenylyl cyclase, they do seem to differ in the pattern of tissue distribution 
(Heidmann et al., 1998; Krobert et al., 2001).  We do not yet know if alternate 
splicing yielding splice variants occurs in the pig, but the number (447) and sequence 
of amino acids present suggest that the present porcine 5-HT7 receptor may represent 
the 5-HT7(a) isoform. 
Tissue distribution of 5-HT7 receptor 
The 5-HT7 receptor mRNA signals were detected in the porcine brain cortex, 
trigeminal ganglion, cerebellum, pulmonary and coronary arteries, superior vena cava 
and saphenous vein.   A similar distribution has been described in the human, 
guinea pig and rat (Bard et al., 1993; Heidmann et al., 1998; Terrón et al., 2001; To et 
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al., 1995) as well as in the pig.  Although the full sequence of the porcine 5-HT7 
receptor had not been established, Ullmer et al. (1995) reported that the 
5-HT7 receptor mRNA was present in the coronary, cerebral and pulmonary arteries 
and cerebral veins.  The ubiquitous presence of the 5-HT7 receptor in blood vessels, 
coupled with the very high affinity for 5-HT (Hoyer et al., 1994), indicates that the 
5-HT7 receptor may be involved in the physiological regulation vascular tone. 
Interestingly, the 5-HT7 receptor mRNA was detected neither in the pig heart 
(present results) nor in the human heart (Bard et al., 1993).  This is in agreement with 
functional characterisation of cardiac 5-HT receptors revealing that, while the 5-HT7 
receptor mediates tachycardia in the cat, that in the pig and human is mediated by the 
5-HT4 receptor (Saxena et al., 1991). 
Clinical relevance 
Being the latest member of the 5-HT receptor family, the 5-HT7 receptor is an 
attractive therapeutic target to explore in depression, migraine and circadian rhythm, 
neuroendocrine, and affective behaviour disorders (Eglen et al., 1997; Vanhoenacker 
et al., 2000; Villalón et al., 1997b).   This may be particularly the case with selective 
5-HT7 receptor antagonists, such as LY215840 (Cushing et al., 1996) and SB269970 
(Lovell et al., 2000; Roberts et al., 2001), for use in migraine.  Indeed, it is possible 
that cranial vasodilatation, which is an integral part of migraine pathophysiology 
(Humphrey et al., 1991; Saxena, 1995b; Tfelt-Hansen et al., 2000a), may be mediated 
by the 5-HT7 receptor (Terrón et al., 1999; Villalón et al., 1997b; Villalón et al., 
2001).  Moreover, 5-HT7 receptors may be involved in pain transmission, 
hyperalgesia and neurogenic inflammation (see Eglen et al., 1997; Terrón, 1998).   
The cloning of the porcine 5-HT7 receptor may help initiate further studies in animal 
models predictive for antimigraine efficacy (De Vries et al., 1999; Saxena, 1995a). 
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Chapter 6 
Characterisation of sumatriptan-induced contractions in human 
isolated blood vessels using selective 5-HT1B and 5-HT1D receptor 
antagonists and in situ hybridisation 
Summary.  The 5-HT1B/1D receptor agonist sumatriptan is effective in aborting 
acute attacks of migraine and is known to cause constriction of cranial arteries 
as well as some peripheral blood vessels.   The present study set out to 
investigate whether 5-HT1B and/or 5-HT1D receptors mediate contractions of 
the human isolated middle meningeal and temporal arteries (models for 
antimigraine efficacy) and coronary artery and saphenous vein (models for 
side-effect potential).  Concentration-response curves were made with 
sumatriptan (1 nM-100 µM) in blood vessels in the absence or presence of 
selective antagonists at 5-HT1B (SB224289) and 5-HT1D (BRL15572) 
receptors.  SB224289 antagonised sumatriptan-induced contractions in all 
blood vessels, although the antagonism profile was different amongst these 
blood vessels.  In the temporal artery, SB224289 abolished contraction to 
sumatriptan, whereas in the middle meningeal artery and saphenous vein, 
sumatriptan-induced contractions were blocked in an insurmountable fashion.  
Moreover, SB224289 acted as a weak surmountable antagonist in the coronary 
artery (pKB: 6.4±0.2).  In contrast, BRL15572 had little or no effect on 
sumatriptan-induced contractions in the four blood vessels investigated.  In situ 
hybridisation revealed the expression of 5-HT1B receptor mRNA in the smooth 
muscle as well as endothelial cells of the blood vessels, whereas the mRNA for 
the 5-HT1D receptor was only very weakly expressed.  These results show that 
the 5-HT1B receptor is primarily involved in sumatriptan-induced contractions 
of human cranial as well as peripheral blood vessels. 
 
 
 
 
 
 
 
 
 
 
Based on: Rémon W. M. van den Broek, Pankaj Bhalla, Antoinette MaassenVanDenBrink, 
René de Vries, Hari S. Sharma and Pramod R. Saxena (2001). Characterisation of 
sumatriptan-induced contractions in human isolated blood vessels using selective 5-HT1B and 
5-HT1D receptor antagonists and in situ hybridisation.  Cephalalgia; In press. 
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Introduction 
Sumatriptan, the first of the 5-HT1B/1D receptor agonists, is highly effective in aborting 
migraine headaches (Goadsby, 1998; Tfelt-Hansen et al., 2000).  It is believed that 
migraine headache results from dilation of extracerebral cranial blood vessels and that 
sumatriptan, as well as other triptans, constrict these dilated vessels (Humphrey et al., 
1991; Tfelt-Hansen et al., 2000).  Although the triptans are known to be 
cranioselective, they all have the propensity to constrict the coronary artery 
(Longmore et al., 1998; MaassenVanDenBrink et al., 2000b; Parsons et al., 1998; 
Van den Broek et al., 2000).  Constriction of the coronary artery may lead to 
cardiovascular adverse events, including myocardial ischaemia and infarction in 
predisposed individuals (Ottervanger et al., 1997). 
The triptans are high affinity agonists at 5-HT1B and 5-HT1D receptors, but their 
vasoconstrictor effect seems to be mediated via the 5-HT1B receptor (Tfelt-Hansen et 
al., 2000).  Using RT-PCR techniques, it has also been shown that the 5-HT1B 
receptor mRNA is predominant over 5-HT1D receptor mRNA in the human middle 
cerebral (Bouchelet et al., 1996; Hamel et al., 1993), middle meningeal (Schmuck et 
al., 1996), temporal (Verheggen et al., 1998) and coronary (Bouchelet et al., 2000; 
Nilsson et al., 1999b) arteries.  The 5-HT1B receptor protein has also been localised in 
the smooth muscle layer as well as endothelium of the human middle cerebral 
(Nilsson et al., 1999a), middle meningeal (Longmore et al., 1998; Longmore et al., 
1997) and coronary (Longmore et al., 1998; Longmore et al., 1997; Nilsson et al., 
1999b) arteries, where the 5-HT1D receptor protein is not, or poorly, expressed.  
Functional pharmacological in vitro studies suggest that sumatriptan behaves as a full 
agonist in blood vessels (Bax et al., 1992; Jansen et al., 1992; Kaumann et al., 1994; 
Kaumann et al., 1993; Verheggen et al., 1996), which do not contract in response to 
selective 5-HT1D receptor agonists (Bouchelet et al., 2000; Ennis et al., 1998). 
A more direct evidence for a 5-HT1B receptor-mediated vasoconstriction to 
sumatriptan can be obtained from antagonist studies.  Until now, studies in the human 
isolated middle meningeal (Jansen et al., 1992; Razzaque et al., 1999; Van den Broek 
et al., 2000) and coronary (Bax et al., 1993; Kaumann et al., 1994; 
MaassenVanDenBrink et al., 2000a; Van den Broek et al., 2000) arteries and 
saphenous vein (Bax et al., 1992), have used non-selective 5-HT1B/1D receptor 
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antagonists (GR127935, GR55562 and GR125743).  Recently, SB224289 and 
BRL15572 have been introduced as selective 5-HT1B and 5-HT1D receptor 
antagonists, respectively (Schlicker et al., 1997; Selkirk et al., 1998).  The use of 
these compounds revealed that sumatriptan-induced contractions in human isolated 
temporal (Verheggen et al., 1998) and small pulmonary (Morecroft et al., 1999) 
arteries as well as canine (De Vries et al., 1998) and porcine (De Vries et al., 1999) 
carotid vascular beds are mediated via the 5-HT1B receptor.  Using both functional 
in vitro and in situ hybridisation techniques, we investigated the role of 5-HT1B and 
5-HT1D receptors in mediating contractions of the human isolated middle meningeal 
and temporal arteries (models for therapeutic efficacy in migraine) and coronary 
artery and saphenous vein (models for peripheral side-effect potential) 
(MaassenVanDenBrink et al., 1998; MaassenVanDenBrink et al., 2000b; Van den 
Broek et al., 2000). 
Material and methods 
Tissue collection 
The middle meningeal (4 male, 5 female; age 30-72 years) and temporal (3 female; 
age 45-59 years) arteries and saphenous vein (8 male, 1 female; age 45-78 years) were 
obtained postoperatively from patients undergoing craniotomy (middle meningeal and 
temporal artery: 8 aneurysms; 4 meningiomas) or coronary artery bypass grafting 
(saphenous vein) at the Erasmus University Medical Centre, Rotterdam, The 
Netherlands.  The blood vessels were placed in a propylene tube filled with ice-cold 
(0-4 °C) physiological saline, transported immediately to the laboratory and used 
within 2 hr of surgery. 
The right epicardial coronary artery was obtained from 9 heart beating organ 
donors (3 male, 6 female; 37-64 years) who died of non-cardiac disorders (6 
cerebrovascular accident, 2 cerebral infarction, 1 head trauma).  The Rotterdam Heart 
Valve Bank, Rotterdam, The Netherlands provided the hearts, after donor mediation 
by Bio Implant Services Foundation/Eurostransplant Foundation, Leiden, The 
Netherlands.  The vessel was stored overnight in a modified Krebs bicarbonate 
solution (see below) and used the next day. 
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Organ bath experiments 
Measurement of vascular contractions.  The methods used were similar to those 
described in detail earlier (MaassenVanDenBrink et al., 2000b; Van den Broek et al., 
2000).  Briefly, approximately 4-mm segments, obtained from pieces of the middle 
meningeal (n=6), temporal (n=3), coronary (n=6) arteries and saphenous vein (n=6), 
were mounted on metal prongs in organ baths, containing a modified Krebs 
bicarbonate solution (pH 7.4; 37 oC), aerated with 95% O2 and 5% CO2.  The 
composition (mM) of the Krebs bicarbonate solution was NaCl 119, KCl 4.7, CaCl2 
1.25 (or 2.5 for coronary artery and saphenous vein), MgSO4 1.2, KH2PO4 1.2, 
NaHCO3 25 and glucose 11.1 (or 8.3 for coronary artery and saphenous vein).  The 
cyclo-oxygenase inhibitor indomethacin (0.1 µM) was added to the Krebs solution to 
prevent prostaglandin synthesis.  In addition, the Krebs solution was enriched with the 
muscarinic receptor antagonist, atropine, the histamine H1 receptor antagonist 
mepyramine, the mixed 5-HT2/7 receptor antagonist mesulergine, the α1-adrenoceptor 
antagonist prazosin, the inhibitor of neuronal uptake1, imipramine (all 1 µM) and the 
inhibitor of extra-neuronal uptake2, corticosterone (10 µM) to exclude the putative 
involvement of these receptors/mechanisms.  Changes in isometric tension were 
registered on recording set-ups from either EMKA Technology (Paris, France) for the 
middle meningeal and temporal arteries or Harvard Apparatus (South Natick, MA, 
USA) for the coronary artery and saphenous vein.  The segments were allowed to 
equilibrate for at least 30 min, stretched to a passive tension of 4 mN (middle 
meningeal and temporal arteries), 15 mN (coronary artery) or 10 mN (saphenous 
vein).  Since sumatriptan is metabolised by monoamine oxidase (Dixon et al., 1994), 
we then treated the segments with pargyline (100 µM) for 15 min to prevent its 
possible breakdown.  After washing, all segments were exposed 2-3 times to either 
0.1 µM prostaglandin F2α (PGF2α; middle meningeal and temporal arteries) or 30 mM 
KCl (coronary artery and saphenous vein) to demonstrate the reproducibility of the 
evoked contractions.  Subsequently, the relaxation response to 10 nM substance P 
(1 nM in case of coronary artery or 0.1 µM bradykinin in the case of saphenous vein) 
in vessel segments pre-contracted with PGF2α (1 µM) was used to verify the 
functional integrity of the endothelium. 
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After washing, the segments were allowed to equilibrate for 60 min, with 
replacement of the Krebs solution every 15 min.  The segments were then studied in a 
paired parallel experimental set-up (MaassenVanDenBrink et al., 2000b; Van den 
Broek et al., 2000), where a single concentration response curve to sumatriptan 
(1 nM-100 µM) was constructed in each segment incubated for 60 min with either the 
vehicle, SB224289, BRL15572 or both antagonists together.  Since only 3 segments 
could be obtained from the human temporal artery, addition of both antagonists 
together was omitted.  In view of the affinity of SB224289 and BRL15572 at 
recombinant h5-HT1B (pKi: 8.0 and 6.1, respectively) and h5-HT1D receptors (pKi: 6.2 
and 7.9, respectively) (Schlicker et al., 1997; Selkirk et al., 1998), we initially 
employed the two antagonists in a concentration range of 10-30 µM in the coronary 
artery (without the cocktail of inhibitors as mentioned above) and saphenous vein.  
Since in these concentrations neither antagonist affected the concentration response 
curves of sumatriptan, all experiments were performed with 1 µM of SB224289 and 
BRL15572. 
Data presentation.  Contractile responses were expressed as percentage of the 
contractile response to 1 µM PGF2α (temporal and middle meningeal arteries) or 
100 mM KCl (coronary artery and saphenous vein).  The occasional spontaneous 
phasic contractions, observed in some coronary artery and saphenous vein segments, 
were ignored where measuring contractions.  When the concentration contraction 
curve to sumatriptan did not attain a plateau, the contraction with its highest 
concentration (100 µM) was considered as the apparent maximum contraction (Emax).  
Initially, the mean value of Emax of sumatriptan observed in individual experiments 
was calculated.  The mean concentration response curves were analysed with a 
non-linear regression fitting technique for sigmoidal functions with variable slope 
using Graphpad Prism 3.0 (Graphpad Software Inc., San Diego, CA, USA) to 
calculate potency (pEC50) and Hill slopes for the agonists in the absence or presence 
of antagonists.  When mean (apparent) Emax and Hill slopes were not significantly 
different in control and antagonist experiments, a surmountable antagonism was 
assumed.  The whole data set was then transformed using SPSS 7.5 non-linear 
regression statistics (SPSS Inc., Chicago, IL, USA) into a dependent fitting model, 
where the mean maximal-induced contraction was set to the respective agonist control 
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value.  In case of a parallel rightward shift, a Schild regression analysis was 
performed with a slope set to unity to calculate the pKB value.  Due to the 
insurmountable behaviour of SB224289 in the middle meningeal artery and 
saphenous vein, pKB values could not be calculated.  Instead, we calculated the 
negative logarithm of the mean concentration of sumatriptan eliciting a contraction 
equivalent to 25% of Emax in the individual control experiments (pEC25%) in the 
absence or presence of antagonists.  This parameter enabled us to compare the 
properties of the antagonists in these vascular preparations against low concentrations 
of sumatriptan. 
Statistical analysis.  Differences between the (apparent) Emax of sumatriptan in 
the absence or presence of antagonists were analysed with a paired t-test, using 
Graphpad Prism 3.0 (Graphpad Software Inc., San Diego, CA, USA).  In case the 
Emax values in the absence of antagonists were similar to those in the presence of 
antagonist, the differences in Hill slopes and pEC50 values of mean concentration 
response curves between vehicle and antagonist groups were analysed with a one-way 
analysis of variance (ANOVA) followed by Dunnett’s multiple comparison t-test.  In 
case Emax values were different between the respective groups, we performed a 
two-way repeated measurement analysis of variance (RM-ANOVA) followed by 
Bonferroni’s multiple comparison t-test to evaluate the effect of treatments (i.e. 
control or antagonist) at repetitive concentrations of sumatriptan.  Differences 
between the pEC25% values of sumatriptan in absence or presence of antagonists were 
calculated according to paired t-test.  In all cases statistical significance was assumed 
when P<0.05.  Data are presented as mean±s.e. mean. 
Molecular biological experiments 
In situ hybridisation.  5-HT1B and 5-HT1D receptor mRNAs were localised employing 
non-radioactive in situ hybridisation on the human middle meningeal artery, coronary 
artery and saphenous vein (n=3 each).  After cleaning the surrounding tissue, the 
blood vessels were fixed for 24 h in 4% paraformaldehyde dissolved in phosphate 
buffered saline.  Chinese hamster ovary (CHO) cells expressing either the human 
recombinant 5-HT1B or 5-HT1D receptor served as positive controls.  After 
dehydration with increasing percentage of ethanol in phosphate buffered saline, the 
blood vessels were embedded in paraffin and 5-µm thick sections were cut with a 
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microtome (model HM325, Microm GmbH, Walldorf, Germany).  The sections were 
mounted on superfrost plus® glass slides (Menzel-Glaser, Braunschweig, Germany) 
and dried at 37 °C for 48 h. 
Recombinant plasmid DNAs encoding the human 5-HT1B (Genbank accession 
number D10995, nucleotide 40-390, length 350 bp) or 5-HT1D (Genbank accession 
number M81589; nucleotide 1-400, length 400 bp) receptor were employed for the 
preparation of non-radioactive cRNA probes.  Linearised DNA templates were 
transcribed to synthesise the sense and antisense cRNAs probes, using T7 or SP6 RNA 
polymerase as per protocol described for the DIG-RNA labelling kit.  DIG-labelled 
cRNA probes were quantified by dot blotting and using serial dilutions of standard 
DIG-labelled control RNA supplied in the kit.  Treatment of tissue sections and cells 
and subsequent hybridisation was performed as described earlier (de Boer et al., 
1998).  The tissues were hybridised with 25 ng of cRNA probe per slide for 16 h at 
55 °C and the DIG-labelled hybrids were detected by incubation with antidigoxigenin 
antibody (1:2000 dilution) conjugated to alkaline phosphatase for 2.5 h at room 
temperature.  The immunodetection of DIG-labelled hybrids was done using 
4-nitroblue tetrazolium chloride (NBT) as chromogen and 
5-bromo-4-chloro-3-indolyl-phosphate (BCIP) as coupling agent. Slides were 
counter-stained with nuclear red solution, dehydrated with ethanol gradients and 
mounted with Euparal (Chroma-Gesellschaft, Schmid GmbH, Köngen, Germany).  
Cells and tissue sections were visualised under a light microscope (model Leica DM 
RBE, Leica NL, BV, Rijswijk, The Netherlands) and photographed using a CCD 
video camera (Sony DXC-950, Sony Corporation, Japan). The sense riboprobes were 
included as negative controls, which showed no or little staining compared to 
antisense riboprobes. 
Endothelial staining.  Serial sections of 5-µm thickness were processed for 
immunohistochemical localisation of endothelial cell marker, CD31.  Sections were 
deparaffinised, rehydrated and incubated with pronase (1 mg/ml) at 37 °C for 10 min 
prior to incubation with specific purified mouse monoclonal antibodies raised against 
human CD31 (Neomarkers, Union City, CA, USA).  To block non-specific binding, 
sections were incubated with 10% normal goat serum diluted in 5% bovine serum 
albumin in phosphate buffered saline (pH = 7.4).  Subsequently, sections were 
incubated overnight at 4 °C with primary antibodies, CD31 (1:75 v/v).  Incubation for 
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30 min with secondary biotinylated anti-immunoglobulins (Multilink, 1:75 v/v, 
Biogenex, San Ramon, USA) and tertiary complex of streptavidin conjugated to 
Alkaline Phosphatase (Label 1:50 v/v, Biogenex, San Ramon, USA) were used to 
enhance the detection sensitivity.  Colour was developed using New Fuchsine as 
chromogen, while endogenous alkaline phosphatase activity was inhibited by 0.01 M 
levamisole (Sigma, St Louis, USA). Slides were counterstained with Mayer's 
hematoxylin.  Positive controls consisted of human cardiac tissue where intense staining 
was seen in the endothelium of all blood vessels.  The optimal dilutions of primary 
antibody were identified by examining the intensity of staining obtained with a series of 
dilutions, which gave specific and easily visible signal on paraffin sections of control 
tissues.  Slides were mounted and visualised using light-microscopy.  Negative 
controls consisted of omission of the primary antibody. 
Ethical approval 
The Medical Ethics Committee of the Erasmus University Medical Centre Rotterdam, 
dealing with the use of the human material for scientific experiments, approved the 
protocols for this investigation. 
Compounds and kits 
For pharmacological study, the following compounds were used: atropine sulphate, 
bradykinin acetate, corticosterone, 5-hydroxytryptamine creatinine sulphate 
(serotonin; 5-HT), imipramine hydrochloride, indomethacin hydrochloride, 
mepyramine maleate, pargyline hydrochloride, prostaglandin F2α tris salt (PGF2α) and 
substance P acetate (all purchased from Sigma Chemical Co., St. Louis, MO, USA), 
mesulergine hydrochloride (gift: Novartis AG, Basel, Switzerland), prazosin 
hydrochloride (gift: Pfizer, Sandwich, UK), sumatriptan succinate, SB224289 
(2,3,6,7- tetrahydro-1'-methyl-5-[2'-methyl-4' (5-methyl-1,2,4-oxadiazo l-3-yl) 
biphenyl-4-carbonyl] furo [2,3f]indole-3-spiro-4'-piperidine hydrochloride) and 
BRL15572 (1-3-chlorophenyl)-4-[3,3-diphenyl (2-(S,R) hydroxypropanyl) 
piperazine] hydrochloride); both from GlaxoSmithKline, Harlow, Essex, UK; 
courtesy: Dr. A.A. Parsons.  Stock solutions of corticosterone (100 mM), 
indomethacin, mesulergine, prazosin, SB224289 and BRL15572 (all 10 mM) were 
dissolved in 100% v/v dimethyl sulphoxide and further diluted in distilled water.  All 
other compounds were dissolved in distilled water. 
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For molecular biology experiments, the materials used were: acetic anhydride, 
diethyl pyrocarbonate, levamisol, maleic acid, triethanolamine and xylene (Sigma 
Chemical Co., St. Louis, MO, USA), antidigoxigenin-AP Fab fragments, blocking 
reagent for nucleic hybridisation, DIG-RNA labelling kit, glycine and RNase T1 
(Boehringer Mannheim, Almere, The Netherlands), bovine serum albumin, dextran 
sulphate, ethylene diaminetetraacetic acid, ficoll, hering sperm DNA, phenol and 
Tris-HCl (Amersham Pharmacia Biotech Benelux, Roosendaal, The Netherlands). 
BCIP, formamide, NBT, proteinase K, sodium citrate and yeast tRNA (Life 
Technologies, Breda, The Netherlands), DNase, RNase inhibitors and Triton-X-100 
(Promega Benelux, Leiden, The Netherlands) and RNase away solution (Molecular 
Bio-products, San Diego, CA, USA). 
Results 
Relaxation responses to substance P and  bradykinin 
The relaxation to substance P (10 nM) amounted to 29% (range: 17-44%, n=6) and 
42% (range: 9-86%, n=3) of precontraction with 1 µM PGF2α in the middle meningeal 
and temporal arteries, respectively.  In the coronary artery, relaxation to substance P 
(1 nM) was 46% (range: 30-66%, n=6) of precontraction to 1 µM PGF2α.  In the 
saphenous vein, relaxation to bradykinin (1 µM)  was 54% (range: 26-82%, n=6) of 
precontraction to 1 µM PGF2α. 
Effects of sumatriptan on cranial arteries 
Concentration response curves to sumatriptan in the middle meningeal and temporal 
arteries are depicted in Figure 6.1.  In both blood vessels, sumatriptan elicited a 
concentration-dependent contraction.  The Emax values (efficacy) of sumatriptan in the 
middle meningeal and temporal arteries were 83±15% and 68±28% of the contraction 
to 1 µM PGF2 α, respectively and the pEC50 values (potency) amounted to 6.7±0.2 and 
6.7±0.3, respectively (Table 6.1).  The responses to sumatriptan in both cranial 
arteries were antagonised by the 5-HT1B receptor antagonist SB224289 (1 µM) and 
the magnitude of antagonism did not correlate with the functional integrity of the 
endothelium (substance P response).   
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Figure 6.1.  Cumulative concentration response curves to sumatriptan in the human 
isolated middle meningeal (n=5-6) and temporal (n=3) arteries in the absence (control) 
or presence of SB224289 (1 µM), BRL15572 (1 µM) or both antagonists (1 µM each).  
Symbols and vertical bars represent the means ± S.E.M. *, Significant difference from 
control contraction elicited by respective concentrations of sumatriptan (Bonferroni 
multiple comparison t-test, P<0.05). 
 
Since SB224289 decreased the Emax of sumatriptan, the antagonism was 
apparently insurmountable and pEC50 values of sumatriptan were not determined 
(Figure 6.1, Table 6.1).  The 5-HT1D receptor antagonist BRL15572 (1 µM) had no 
effect on either the Emax or pEC50 values of sumatriptan.  Also, no additional 
antagonism was observed with the combination of the two antagonists (Figure 6.1, 
Table 6.1). 
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Table 6.1.  Apparent Emax and pEC50 values of sumatriptan in contracting human isolated blood vessels in the absence or presence of antagonists 
Middle meningeal artery Temporal artery Coronary artery Saphenous vein Antagonist 
Emax (%) pEC50 Emax (%) pEC50 Emax (%) pEC50 Emax (%) pEC50 
None 83±15 6.7±0.2 68±28 6.7±0.3 13±2 5.7±0.1 62±4 6.1±0.1 
SB224289 (1 µM) 40±11* ND 2±1* ND 11±3 5.0±0.1* 35±7* ND 
BRL15572 (1 µM) 72±10 6.8±0.2 47±24 6.5±0.2 14±2 5.7±0.1 44±7* 6.1±0.1 
SB224289 (1 µM) + 
BRL15572 (1 µM) 
53±14 ND - - 10±2 5.0±0.2* 32±4* ND 
Data are means±s.e.m. (n=3-6).  Apparent Emax is presented as % of contraction elicited by either 1 µM PGF2α (middle meningeal and temporal artery) or 
100 mM KCl (coronary artery and saphenous vein).  ND, Not determined because of insurmountable nature of the antagonism;  -, not investigated.  *, 
Significantly different from sumatriptan control  (P<0.05). 
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Due to the insurmountable antagonism of sumatriptan by SB224289, pKB values 
could not be estimated.  Alternatively, we calculated the negative logarithm of 
sumatriptan concentration eliciting a response equivalent to 25% of sumatriptan 
control Emax (pEC25%) in the absence or presence of the antagonists in the middle 
meningeal artery; the temporal artery data was not further processed as SB224289 
virtually abolished sumatriptan-induced contractions (Table 6.2).   
 
Table 6.2.  pEC25% of sumatriptan in contracting the middle meningeal artery and 
saphenous vein in the absence or presence of antagonists 
Antagonist Middle meningeal 
artery 
Coronary 
artery 
 
Saphenous vein 
 
None 6.8±0.2 6.3±0.1 6.4±0.1 
SB224289 (1 µM) 5.6±0.4* 5.7±0.3 5.3±0.2* 
BRL15572 (1 µM) 7.0±0.5 6.1±0.1 6.3±0.1 
SB224289 (1 µM) + 
BRL15572 (1 µM) 
6.0±0.5 5.7±0.2* 5.7±0.3* 
Data are mean±s.e.m. (n=4-6).  pEC25% represents the negative logarithm of the 
concentrations of sumatriptan eliciting a contraction equivalent to 25% of individual control 
Emax (middle meningeal artery, 20.8±3.8% of the response to 1 µM PGF2α;  coronary artery, 
3.3±0.4% of the response to 100 mM KCl; saphenous vein, 15.2±0.9% of the response to 
100 mM KCl).  * Significantly different from sumatriptan control (P<0.05). 
 
While BRL15572 was ineffective, the pEC25% of sumatriptan was significantly 
decreased by SB224289.  No additional antagonism was observed with the 
combination of the two antagonists (Table 6.2). 
Effect of sumatriptan on peripheral vessels 
Sumatriptan also contracted the human coronary artery and saphenous vein in a 
concentration-dependent manner.  The pEC50 and (apparent) Emax of sumatriptan were, 
respectively, 5.7±0.1 and 13±2% of the response to 100 mM KCl in the coronary 
artery and 6.1±0.1 and 62±1% of the response to 100 mM KCl in the saphenous vein 
(Figure 6.2, Table 6.1). 
In the coronary artery, SB224289 caused a small parallel rightward shift in the 
concentration response curve to sumatriptan, yielding a significant decrease in the 
pEC50 (5.0±0.1) with no change in the apparent Emax (11±3% of the response to 100 
mM KCl) of sumatriptan.  Schild regression analysis revealed a pKB value of 6.4±0.2 
for SB224289 against sumatriptan.  The shift in the concentration response curve of 
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sumatriptan by SB224289 was independent of the functional integrity of the 
endothelium.  BRL15572 did not have any effect on sumatriptan-induced contraction.  
Incubation with both antagonists together resulted in a small parallel rightward shift 
as was noticed with SB224289 alone (Figure 6.2, Table 6.1). 
 
 
Figure 6.2. Cumulative concentration response curves to sumatriptan in the human 
isolated coronary artery (n=5-6) and saphenous vein (n=4-6) in the absence (control) 
or presence of SB224289 (1 µM), BRL15572 (1 µM) or both antagonists (1 µM each).  
Symbols and vertical bars represent the means ± S.E.M. *, Significant difference from 
control contraction elicited by respective concentrations of sumatriptan (Bonferroni 
multiple comparison t-test, P<0.05). 
 
In the saphenous vein, the response to sumatriptan was antagonised by SB224289 
(1 µM).  Although the contraction to sumatriptan increased with concentration, the 
response did not reach a plateau with the highest concentration used and, therefore, 
pEC50 and pKB values after SB224289 were not determined.  As observed in the other 
blood vessels, the antagonism of SB224289 was independent of the functional 
integrity of the endothelium. Incubation with BRL15572 (1 µM) resulted in a slight 
attenuation of the response to 10 µM sumatriptan as well as its Emax, but no change 
was observed in the pEC50 value of sumatriptan.  Also, no additional antagonism was 
observed with the combination of the two antagonists (Figure 6.2, Table 6.1).  The 
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pEC25% of sumatriptan was not affected by BRL15572, but was reduced after 
SB224289 alone or in combination with BRL15572 (Table 6.2). 
In situ hybridisation 
The specificity of mRNA signals and standardisation of the in situ hybridisation 
conditions were first established by the use of specific sense and antisense probes in 
CHO cells expressing either the human 5-HT1B or 5-HT1D receptor.     
 
Endothelium
CD31 staining
5-HT1D mRNA
5-HT1D mRNA
Middle meningeal
artery Coronary artery Saphenous vein
 
Figure 6.3.  Photographs of immunohistochemical staining with CD31 endothelial 
marker (top panels) and in situ hybridisation with DIG-labelled cRNA probes for 
h5-HT1B (middle panels) and h5-HT1D (lower panels) receptor mRNAs in the human 
middle meningeal and coronary arteries and saphenous vein.  The reddish colour in the 
top panels denotes endothelial cells, while the purple precipitates in the middle panels 
correspond to 5-HT1B receptor mRNA signals. The 5-HT1D receptor mRNA (lower 
panels) as well as the sense riboprobes, as exemplified by the left middle panel inset, 
did not show signals in the three blood vessels.  Scale bar = 50 µm. 
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Strong cytoplasmic and nuclear mRNA expression as a dark purple/blue colour 
for respective antisense riboprobes was observed in these cells, whereas sense 
riboprobes depicted no staining.  Furthermore, the sense riboprobes did not show any 
specific mRNA expression assessed as purple/blue staining in the tissue samples 
included in this study.  If at all staining with sense riboprobes was detected, it was 
always far less than the staining with antisense probes (data not shown). 
Cellular localisation of mRNAs for the 5-HT1B and 5-HT1D receptors in the 
human middle meningeal and coronary arteries and saphenous vein is depicted in 
Figure 6.3.  In the middle meningeal artery, hybridisation with antisense riboprobe 
showed 5-HT1B receptor mRNA signals in the medial smooth muscle layer as well as 
in the endothelial cells, whereas adventitial cells showed only a faint staining.  
Although not so intense, the coronary artery and saphenous vein also expressed the 
5-HT1B receptor mRNA in the vascular smooth muscle cells.  Specific expression for 
the 5-HT1B receptor was seen in the luminal endothelial cells in the case of coronary 
artery.  In order to verify the in situ hybridisation data for the endothelial cell 
expression of 5-HT1B receptor mRNA, CD31 immunohistochemistry was performed 
and it confirmed a cytoplasmic endothelial cell staining (Figure 6.3).  In contrast to 
the 5-HT1B receptor mRNA, no signals were detected for the 5-HT1D receptor mRNA 
in both smooth muscle and endothelial cells in the middle meningeal artery and 
saphenous vein. However, a weak staining for the 5-HT1D receptor mRNA was 
noticed in some endothelial cells in the coronary artery and in adventitial cells in the 
case of middle meningeal as well as coronary arteries (Figure 6.3). 
Discussion 
Craniovascular selectivity of sumatriptan 
Sumatriptan contracted in a concentration-dependent manner both cranial and 
peripheral blood vessels, used as models for antimigraine activity (middle meningeal 
and temporal artery) and possible peripheral side-effect potential (coronary artery and 
saphenous vein), respectively.  The potency of sumatriptan was higher at the middle 
meningeal and temporal arteries (pEC50: 6.7 each) than at the coronary artery (pEC50: 
5.7) and saphenous vein (pEC50: 6.1).   Compared to the other vessels, the efficacy 
(Emax) of sumatriptan in the coronary artery was clearly lower (see Table 6.1).  These 
data, which confirm the cranioselectivity of sumatriptan, are in accordance with other 
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studies dealing with middle meningeal (Jansen et al., 1992; Longmore et al., 1998; 
MaassenVanDenBrink et al., 2000b; Razzaque et al., 1999), temporal (Jansen et al., 
1992; Verheggen et al., 1998) and coronary (Connor et al., 1989; Kaumann et al., 
1994; MaassenVanDenBrink et al., 1998; MaassenVanDenBrink et al., 2000b; 
Nilsson et al., 1999b; Van den Broek et al., 2000) arteries and saphenous vein (Bax et 
al., 1992; MaassenVanDenBrink et al., 2000b; Van den Broek et al., 2000). 
Receptors mediating sumatriptan-induced contractions 
The data obtained in in vitro functional studies show that the 5-HT1B receptor 
antagonist SB224289 clearly attenuated sumatriptan-induced contractions, while the 
5-HT1D receptor antagonist BRL15572 had little effect on the concentration response 
curves to sumatriptan; the combination of SB224289 and BRL15572 did not reveal 
any additional antagonism.  These results establish that the 5-HT1B receptor mediates 
the contractile effects of sumatriptan in both cranial and peripheral blood vessels, 
while the 5-HT1D receptor does not seem to play any role.  The latter conclusion is 
also supported by the fact that selective 5-HT1D receptor agonists (PNU-109291 and 
L775,606) did not contract isolated blood vessels (Bouchelet et al., 2000; Ennis et al., 
1998; Longmore et al., 2000) and, interestingly, one such compound (PNU-142633) 
was also found ineffective in migraine (Cutler et al., 2000).  Based on the high 
affinity of sumatriptan for the 5-HT1F receptor (pKi: 7.9, Leysen et al., 1996), it has 
been argued that this receptor might play a role in the therapeutic action of 
sumatriptan (Johnson et al., 1997).  Although we cannot rule this out, the 5-HT1F 
receptor is not involved in vasoconstriction, since selective 5-HT1F receptor agonists 
(LY344864 and LY334370) show no vasoconstrictor effect (Bouchelet et al., 2000; 
Cohen et al., 1999; Shepheard et al., 1999).  In addition, Verheggen et al. (1998) have 
suggested that in the presence of SB224289 high concentrations of sumatriptan can 
elicit contractions of the human isolated temporal artery via the 5-HT2A receptor.  This 
was not the case in the present studies, probably because we included the mixed 
5-HT2/7 receptor antagonist mesulergine (pKB: 9.1 and 8.2, respectively, Hoyer et al., 
1994) in the Krebs solution.  However, the 5-HT2 receptor antagonist ketanserin was 
unable to block sumatriptan-induced contractions in the human middle meningeal 
(Jansen et al., 1992) and coronary (Connor et al., 1989; Kaumann et al., 1994) arteries 
as well as the saphenous vein (Bax et al., 1992). 
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It may be noted that SB224289 antagonised the responses to sumatriptan in an 
insurmountable manner in the middle meningeal artery, whereas in the temporal artery 
the contractions were virtually abolished.  In the coronary artery, there was a weak 
competitive (surmountable) antagonism, whilst in the saphenous vein an intermediate 
antagonistic response was observed. The nature of the difference in the antagonistic 
behaviour of SB224289 in these blood vessels is not clear.  A possible explanation 
(Schutz et al., 1992) could be that SB224289, which acts as an inverse agonist in cells 
expressing recombinant 5-HT1B receptors (Gaster et al., 1998), may also do so at 
constitutive 5-HT1B receptors.  Another explanation for the observed differences could 
be the influence of receptor density and receptor reserve, but, in view of considerably 
higher 5-HT1B receptor density in meningeal artery as compared to coronary artery 
(Longmore et al., 1997), we should have observed a surmountable antagonism in the 
middle meningeal artery and insurmountable antagonism in the coronary artery.  
Finally, in view of the localisation of the 5-HT1B receptor on the endothelium (see 
below), the effect of SB224289 may be influenced to a different degree by endothelial 
factors (either contractile or relaxing) released upon activation of the 5-HT1B receptor.  
Whatever the mechanism, differences in the nature of antagonism have also been 
observed between sumatriptan and the non-selective 5-HT1B/1D receptor antagonist 
GR127935 (Bouchelet et al., 2000; Razzaque et al., 1999). 
It is surprising that SB224289 proved to be a weak antagonist in our experiments 
as its pKB (6.4±0.2) against sumatriptan in the coronary artery resembled more its pKi 
(6.2) at the 5-HT1D receptor and was far less than its pKi at the 5-HT1B receptor (8.2) 
(Schlicker et al., 1997; Selkirk et al., 1998).  However, if 5-HT1D receptors were 
involved, we would have found BRL15572 to be an even more potent antagonist than 
SB224289; this was obviously not the case.  The involvement of 5-HT1B receptor in 
the sumatriptan-induced coronary artery contraction is also supported by previous 
investigations using non-selective 5-HT1B/1D receptor antagonists (Bax et al., 1993; 
Connor et al., 1989; MaassenVanDenBrink et al., 2000b; Nilsson et al., 1999b; Van 
den Broek et al., 2000).  However, the weaker antagonism by SB224289 than these 
non-selective antagonists suggests that an additional mechanism is partly responsible 
for the coronary contraction induced by sumatriptan.  The nature of this additional 
mechanism is not known, but it cannot be related to 5-HT2 receptors in view of the 
presence of mesulergine in the organ bath.  Certainly, this additional mechanism is of 
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interest in regard to the sumatriptan related cardiac side effects and may prove 
relevant in future antimigraine drug development. 
Vascular localisation of 5-HT1B and 5-HT1D  receptor mRNA 
Although RT-PCR studies have shown the presence of 5-HT1B receptor mRNA in the 
human middle meningeal (Schmuck et al., 1996) and coronary (Bouchelet et al., 
2000; Nilsson et al., 1999b) arteries, the cellular localisation of 5-HT receptor 
subtypes at mRNA level has not been demonstrated.  Our results of in situ 
hybridisation showed the mRNA expression of 5-HT1B receptor in both smooth 
muscle and endothelium, whereas the expression of 5-HT1D receptor mRNA was 
weak, if any, in the three human blood vessels investigated (Figure 6.3).  These results 
are in agreement with the 5-HT1B and 5-HT1D receptor protein localisation in coronary 
and middle meningeal arteries (Longmore et al., 1998; Longmore et al., 1997; Nilsson 
et al., 1999b).  The localisation of 5-HT1B receptor mRNA within the smooth muscle 
cells of these blood vessels, and the lack of 5-HT1D receptor mRNA, strongly suggest 
that contraction to sumatriptan is mediated via the 5-HT1B receptor rather than the 
5-HT1D receptor.  Although the exact role of the endothelial 5-HT1B receptor in these 
vessels is not well understood, we cannot rule out the release of relaxing and/or 
contractile substances upon stimulation. 
Conclusion 
In conclusion, our data show that sumatriptan contracts the human middle meningeal, 
temporal and coronary arteries and saphenous vein via the 5-HT1B receptor, but not 
5-HT1D receptor.  In the human coronary artery, the contraction may also be mediated 
by an unknown, SB224289-resistant, mechanism. 
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Chapter 7 
General Discussion 
The treatment and management of patients with migraine and headache still remains a 
major problem world-wide.  Migraine is a neurovascular disorder of which the 
pathophysiology is not completely understood.  However, more information is 
emerging on the underlying mechanisms for the initiation of a migraine attack, the 
subsequent events leading to the aura and headache (Ferrari et al., 1995; Saxena, 
1995a; De Vries et al., 1999; 2000).  In line with the proposed neurovascular 
hypothesis, several experimental animal models have been developed that may 
explain the efficacy of acutely acting antimigraine drugs, as reviewed by De Vries et 
al. (1999).  The predictive value of these models for migraine therapy is based on: (i) 
the involvement of the trigeminovascular system, i.e. inhibition of plasma protein 
extravasation (Moskowitz, 1993; 1979); (ii) central trigeminal inhibition and, thereby, 
reducing the release of neuropeptides (e.g. calcitonin gene related peptide) (Goadsby, 
1999; May et al., 2001); (iii) vasoconstriction of cranial extracerebral (e.g. within 
carotid) vascular beds or isolated blood vessels (Verheggen et al., 1998; De Vries et 
al., 1999b; 1999; Saxena et al.,1995a; 2000); or (iv) by a combination of these 
mechanisms.  It is important to note, however, that irrespective of the mechanisms 
involved, selective vasoconstriction within the carotid circulation is an important 
property of acutely acting antimigraine drugs (De Vries et al., 1999; Dahlöf et al., 
2000; May et al., 2001). 
Several lines of evidence support the involvement of serotonin 
(5-hydroxytryptamine; 5-HT) and its receptors in migraine (see Introduction).  
Subsequently, it is evidenced by a general feature of commonly used acute 
antimigraine drugs (ergot alkaloids and triptans), which all have a high affinity at 
5-HT1 receptor subtypes, particularly at 5-HT1B, 5-HT1D and 5-ht1F receptors (see 
Table 1.2, 1.3 and 1.5) (Bhalla et al., 2000; Saxena et al., 2000; Bhalla et al., 2001).  
Pharmacological findings, supported by molecular and immunohistochemical 
investigations (Verheggen et al., 1998; De Vries et al., 1999a; Bouchelet et al., 1996; 
2000), clearly revealed that mainly 5-HT1B receptors mediate sumatriptan-induced 
cranial vasoconstriction and may, thereby, explain its therapeutic efficacy in migraine 
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therapy.  On the other hand, 5-HT1D and/or 5-ht1F receptors may mediate the 
presynaptic inhibition of the trigeminovascular inflammatory responses implicated in 
headache (Bouchelet et al., 2000).  Indeed, selective 5-HT1D (e.g. PNU109291, 
PNU142633, L-775,606) as well as 5-ht1F receptor (LY344864) agonists elicit the 
above effect and these compounds are devoid of vasoconstrictor effects in human and 
bovine isolated cerebral blood vessels (Bouchelet et al., 2000).  However, 
PNU142633 proved to be ineffective in the treatment of acute migraine (Gomez-
Mancilla et al., 2001; May et al., 2001) and LY344864, which did show some efficacy 
(Roon, 2000), was used in doses which provided plasma concentrations where  
5-HT1B receptor activity cannot be ruled out.  The introduction of a potent and 
selective 5-HT1B receptor agonist for the treatment of migraine is awaited with great 
interest. 
Although, the triptans are clearly established as acutely acting antimigraine 
agents, some research groups are trying to develop other effective antimigraine 
agents, acting via different mechanisms and/or receptors, which will hopefully lead to 
less side-effects (MaassenVanDenBrink et al., 1998; Saxena et al., 2000).   Examples 
of possible novel avenues for the development of acute antimigraine agents include 
CGRP receptor antagonists, neurokinin NK1 receptor antagonists and drugs that affect 
nitric oxide biosynthesis (Dahlöf et al., 2000; May et al., 2001).  Furthermore, apart 
from specific 5-HT1 receptor subtypes, the 5-HT7 receptor has also been proposed as a 
potential avenue for the development of antimigraine agents.  To date, several studies 
have shown that stimulation of 5-HT7 receptors causes relaxation of vascular smooth 
muscle in different species, including dog (Terrón et al., 1999; Centurion et al., 2000) 
and pig (De Vries et al., 1998b; Saxena et al., 1998).  The effectiveness of selective 
5-HT7 receptor antagonists (e.g. SB258719) may prevent the aforementioned cranial 
vasodilatation and, therefore, could be very useful as prophylactic antimigraine agents 
in the near future (Thomas et al., 1998). 
Molecular cloning of porcine 5-HT1B, 5-HT1D, 5-ht1F and 5-HT7 receptors 
Molecular cloning of 5-HT receptors not only opened the path for the discovery of 
several novel 5-HT receptors but has also made it possible to elucidate their 
pharmacological profile, tissue distribution and functional characterisation in more 
detailed manner (Hoyer et al., 1994).  To date, 5-HT1B, 5-HT1D, 5-ht1F and 5-HT7 
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receptors have been cloned and characterised from human and other mammalian 
species (Weinshank et al., 1992; Adham et al., 1993b; Lovenberg et al., 1993; Tsou et 
al., 1994; Zgombick et al., 1997).  However, the divergence in pharmacological 
profile of a receptor across different species may vary considerably despite a high 
sequence homology (Hamblin et al., 1992).  Interestingly, this was the case for human 
and rat 5-HT1B receptors; a phenomenon that was most likely manifested due to a 
single amino acid difference in the seventh transmembrane region (Oksenberg et al., 
1992).  Thus, it seems evident that extending particular pharmacological 
characteristics of a compound targeted for a specific human receptor across 
mammalian species may have serious consequences across mammalian species for the 
functional outcome.  Therefore, drug receptor interactions should not be extended as 
such from animal to human species without verification of their molecular structures 
and pharmacological profiles.  Moreover, identification of a receptor subtype from a 
species closer in structure and pharmacological profile with its human homologue 
may be useful in the screening and development of novel therapeutic strategies.  In 
this connection, previous investigations from our laboratory have established that 
vasoconstriction of carotid arteriovenous anastomoses in anaesthetised pigs can serve 
as a predictive model for acute antimigraine activity, produced by 5-HT 
receptor-based drugs (De Vries et al., 1999).  However, the lack of information about 
the pharmacological profiles of recombinant porcine 5-HT receptors restricts 
extrapolation of the derived experimental in vivo results to their therapeutic value in 
migraineurs.  For above-mentioned reasons, it is important to clone and 
pharmacologically characterise porcine receptors, thus facilitating the development of 
antimigraine drugs.  Moreover, a precise comparison of recombinant expression 
studies with in vivo experiments may eventually lead to a better understanding in the 
physiological role(s) of a specific receptor in a particular tissue or vascular bed 
(Mialet et al., 2000).  Hence, we set out to clone and characterise porcine specific 
5-HT1B, 5-HT1D, 5-ht1F and 5-HT7 receptors cDNAs and attempted to characterise 
them pharmacologically.  The data presented in chapter 2, 3, 4 and 5 describes about 
porcine 5-HT1B, 5-HT1D, 5-ht1F, and 5-HT7 receptor respectively. 
Several classical molecular techniques, i.e. reverse transcriptase (RT) and 
inverse polymerase chain reaction (PCR), enabled us to clone and sequence porcine 
5-HT receptors (namely 5-HT1B, 5-HT1D, 5-ht1F and 5-HT7).  It may be mentioned that 
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the RT-PCR and inverse PCR techniques were employed on either cDNA or genomic 
DNA, which was prepared from porcine tissues and blood respectively.  Porcine 
5-HT1B, 5-HT1D and 5-ht1F receptors showed a nucleotide sequence of 1173bp, 
1134bp and 1101bp, which encodes for 390, 377 and 366 amino acid protein 
respectively.  Both the 5’ and 3’ ends of the three cDNAs were verified by inverse 
PCR.  These recombinant porcine 5-HT1 receptor subtypes (5-HT1B, 5-HT1D, 5-ht1F) 
showed a typical G-protein coupled receptor structure with predicted seven 
transmembrane domains as well as putative N-glycosylation and phoshorylation sites 
as observed in other species (Weinshank et al., 1992; Adham et al., 1993b; Harwood 
et al., 1995). Although some of the amino acids in porcine 5-HT1 receptor subtypes 
(5-HT1B, 5-HT1D, 5-ht1F) were observed to be different from other species, but an 
overall high amino acid homology (88-95%) was observed across a variety of species, 
including human (Weinshank et al., 1992; Adham et al., 1993b; Harwood et al., 1995; 
Bard et al., 1996; Adham et al., 1997; Wurch et al., 1997; Zgombick et al., 1997).  
Moreover, the comparison between the deduced amino acid sequence of the porcine 
5-HT1B and 5-HT1D receptor displayed an overall (61%) homology, which was 
considerably higher in the transmembrane domains (77%) similar as observed in case 
of human receptors (Weinshank et al., 1992).  The porcine 5-HT1B receptor has 
exactly the same number of amino acids (390) as found in human and rabbit 
(Weinshank et al., 1992; Harwood et al., 1995); the rat and mouse 5-HT1B receptors 
contain 386 (Voigt et al., 1991), while the guinea pig 5-HT1B receptor contains 389 
(Zgombick et al., 1997) amino acids.  Recombinant porcine 5-HT1B receptor revealed 
a conserved threonine (amino acid) at an identical position in the seventh 
transmembrane domain (at position 355) as observed in human, rabbit and guinea pig 
(Weinshank et al., 1992; Harwood et al., 1995; Zgombick et al., 1997).  However, in 
case of rodents 5-HT1B receptor, an asparagine is found at this position (Voigt et al., 
1991).  As mentioned before, this amino acid mutation is of particular interest because 
it alters the pharmacological properties drastically in the rodent 5-HT1B receptor as 
compared to human 5-HT1B receptor (Oksenberg et al., 1992). 
Similarly, the number of total amino acids in the porcine 5-HT1D receptor 
protein were the same as found in other species, e.g. human, rabbit, dog and guinea 
pig, while three amino acids are less in rodents (Wurch et al., 1997).  As discussed for 
the 5-HT1B receptor, the presence of threonine at the seventh transmembrane domain 
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was also observed in porcine 5-HT1D receptor, similar to the other mammalian 
species, such as human, guinea pig, rat, mouse and rabbit (Weinshank et al., 1992; 
Harwood et al., 1995; Zgombick et al., 1997).  Unlike the 5-HT1B receptor, the 
presence of this threonine in 5-HT1D receptor across these mammalian species seems 
to be responsible for the similar pharmacological profile of 5-HT1D receptor across 
different species.   
The porcine 5-ht1F receptor polypeptide showed exactly the same number of 
amino acid as observed in other mammalian species (Adham et al., 1993b; Lovenberg 
et al., 1993; Adham et al., 1997).  However, a threonine at position 333 in place of 
alanine (as observed in human, chimpanzee, gorilla, guniea pig, mouse and rat) was 
found in porcine and orang-utan 5-ht1F receptor.  In order to verify this difference at 
position 333, we sequenced a large number of cDNA as well as genomic DNA 
derived PCR products and eventually established the polypeptide sequence of 5-ht1F 
receptor.  As discussed in the next section, this particular modification in amino acid 
at this position may be the reason for the observed low affinity of some serotonergic 
ligands for the porcine compared to the human receptor (see Table 4.4).  This could 
also be addressed by using site directed mutation or chimeric receptor studies on 
porcine 5-ht1F receptor. Interestingly, it has been shown for human 5-ht1F receptor that 
the change of alanine to asparagine at position 333 also resulted in a drastic increase 
of affinity for β adrenoceptor antagonists (such as propranolol and pindolol), but not 
for 5-HT (Adham et al., 1994).   The porcine 5-ht1F receptor also showed a low 
affinity for pindolol in analogy to human, but, unlike the human receptor, some 
triptans (rizatriptan, sumatriptan and zolmitriptan) showed several folds less affinity 
for porcine 5-ht1F receptor. 
The porcine 5-HT7 receptor protein consists of 447 amino acids.  The BLAST 
search at GenBank revealed high resemblance (92-96%) with the sequence of 5-HT7 
receptors from other species, including human, mouse, rat and guinea pig.  It may be 
important to note that the amino acid homology between the cloned porcine and 
human 5-HT7 receptors was the highest (96%).  Nevertheless, the porcine 5-HT7 
receptor showed some different amino acids as compare to other species.  For 
example, at the N-terminal, Ser33, Gly37, His49, Val59 and Arg66 were shown to be 
located, while a Leu433 and Lys436 were found towards the C-terminal ends.  
Chapter 7 General discussion 
160 
Moreover, Leu221 and Met248 were found in the fourth and fifth transmembrane 
domains, while a Glu283 in the fifth and sixth transmembrane domains. 
Pharmacological characterisation of porcine 5-HT1 receptor subtypes 
The characterisation of receptors is based on structural (molecular), operational 
(pharmacological profile) and transductional (receptor-effector coupling) criteria 
(Hoyer et al., 1994; Hoyer et al., 1997).  Therefore, we studied the ligand binding 
profile of the different recombinant porcine 5-HT1 receptor subtypes (5-HT1B, 5-HT1D 
and 5-ht1F) in membranes obtained from mammalian cells expressing these receptors.   
Unfortunately, the ligand binding profile of the porcine 5-HT7 receptor has not yet 
been studied due to the unavailability of a full-length cDNA insert for expression in 
cells. 
In case of recombinant porcine 5-HT1B receptors, the competitive binding assay 
using [3H]GR125743 showed the following rank order: L694247 > ergotamine ≥ 
5-carboxamidotryptamine = dihydroergotamine = 5-HT > CP122638 = zolmitriptan > 
sumatriptan for agonists; GR127935 > methiothepin > SB224289 >> ritanserin > 
ketanserin ≥ BRL15572 for putative antagonists.  The pKi values showed a high 
correlation with those reported for the recombinant human receptor (rs=0.988).  On 
the other hand, the comparison between the pKi values at porcine and rat 5-HT1B 
receptors showed a lower correlation (rs =0.808).  The human 5-HT1B receptor 
selective antagonist SB224289 (Selkirk et al., 1998) also displayed a high affinity for 
the recombinant porcine 5-HT1B receptor, but the human selective 5-HT1D receptor 
antagonist BRL15572 (Price et al., 1997) exhibited more than 100-fold lower affinity.  
Moreover, functional characterisation of porcine 5-HT1B receptor showed that both 
5-HT and zolmitriptan potently increased [35S]GTPγS binding and this was similar to 
the recombinant human 5-HT1B receptor (Pauwels et al., 1997).  Interestingly, the 
5-HT1B-receptor antagonist SB224289 inhibited [35S]GTPγS binding and acted as an 
inverse agonist at porcine 5-HT1B receptor, as noticed earlier using the recombinant 
human 5-HT1B receptor (Selkirk et al., 1998).  Thus, the porcine 5-HT1B receptor 
closely resembles the human 5-HT1B receptor in its pharmacology and, therefore, it 
can be used for screening 5-HT1B receptor ligands likely to be of therapeutic value in 
humans. 
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The competitive binding assay using either [3H]GR125743 or 
[3H]5-carboxamidotryptamine at porcine 5-HT1D receptor revealed the following 
potency rank order: L694247 > 5-CT > zolmitriptan > 5-HT > sumatriptan = 
CP122638 = ergotamine > dihydroergotamine for agonists and methiothepin > 
GR127935 > ketanserin > ritanserin >> SB224289 ≥ BRL 15572 for antagonists.  The 
pKi values showed a high correlation with human 5-HT1D receptor (rs=.903) and, as in 
the human, ketanserin was found to be 40-fold more potent at the porcine 5-HT1D than 
at the porcine 5-HT1B receptor.  However, in contrast to a selective and high 
antagonist potency at the human 5-HT1D receptor (Price et al., 1997), BRL15572 had 
a poor affinity at the porcine 5-HT1D receptor.  This example shows that one should 
be cautious in extrapolating the affinity and efficacy of compounds from one species 
to the other.  As seen with the 5-HT1B receptor, both 5-HT and zolmitriptan increased 
[35S]-GTPγS binding in membranes obtained from cells expressing porcine 5-HT1D 
receptor. 
As described in Chapter 4, the recombinant porcine 5-ht1F receptor showed a 
high affinity for [3H]5-HT.  Competitive binding assay revealed that the selective 
5-ht1F receptor agonist LY 334370 displayed a high affinity for the porcine 5-ht1F 
receptor. The rank order of affinity of the putative agonists was LY334370 > 
CP122638 = naratriptan = 5-HT > eletriptan > sumatriptan > frovatriptan = avitriptan 
> dihydroergotamine > zolmitriptan > 5-carboxamidotryptamine > rizatriptan > 
alniditan = donitriptan > L694247, while that of putative antagonists was 
methiothepin > GR127935 > ritanserin > SB224289 > BRL15572 > ketanserin = 
pindolol.  The pKi values obtained at the porcine 5-ht1F receptor showed a high 
correlation (rs=0.911) with those reported for the human 5-ht1F receptor.  
Nevertheless, it may be important to mention that some triptans (sumatriptan, 
rizatriptan and zolmitriptan) exhibited more than 10 -fold less affinity for porcine 
5-ht1F receptor as compared to the human receptor.  The molecular basis for the 
selectivity of these receptors among the species may be due to the differences in the 
transmembrane domain structure of the receptor and could be addressed by site 
directed mutation and chimeric receptor studies. 
In conclusion, the porcine 5-HT1B, 5-HT1D and 5-HT1F receptors revealed a high 
homology in amino acid sequence as well as a high correlation in pharmacological 
properties as compared to the human. 
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Expression of specific porcine 5-HT receptor subtype mRNA 
By means of RT-PCR techniques, we have studied the presence of 5-HT1B, 5-ht1F and 
5-HT7 receptor mRNAs in various porcine blood vessels and brain tissues.  This 
information may be of interest for the understanding of the pathophysiology and 
treatment of migraine. 
As described in Chapter 2, porcine 5-HT1B receptor mRNA was detected 
ubiquitously in brain (cortex and cerebellum), trigeminal ganglion, heart (left 
ventricle) and blood vessels (left anterior descending coronary, pulmonary, common 
carotid, superior mesenteric and femoral arteries and saphenous vein).  Furthermore, 
other reports have also shown 5-HT1B receptor mRNA expression in various cerebral 
arteries of rat, bovine and human (Hamel et al., 1993; Ullmer et al., 1995).  The 
ubiquitous presence of 5-HT1B receptor in various blood vessels suggests that 
peripheral vasoconstriction is mediated via 5-HT1B receptor (Chapter 6, Van den 
Broek et al., 2001).  On the other hand, the presence of 5-HT1B receptor in brain 
cortex (also demonstrated by in situ hybridisation) and trigeminal ganglion indicates 
its role in inhibiting the release of neurotransmitters in the brain as well as peptides 
(CGRP, substance P, etc) from the trigeminal neurones.  
As reported for the human trigeminal ganglion (Bouchelet et al., 1996), we also 
noticed the presence of the 5-ht1F receptor in porcine trigeminal ganglion.  The 
expression of the 5-ht1F receptor in porcine trigeminal ganglion supports the notion 
that this receptor may mediate the inhibition of dural plasma protein extravasation by 
serotonergic ligands (Johnson et al., 1997; Phebus et al., 1997).  The selective 5-ht1F 
receptor agonist (LY334370) has been shown to block neurogenic plasma protein 
extravasation in the dura mater and reduce c-fos expression in the trigeminal nucleus 
caudalis without constricting cerebral or coronary arteries (Johnson et al., 1997; 
Phebus et al., 1997).  Thus, a specific 5-ht1F-receptor agonist may be useful as an 
antimigraine drug without causing vasoconstriction.  However, in a recent study the 
selective 5-HT1D receptor agonist (PNU-142633), but not LY334370, blocked 
neurogenic dural vasodilatation in anaesthetised guinea pig (Williamson et al., 2001), 
suggesting that 5-HT1D rather than 5-HT1F receptor may be the preferential target for 
the antimigraine action.  The presence of mRNA signals for the 5-ht1F receptor in 
brain cortex and cerebellum were similar to those reported by Lovenberg (1993) and 
point towards its function as an autoreceptor.  While vasoconstrictor properties of 
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5-ht1F receptors were ruled out in rabbit saphenous vein (Cohen et al., 1999), we 
found some mRNA signals in porcine saphenous vein and coronary artery; the latter 
was qualitatively similar with the recent findings in the human coronary artery 
(Bouchelet et al., 2000).  The physiological implication of this finding is not clear as 
till date no functional role of the 5-ht1F in blood vessels has been demonstrated.  Since 
several triptans (e.g. rizatriptan and alniditan) display a poor affinity for the 5-HT1F 
receptor, it would appear that an agonist action at the 5-HT1F receptor is not a pre-
requisite for the antimigraine efficacy (Saxena et al., 2000). 
The 5-HT7 receptor mRNA was observed in porcine brain (cortex, hemisphere, 
cerebellum) as well as in blood vessels (pulmonary and coronary artery and 
saphenous vein), but not in the heart.  The 5-HT7 receptor has also been observed in 
both brain and blood vessels of rat and human tissues (Ullmer et al., 1995; Heidmann 
et al., 1998).  The distribution of the receptor in both central and peripheral tissues 
and vascular bed indicates that it may play an important physiological role.  
Expression of 5-HT7 mRNA in brain tissues as well as high affinity of antipsychotic 
drugs (risperidone and clozapine) for this receptor suggests that the 5-HT7 receptor 
may be a target for the treatment of psychotic disorders (Roth et al., 1994). 
Pharmacological studies have shown that 5-HT7 receptor mediates smooth muscle 
relaxation in the guinea pig ileum (Carter et al., 1995), rabbit pulmonary artery 
(Morecroft et al., 1998), rabbit femoral vein (Martin et al., 1995), monkey jugular 
vein (Leung et al., 1996) and dog external carotid vasculature (Villalón et al., 1997) as 
well as tachycardia in the cat (Villalon et al., 1997).  Interestingly, tachycardia in the 
pig and human heart is mediated by 5-HT4 but not 5-HT7 receptors (Saxena, 1995b) 
and this corresponds to the presence of 5-HT4 (and not 5-HT7) receptor mRNA in the 
human and porcine heart (Bard et al., 1993/, Chapter 5). 
 To correlate the porcine tissue distribution of 5-HT1B and 5-HT1D receptors in 
the view of clinical implication for humans, we performed in vitro functional and 
molecular biological studies using human isolated blood vessels relevant for the 
underlying mechanisms inducing a migraine attack (Chapter 6).  For this reason, we 
used the middle meningeal and temporal arteries (to evaluate the therapeutic efficacy 
of current used antimigraine agents) and the coronary artery and saphenous vein (in 
order to evaluate potential side effects).  Sumatriptan, a non-selective 5-HT1B/1D 
receptor agonist induces contraction of these blood vessels (De Vries et al., 1999; 
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Goadsby, 1999; Saxena et al., 2000).  We found that the selective 5-HT1B receptor 
antagonist SB224289 blocked these responses, while the selective 5-HT1D receptor 
antagonist BRL15572 proved to be ineffective, thus showing that vasoconstriction 
was mediated by the 5-HT1B but not 5-HT1D receptor.  As mentioned above, the 
localisation of these individual receptors in blood vessels was in agreement with this 
conclusion.  Even though the protein distribution of 5-HT1B and 5-HT1D receptor in 
blood vessels has been reported by Longmore (1997), we feel that the precise 
localisation of mRNA provides more detailed information concerning the synthesis 
and expression of these receptors in a given cell type. 
Limitations and precautions 
In the present thesis, we have described the cloning (RT-PCR and inverse PCR), 
pharmacological characterisation (radioligand binding assays and functional assays) 
and localisation (non-radioactive in situ hybridisation) of porcine 5-HT receptors.  
The studies compiled in this thesis may have some limitations.  Such limitations and 
precautions taken are itemised below: 
 
1. Due to the very high sensitivity of the polymerase chain reaction (PCR) technique, 
any incorrect incorporation of a nucleotide will further be amplified in the cloned 
product.  To rectify this, several full-length PCR amplified products were cloned 
and sequenced.  Alternatively, one can screen the genomic or cDNA library 
derived from the porcine tissue to establishing the full-length sequence. 
 
2. In some cases, two products were visible from inverse PCR technique on genomic 
DNA circles, even at a high (>60°C) annealing temperature.  In such cases, the 
specific band of the larger product length was selected for further cloning and 
sequencing, as smaller bands showed only the partial sequence of the product. 
 
3. For the localisation of 5-HT1 receptors in various tissue, we performed 
non-radioactive in situ hybridisation technique, which is relatively less sensitive to 
detect mRNA.  It would be better to complement our finding on localisation using 
radioactive in situ hybridisation also. 
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4. Pharmacological studies using membranes obtained from cells expressing the 
recombinant receptor provide useful data with respect to the affinity and efficacy, 
but one should keep in mind that drug activity may vary according to the level of 
expression of a particular receptor.  For example, the arylkylamines propranolol 
and pindolol and the ergot derivative metergoline, which have been described as 
antagonists or partial agonists in in vivo or in vitro studies, were found to behave 
as full agonists in cells expressing the rat or human 5-HT1B receptor (Miller et al., 
1992; Adham et al., 1993a). 
 
5. The in vitro studies performed with the isolated blood vessels in organ baths 
provide the possibility of a more detailed study than the in vivo studies on animals 
and/or patients.  However, in organ bath studies, drugs are acting at both 
intraluminal and extraluminal sides of the blood vessels, while in in  vivo 
experiments the intraluminal side of the blood vessels is only exposed. 
Implication in future research 
The results compiled in this thesis showing the amino acid sequence and 
pharmacological properties of porcine 5-HT1B, 5-HT1D, 5-ht1F and 5-HT7 receptors 
could be useful for the subsequent studies as outlined below: 
 
1. To understand the potential role of these receptors in the pathophysiological 
processes leading to migraine attacks and, possibly, their usefulness in migraine 
therapy. 
 
2. To investigate why the selective 5-HT1D receptor antagonist BRL15572 showed a 
low affinity at porcine 5-HT1D receptors.  By means of site directed mutation / 
deletion experiments, it may be possible to recognise specific amino acid(s) in the 
transmembrane domain that may explain this interesting feature. 
 
3. Similarly, by mutating a single amino acid (threonine at position 333) or multiple 
nucleotides in the porcine 5-ht1F receptor may explain why the antimigraine 
triptans display lower affinity at this receptor in pigs as compared to that at the 
human 5-ht1F receptor. 
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4. The recombinant porcine receptors (5-HT1B, 5-HT1D, 5-ht1F and 5-HT7) may be 
exploited to investigate possible signal transduction mechanisms involved in the 
vasomotor activity (constriction and dilatation) of blood vessels.  In this regards, 
several mechanism(s) are still not clear, e.g.: (1) stimulation/inhibition of adenylyl 
cyclase activity; (2) increase/decrease of intracellular calcium concentration and 
the role of inositol triphosphates; and (3) opening/closing of calcium channels 
(e.g. Ca2+ dependent K+, Ca2+ activated Cl- channels) that couple after activation 
of the individual receptor. 
 
5. Tissue localisation of 5-HT7 receptor by using a specific probe derived from the 
recombinant receptor might be helpful to know the expression and functional 
relevance of this receptor in that particular tissue.  Additionally, attempts should 
be made to clone a single full-length cDNA encoding porcine 5-HT7 receptor that 
could further be used to express in mammalian cell lines to establish the 
pharmacological profile of porcine 5-HT7 receptor.  The distribution pattern, 
functional characterisation and pharmacological profile of various isoforms of 
porcine 5-HT7 receptor (if present) would be helpful to know the differential 
properties of 5-HT7 receptor family. 
Chapter 7 General discussion 
167 
References 
ADHAM, N., BARD, J.A., ZGOMBICK, J.M., DURKIN, M.M., KUCHAREWICZ, S., WEINSHANK, R.L. & 
BRANCHEK, T.A. (1997). Cloning and characterization of the guinea pig 5-HT1F receptor 
subtype: a comparison of the pharmacological profile to the human species homolog. 
Neuropharmacology, 36, 569-576. 
ADHAM, N., ELLERBROCK, B., HARTIG, P., WEINSHANK, R.L. & BRANCHEK, T. (1993a). Receptor 
reserve masks partial agonist activity of drugs in a cloned rat 5-hydroxytryptamine1B receptor 
expression system. Mol. Pharmacol., 43, 427-433. 
ADHAM, N., KAO, H.T., SCHECTER, L.E., BARD, J., OLSEN, M., URQUHART, D., DURKIN, M., HARTIG, 
P.R., WEINSHANK, R.L. & BRANCHEK, T.A. (1993b). Cloning of another human serotonin 
receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate 
cyclase. Proc. Natl. Acad. Sci. U S A, 90, 408-412. 
ADHAM, N., TAMM, J.A., SALON, J.A., VAYSSE, P.J.-J., WEINSHANK, R.L. & BRANCHEK, T.A. (1994). 
A single point mutation increases the affinity of serotonin 5-HT1Dα, 5-HT1Dβ, 5-HT1Eand 5-
HT1F receptors for α-adrenergic antagonists. Neuropharmacology, 33, 387-391. 
BARD, J.A., KUCHAREWICZ, S.A., ZGOMBICK, J.M., WEINSHANK, R.L., BRANCHEK, T.A. & COHEN, 
M.L. (1996). Differences in ligand binding profiles between cloned rabbit and human 5-HT1Dα  
and 5-HT1Dβ receptors: ketanserin and methiothepin distinguish rabbit 5-HT1D receptor 
subtypes. Naunyn-Schmiedeberg's Arch. Pharmacol., 354, 237-244. 
BARD, J.A., ZGOMBICK, J., ADHAM, N., VAYSSE, P., BRANCHEK, T.A. & WEINSHANK, R.L. (1993). 
Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase. J. 
Biol. Chem., 268, 23422-23426. 
BHALLA, P., SHARMA, H.S., MA, X., WURCH, T., PAUWELS, P.J. & SAXENA, P.R. (2001). Molecular 
cloning, pharmacological properties and tissue distribution of the porcine 5-HT1B receptor. Br. 
J. Pharmacol., 133, 891-901. 
BHALLA, P., SHARMA, H.S., WURCH, T., PAUWELS, P.J. & SAXENA, P.R. (2000). Molecular cloning, 
sequence analysis and pharmacological properties of the porcine 5-HT1D receptor. Br. J. 
Pharmacol., 131, 949-957. 
BOUCHELET, I., CASE, B., OLIVIER, A. & HAMEL, E. (2000). No contractile effect for 5-HT1D and 5-
HT1F receptor agonists in human and bovine cerebral arteries: similarity with human coronary 
artery. Br. J. Pharmacol., 129, 501-508. 
BOUCHELET, I., COHEN, Z., CASE, B., SEGUELA, P. & HAMEL, E. (1996). Differential expression of 
sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral 
blood vessels. Mol. Pharmacol., 50, 219-223. 
CARTER, D., CHAMPNEY, M., HWANG, B. & EGLEN, R.M. (1995). Characterization of a postjunctional 
5-HT receptor mediating relaxation of guinea-pig isolated ileum. Eur. J. Pharmacol., 280, 
243-250. 
CENTURION, D., ARACELI SANCHEZ-LOPEZ, A., ORTIZ, M.I., DE VRIES, P., SAXENA, P.R. & VILLALON, 
C.M. (2000). Mediation of 5-HT-induced internal carotid vasoconstriction in GR127935- and 
ritanserin-pretreated dogs by 5-HT7 receptors. Naunyn-Schmied. Arch. Pharmacol., 362, 169-
176. 
COHEN, M.L. & SCHENCK, K. (1999). 5-Hydroxytryptamine1F receptors do not participate in 
vasoconstriction: lack of vasoconstriction to LY344864, a selective serotonin1F receptor 
agonist in rabbit saphenous vein. J. Pharmacol. Exp. Ther., 290, 935-939. 
DAHLÖF, C.G.H. & SAXENA, P.R. (2000). Novel compounds in development for acute treatment of 
migraine. In The Migraines (Second Eddition). ed. Olesen, J., Tfelt-Hansen, P. & Welch, 
K.M.A. pp. 439-443. Philadelphia: Lippincott Wiliams & Wilkins. 
DE VRIES, P., SANCHEZ-LOPEZ, A., CENTURION, D., HEILIGERS, J.P.C., SAXENA, P.R. & VILLALON, 
C.M. (1998a). The canine external carotid vasoconstrictor 5-HT1 receptor: blockade by 5-
HT1B (SB224289), but not by 5-HT1D (BRL15572) receptor antagonists. Eur. J. Pharmacol., 
362, 69-72. 
DE VRIES, P., WILLEMS, E.W., HEILIGERS, J.P.C. & SAXENA, P.R. (1998b). Constriction of porcine 
arteriovenous anastomoses as indicator of antimigraine activity. Involvement of 5-HT1B/1D and 
novel receptors. Br. J. Pharmacol., 123, 1561-1570. 
Chapter 7 General discussion 
168 
DE VRIES, P., WILLEMS, E.W., HEILIGERS, J.P.C., VILLALON, C.M. & SAXENA, P.R. (1999a). 
Investigations of the role of 5-HT1B and 5-HT1D receptors in the sumatriptan-induced 
constrction of porcine carotid arteriovenous anastomoses. Br. J. Pharmacol., 127, 405-412. 
DE VRIES, P., WILLEMS, E.W., HEILIGERS, J.P.C., VILLALÓN, C.M. & SAXENA, P.R. (1999b). 
Constriction of porcine carotid arteriovenous anastomoses as indicator of antimigraine 
activity: the role of 5-HT1B/1D, as well as unidentified receptors. In Migraine & headache 
pathophysiology. ed. Edvinsson, L. London: Martin Dunitz Ltd. 
DE VRIES, P., VILLALÓN, C.M. & SAXENA, P.R. (1999). Pharmacological aspects of experimental 
headache models in relation to acute antimigraine therapy. Eur. J. Pharmacol., 375, 61-74. 
FERRARI, M.D. & SAXENA, P.R. (1995). 5-HT1 receptors in migraine pathophysiology and treatment. 
European Journal of Neurology, 2, 5-21. 
GOADSBY, P.J. (1999). Advances in the pharmacotherapy of migraine. How knowledge of 
pathophysiology is guiding drug development. Drugs R D, 2, 361-374. 
GOMEZ-MANCILLA, B., CUTLER, N., LEIBOWITZ, M., SPIERINGS, E., KLAPPER, J., DIAMOND, S., 
GOLDSTEIN, J., SMITH, T., COUCH, J., FLEISHAKER, J., AZIE, N. & BLUNT, D. (2001). Safety 
and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine. 
Cephalalgia, 21, 727-732. 
HAMBLIN, M.W., METCALF, M.A., MCGUFFIN, R.W. & KARPELLS, S. (1992). Molecular cloning and 
functional characterization of a human 5-HT1B serotonin receptor: a homologue of the rat 5-
HT1B receptor with 5-HT1D- like pharmacological specificity. Biochem. Biophys. Res. 
Commun., 184, 752-759. 
HAMEL, E., FAN, E., LINVILLE, D., TING, V., VILLEMURE, J.G. & CHIA, L.S. (1993). Expression of 
mRNA for the serotonin 5-hydroxytryptamine1D beta receptor subtype in human and bovine 
cerebral arteries. Mol. Pharmacol., 44, 242-246. 
HARWOOD, G., LOCKYER, M., GILES, H. & FAIRWEATHER, N. (1995). Cloning and characterisation of 
the rabbit 5-HT1Dα  and 5-HT1Dβ  receptors. FEBS Lett., 377, 73-76. 
HEIDMANN, D.E., SZOT, P., KOHEN, R. & HAMBLIN, M.W. (1998). Function and distribution of three 
rat 5-hydroxytryptamine7 (5-HT7) receptor isoforms produced by alternative splicing. 
Neuropharmacology, 37, 1621-1632. 
HOYER, D., CLARKE, D.E., FOZARD, J.R., HARTIG, P.R., MARTIN, G.R., MYLECHARANE, E.J., SAXENA, 
P.R. & HUMPHREY, P.P.A. (1994). International Union of Pharmacology classification of 
receptors for 5-hydroxytryptamine (Serotonin). Pharmacol. Rev., 46, 157-203. 
HOYER, D. & HUMPHREY, P.P. (1997). Nomenclature and classification of transmitter receptors: an 
integrated approach. J. Recept. Signal Transduct. Res., 17, 551-568. 
JOHNSON, K.W., SCHAUS, J.M., DURKIN, M.M., AUDIA, J.E., KALDOR, S.W., FLAUGH, M.E., ADHAM, 
N., ZGOMBICK, J.M., COHEN, M.L., BRANCHEK, T.A. & PHEBUS, L.A. (1997). 5-HT1F 
receptor agonists inhibit neurogenic dural inflammation in guinea pigs. Neuroreport, 8, 2237-
2240. 
LEUNG, E., WALSH, L.K.M., PULIDO-RIOS, M.T. & EGLEN, R.M. (1996). Characterization of putative 
5-ht7 receptors mediating direct relaxation in Cynomolgus monkey isolated jugular vein. Br. J. 
Pharmacol., 117, 926-930. 
LONGMORE, J., SHAW, D., SMITH, D., HOPKINS, R., MCALLISTER, G., PICKARD, J.D., SIRINATHSINGHJI, 
D.J., BUTLER, A.J. & HILL, R.G. (1997). Differential distribution of 5HT1D- and 5HT1B-
immunoreactivity within the human trigemino-cerebrovascular system: implications for the 
discovery of new antimigraine drugs. Cephalalgia, 17, 833-842. 
LOVENBERG, T.W., ERLANDER, M.G., BARON, B.M., RACKE, M., SLONE, A.L., SIEGEL, B.W., CRAFT, 
C.M., BURNS, J.E., DANIELSON, P.E. & SUTCLIFFE, J.G. (1993). Molecular cloning and 
functional expression of 5-HT1E-like rat and human 5-hydroxytryptamine receptor genes. 
Proc. Natl. Acad. Sci. U S A, 90, 2184-2188. 
MAASSENVANDENBRINK, A., REEKERS, M., BAX, W.A., FERRARI, M.D. & SAXENA, P.R. (1998). 
Coronary side-effect potential of current and prospective antimigraine drugs. Circulation, 98, 
25-30. 
MARTIN, G.R. & WILSON, R.J. (1995). Operational characteristics of a 5-HT receptor mediating direct 
vascular relaxation: identity with the 5-ht7 receptor? Br. J. Pharmacol., 114, 383P. 
Chapter 7 General discussion 
169 
MAY, A. & GOADSBY, P.J. (2001). Pharmacological opportunities and pitfalls in the therapy of 
migraine. Curr. Opin. Neurol., 14, 341-345. 
MIALET, J., BERQUE-BESTEL, I., EFTEKHARI, P., GASTINEAU, M., GINER, M., DAHMOUNE, Y., 
DONZEAU-GOUGE, P., HOEBEKE, J., LANGLOIS, M., SICSIC, S., FISCHMEISTER, R. & 
LEZOUALC'H, F. (2000). Isolation of the serotoninergic 5-HT4(e) receptor from human heart and 
comparative analysis of its pharmacological profile in C6-glial and CHO cell lines. Br. J. 
Pharmacol., 129, 771-781. 
MILLER, K.J., KING, A., DEMCHYSHYN, L., NIZNIK, H. & TEITLER, M. (1992). Agonist activity of 
sumatriptan and metergoline at the human 5-HT1D beta receptor: further evidence for a role of 
the 5-HT1D receptor in the action of sumatriptan. Eur. J. Pharmacol., 227, 99-102. 
MORECROFT, I. & MACLEAN, M.R. (1998). 5-hydroxytryptamine receptors mediating vasoconstriction 
and vasodilation in perinatal and adult rabbit small pulmonary arteries. Br. J. Pharmacol., 125, 
69-78. 
MOSKOWITZ, M.A. (1993). Neurogenic inflammation in the pathophysiology and treatment of 
migraine. Neurology, 43, S16-20. 
MOSKOWITZ, M.A., REINHARD, J.F., JR., ROMERO, J., MELAMED, E. & PETTIBONE, D.J. (1979). 
Neurotransmitters and the fifth cranial nerve: is there a relation to the headache phase of 
migraine? Lancet, 2, 883-885. 
OKSENBERG, D., MARSTERS, S.A., O'DOWD, B.F., JIN, H., HAVLIK, S., PEROUTKA, S.J. & ASHKENAZI, 
A. (1992). A single amino-acid difference confers major pharmacological variation between 
human and rodent 5-HT1B receptors. Nature, 360, 161-163. 
PAUWELS, P.J., TARDIF, S., PALMIER, C., WURCH, T. & COLPAERT, F.C. (1997). How efficacious are 5-
HT1B/D receptor ligands: an answer from GTP gamma S binding studies with stably transfected 
C6-glial cell lines. Neuropharmacology, 36, 499-512. 
PHEBUS, L.A., JOHNSON, K.W., ZGOMBICK, J.M., GILBERT, P.J., VAN BELLE, K., MANCUSO, V., 
NELSON, D.L., CALLIGARO, D.O., KIEFER, A.D., JR., BRANCHEK, T.A. & FLAUGH, M.E. 
(1997). Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: 
binding affinities, brain penetration and activity in the neurogenic dural inflammation model 
of migraine. Life Sci., 61, 2117-2126. 
PRICE, G.W., BURTON, M.J., COLLIN, L.J., DUCKWORTH, M., GASTER, L., GÖTHERT, M., JONES, B.J., 
ROBERTS, C., WATSON, J.M. & MIDDLEMISS, D.N. (1997). SB-216641 and BRL-15572-
compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn-
Schmiedeberg's Arch. Pharmacol., 356, 312-320. 
ROON, K.I. (2000). New 5-HT1 agonists in migraine, Clinical efficacy and mechanisms. In Department 
of Neurology. pp. 174. Leiden: Leiden University Medical Centre. 
ROTH, B.L., CRAIGO, S.C., CHOUDHARY, M.S., ULUER, A., MONSMA, F.J., JR., SHEN, Y., MELTZER, 
H.Y. & SIBLEY, D.R. (1994). Binding of typical and atypical antipsychotic agents to 5-
hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J. Pharmacol. Exp. Ther., 268, 
1403-1410. 
SAXENA, P.R. (1995a). Cranial arteriovenous shunting, an in vivo animal model for migraine. In 
Experimental headache models. ed. Olesen, J. & Moskowitz, M.A. pp. 189-198. Philadelphia: 
Lippincott-Raven Publishers. 
SAXENA, P.R. (1995b). Serotonin receptors: subtypes, functional responses and therapeutic relevance. 
Pharmacol. Ther., 66, 339-368. 
SAXENA, P.R., DE VRIES, P. & VILLALON, C.M. (1998). 5-HT1-like receptors: a time to bid goodbye. 
Trends Pharmacol. Sci., 19, 311-316. 
SAXENA, P.R. & TFELT-HANSEN, P. (2000). Triptans, 5-HT1B/1D receptor agonists in the acute treatment 
of migraine. In The headaches. ed. Olesen, J., Tfelt-Hansen, P. & Welch, K.M.A. pp. 411-438. 
Philadelphia: Lippincott Williams & Wilkins. 
SELKIRK, J.V., SCOTT, C., HO, M., BURTON, M.J., WATSON, J., GASTER, L.M., COLLIN, L., JONES, B.J., 
MIDDLEMISS, D.N. & PRICE, G.W. (1998). SB-224289 - a novel selective (human) 5-HT1B 
receptor antagonist with negative intrinsic activity. Br. J. Pharmacol., 125, 202-208. 
TERRÓN, J.A. & FALCÓN-NERI, A. (1999). Pharmacological evidence for the 5-HT7 receptor mediating 
smooth muscle relaxation in canine cerebral arteries. Br. J. Pharmacol., 127, 609-616. 
Chapter 7 General discussion 
170 
THOMAS, D.R., GITTINS, S.A., COLLIN, L.L., MIDDLEMISS, D.N., RILEY, G., HAGAN, J., GLOGER, I., 
ELLIS, C.E., FORBES, I.T. & BROWN, A.M. (1998). Functional characterisation of the human 
cloned 5-HT7 receptor (long form); antagonist profile of SB-258719. Br. J. Pharmacol., 124, 
1300-1306. 
TSOU, A.P., KOSAKA, A., BACH, C., ZUPPAN, P., YEE, C., TOM, L., ALVAREZ, R., RAMSEY, S., 
BONHAUS, D.W., STEFANICH, E. & ET AL. (1994). Cloning and expression of a 5-
hydroxytryptamine7 receptor positively coupled to adenylyl cyclase. J. Neurochem., 63, 456-
464. 
ULLMER, C., SCHMUCK, K., KALKMAN, H.O. & LUBBERT, H. (1995). Expression of serotonin receptor 
mRNAs in blood vessels. FEBS Lett., 370, 215-221. 
VAN DEN BROEK, R.W.M., BHALLA, P., MAASSENVANDENBRINK, A., DE VRIES, R., SHARMA, H.S. & 
SAXENA, P.R. (2001). Characterisation of sumatriptan-induced contractions in human isolated 
blood vessels using selective 5-HT1B and 5-HT1D receptor antagonists and in situ 
hybridisation. Cephalalgia, In press. 
VERHEGGEN, R., HUNDESHAGEN, A.G., BROWN, A.M., SCHINDLER, M. & KAUMANN, A.J. (1998). 5-
HT1B receptor-mediated contractions in human temporal artery: evidence from selective 
antagonists and 5-HT receptor mRNA expression. Br. J. Pharmacol., 124, 1345-1354. 
VILLALÓN, C.M., CENTURIÓN, D., LUJÁN-ESTRADA, M., TERRÓN, J.A. & SÁNCHEZ-LÓPEZ, A. (1997). 
Mediation of 5-HT-induced external carotid vasodilatation in GR127935-pretreated 
vagosympathectomized dogs by the putative 5-HT7 receptor. Br. J. Pharmacol., 120, 1319-
1327. 
VILLALON, C.M., HEILIGERS, J.P., CENTURION, D., DE VRIES, P. & SAXENA, P.R. (1997). 
Characterization of putative 5-HT7 receptors mediating tachycardia in the cat. Br. J. 
Pharmacol., 121, 1187-1195. 
VOIGT, M.M., LAURIE, D.J., SEEBURG, P.H. & BACH, A. (1991). Molecular cloning and 
characterization of a rat brain cDNA encoding a 5- hydroxytryptamine1B receptor. Embo J., 
10, 4017-4023. 
WEINSHANK, R.L., ZGOMBICK, J.M., MACCHI, M.J., BRANCHEK, T.A. & HARTIG, P.R. (1992). Human 
serotonin 1D receptor is encoded by a subfamily of two distinct genes: 5-HT1Dα and 5-HT1Dβ. 
Proc. Natl. Acad. Sci. USA, 89, 3630-3634. 
WILLIAMSON, D.J., HILL, R.G., SHEPHEARD, S.L. & HARGREAVES, R.J. (2001). The anti-migraine 5-
HT1B/1D agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guinea-pigs. 
Br. J. Pharmacol., 133, 1029-1034. 
WURCH, T., PALMIER, C., COLPAERT, F.C. & PAUWELS, P.J. (1997). Sequence and functional analysis 
of cloned guinea pig and rat serotonin 5-HT1D receptors: common pharmacological features 
within the 5-HT1D receptor subfamily. J. Neurochem., 68, 410-418. 
ZGOMBICK, J.M., BARD, J.A., KUCHAREWICZ, S.A., URQUHART, D.A., WEINSHANK, R.L. & 
BRANCHEK, T.A. (1997). Molecular cloning and pharmacological characterization of guinea 
pig 5- HT1B and 5-HT1D receptors. Neuropharmacology, 36, 513-524. 
 
 
 171 
Chapter 8 
Summaries 
Summary in English 
This thesis focuses on the molecular and pharmacological aspects of porcine 5-HT1B, 
5-HT1D, 5-ht1F and 5-HT7 receptors, which seem to play important role in the 
pathogenesis and treatment of migraine headache.  Constriction of porcine carotid 
arteriovenous anastomoses is a well-established model for evaluating antimigraine 
activity of 5-HT-based compounds.  To complement this in vivo experimental model, 
we developed strategies for rapidly screening a number of potential antimigraine 
drugs.  For this purpose, we have cloned, sequenced and pharmacologically 
characterised porcine specific 5-HT1B, 5-HT1D and 5-ht1F receptors.  The result 
embodied in this thesis could be of importance in unravelling mechanisms underlying 
the pathogeneses of migraine and may help in developing effective therapeutic 
strategies. 
 
Chapter 1 reviews the current knowledge about the role of 5-HT and its receptors in 
migraine as well as the rationale for the studies described in the present thesis.  Since 
the pathophysiology of migraine is still not completely understood, a brief summary 
on the current hypotheses as well as possible mechanisms of action of current acute 
antimigraine drugs has been included. 
To date, it is widely accepted that certain subtypes of the 5-HT1 (i.e. 5-HT1B and 
5-HT1D) receptor subfamily may be important targets for acutely acting antimigraine 
agents, like sumatriptan.  In addition, there is some evidence suggesting the 
involvement of the 5-ht1F receptor subtype.  Regarding the prophylactic treatment of 
migraineurs, some studies have advocated that selective antagonists at 5-HT7 
receptors may also be clinically efficacious.  Investigating the molecular 
pharmacological aspects of 5-HT7 receptor is of particular interest due to the presence 
of different splice variants and the ubiquitous receptor distribution in both central and 
peripheral tissues.  Thus, due to their importance, a detailed account has been 
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provided on the molecular biology of 5-HT1B, 5-HT1D 5-ht1F and 5-HT7 receptors and 
their potential relation with respect to migraine treatment. 
It is interesting to note that even though human and rat 5-HT1B receptor show 
high (>90%) similarity in molecular mRNA or amino acid sequence, their 
pharmacological profile differs markedly.  On the other hand, human 5-HT1B and 
5-HT1D receptors show relatively low homology (61%), but a similar pharmacological 
profile has been reported for these two receptors.  From these reports it is evident that 
great care should be exercised when extrapolating results from experimental animal 
models to human.  For several years, we have used anaesthetised pigs to investigate 
the ability of a number of compounds, including triptans, to produce constriction of 
carotid arteriovenous anastomoses as a predictive tool for antimigraine activity; the 
porcine shunt migraine model has been briefly discussed.  For a more critical 
evaluation of current and potential novel antimigraine drugs that are being tested 
based on our porcine AVA model, we set out to elucidate the molecular and 
pharmacological aspects of the porcine 5-HT1 receptor subtypes namely 5-HT1B 
5-HT1D 5-ht1F and 5-HT7 receptors.  Subsequently, molecular structures and 
pharmacological profiles of these receptors were compared across other species, 
including human. 
At the end of this chapter, the aims of the present investigation have been listed. 
 
Chapter 2 describes the molecular and pharmacological characteristics of 
recombinant porcine 5-HT1B receptor.  The main criteria for cloning this receptor 
were twofold: (i) the 5-HT1B receptor has been shown to be an important molecular 
target for acute antimigraine drugs and (ii) the divergence in pharmacological 
properties of this receptor subtype when compared with human and rat.  The 
full-length porcine 5-HT1B receptor cDNA was derived from the pig cerebral cortex 
and the 5' and 3' ends of the cDNA were verified by inverse-PCR.  The cDNA 
sequence of porcine 5-HT1B receptor encoded a polypeptide of 390 amino acids and 
showed high homology (~90%) across other species, including human.  Interestingly, 
the sequence of porcine 5-HT1B receptor showed the conserved threonine at position 
355 in the seventh transmembrane domain as observed in human, rabbit and guinea 
pig, rather than an aspargine at corresponding position 351 in the case of mouse and 
rat.  Furthermore, competitive binding assays demonstrated that the pharmacological 
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profile of porcine 5-HT1B receptor showed high correlation with the human 5-HT1B 
receptor and weak correlation with rat 5-HT1B receptor.  Moreover, functional 
characterisation of porcine 5-HT1B receptor employing [35S]GTPγS binding showed 
that both 5-HT and the 5-HT1B/1D receptor agonist zolmitriptan potently increased 
[35S]GTPγS binding, according to their affinity at 5-HT1B receptors; since SB224289, 
a selective antagonist at 5-HT1B receptor, decreased [35S]GTPγS binding indicating 
that this compound may as an inverse agonist at this receptor.  The 5-HT1B receptor 
mRNA was expressed in various porcine blood vessels and in brain tissues.  In situ 
localisation of the 5-HT1B receptor mRNA was mainly observed in in pyramidal cells 
of porcine cerebral cortex.   
 
Chapter 3 comprises data on the molecular cloning and pharmacological 
characterisation of the porcine 5-HT1D receptor.  Similar to the 5-HT1B receptor, the 
5-HT1D receptor has also been implicated as a molecular target for acute antimigraine 
drugs.  Thus, specific 5-HT1D receptor agonists may be efficacious in acute migraine 
therapy, perhaps without causing vasoconstriction.  Additionally, although the exact 
underlying mechanisms mediated by 5-HT1D receptors in the pathophysiology of 
migraine are not yet clear, some agonists directed to this receptor have been 
demonstrated to reduce dural plasma extravasation and inflammation following 
trigeminal nerve stimulation.  A cDNA encoding the full-length 5-HT1D receptor was 
derived from porcine cerebral cortex and used for sequencing and pharmacological 
characterisation of this receptor.  The 5' and 3' ends of the porcine 5-HT1D receptor 
cDNA were confirmed by inverse PCR.  The cDNA sequence of a PCR product of 
1134 bp encoded a polypeptide of 377 amino acid with high homology to human as 
well as other species 5-HT1D receptor.  In contrast to the structure of recombinant 
human and rodent 5-HT1B receptor (aspargine instead of threonine, as discussed 
above), the porcine 5-HT1D receptor showed the presence of threonine at position 342 
in the seventh transmembrane domain, as is the case in other species, including human 
and rodents.  The presence of threonine at this position seems to be important largely 
for the similar ligand properties of 5-HT1B and 5-HT1D receptors.  Pharmacological 
characterisation of the recombinant porcine 5-HT1D receptor showed high affinity for 
a potent and selective agonist (5-carboxytryptamine; 5-CT) and antagonist 
Chapter 8 Summaries 
174 
(GR125743) at this receptor.  Subsequent competitive radioligand binding assay 
showed a typical 5-HT1D receptor pharmacology and a high correlation with its 
human homologue.  Ketanserin was found to discriminate between porcine 5-HT1B 
and 5-HT1D receptors displaying an approximately 40-fold higher affinity for the 
5-HT1D receptor.  In contrast, the human selective 5-HT1D receptor antagonist 
BRL15572 displayed several fold less affinity for the porcine 5-HT1D receptor.  As 
described for the 5-HT1B receptor, both 5-HT and zolmitriptan increased, while 
ketanserin decreased the basal [35S]GTPγS binding.  The data presented in this chapter 
has provided further evidence on the differential binding mechanisms that explain the 
distinct pharmacological characteristics of BRL15572 at porcine in comparison to 
human 5-HT1D receptor. 
 
Chapter 4 demonstrates the molecular cloning and characterisation of porcine 
5-ht1F receptor.  In addition to 5-HT1B and 5-HT1D receptors (see previous two 
chapters), the acute antimigraine drug sumatriptan also displays high affinity for 
5-ht1F receptor and, therefore, its antimigraine efficacy may possibly be due a direct 
action at the 5-ht1F receptor receptor.  In various animal models, the selective 5-ht1F 
receptor agonist (LY334370) blocks neurogenic plasma protein extravasation in the 
dura mater, inhibits central c-fos expression in the trigeminal nucleus caudalis, 
without constricting the cerebral or coronary artery.  Thus, a specific 5-ht1F receptor 
agonist may be useful as an antimigraine drugs with less cardiovascular side effects.  
In this study, we firstly cloned and sequenced a cDNA derived from the trigeminal 
ganglion.  The cDNA sequence analysis revealed a polypeptide of 366 amino acids, 
which showed a high homology with other species homologues, including human.  
Interestingly, in other species the amino acid alanine has been reported at position 
333, while we found a threonine at this position in the recombinant porcine 5-ht1F 
receptor.  Even though the porcine 5-HT1F receptor showed an expected 
pharmacological profile, quite similar to what is found in the human, some triptans 
showed a 10- to 15-fold less affinity.  This may be due to few amino acid differences 
in the transmembrane domains (site of ligand binding) and could be addressed by site 
directed mutagenesis experiments and/or by chimeric receptor studies. 
The tissue distribution of porcine 5-ht1F receptor mRNA revealed that both 
brain and peripheral tissues (also blood vessels) contain the 5-ht1F receptor mRNA.  
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Activation of 5-ht1F receptor seemingly inhibits neuropeptide (e.g. CGRP, substance 
P) release from trigeminal nerves as well as dural neurogenic inflammation.  Even 
though 5-ht1F receptor mRNA has been found in blood vessels, activation of this 
receptor does not participate in vasoconstriction.  The vascular expression of 5-ht1F 
receptor still remains to be further evaluated for assigning a role to this receptor in the 
circulatory system.   
 
Chapter 5 describes the molecular cloning of the porcine 5-HT7 receptor.  At present, 
the exact physiological role of 5-HT7 receptors is still not clear.  However, several 
reports have shown that activation of this receptor produces relaxation of vascular 
smooth muscles.  Since dilatation of cranial blood vessels has been proposed in the 
pathophysiology of migraine, a potent and selective 5-HT7 receptor antagonist may be 
efficacious for the treatment of migraine.  Total mRNA was isolated from the porcine 
cerebral cortex and by using multiple set of internal primers the porcine 5-HT7 
receptor cDNA was amplified.  Consensus aligned cDNA sequence revealed a 
polypeptide of 447 amino acids.  The recombinant porcine 5-HT7 showed high 
homology with other species homologues, including human, whereas all 
transmembrane domains were identical to porcine 5-HT7 receptor except for numbers 
IV and V.  The tissue distribution pattern of porcine 5-HT7 receptor mRNA was 
observed in brain (cortex, hemisphere and cerebellum) and peripheral blood vessels 
(pulmonary and coronary arteries, superior vena cava and saphenous vein).  The tissue 
distribution provides additional information in the (patho)physiological role of 5-HT7 
receptors, both in the central nervous system and peripheral system.  In this sense, 
selective 5-HT7 receptor antagonists with prophylactic antimigraine properties are 
awaited with great interest. 
 
Chapter 6 shows the localisation of both human 5-HT1B and 5-HT1D receptors in 
human isolated blood vessels.  As discussed in Chapter 1, we investigated the role of 
5-HT1B and 5-HT1D receptors in mediating sumatriptan-induced contractions of 
human cranial (middle meningeal and temporal arteries) as well as peripheral 
(coronary artery and saphenous vein) blood vessels.  Our results, using in situ 
hybridisation, show that 5-HT1B receptor mRNA is mainly present in smooth muscle 
and endothelial cells of middle meningeal and coronary arteries as well as in 
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saphenous veins, whereas only a weak expression of 5-HT1D receptor was observed in 
these blood vessels.  In agreement with the mRNA localisation of these receptors, the 
use of selective antagonists at human 5-HT1B (SB224289) and 5-HT1D (BRL15572) 
receptors revealed that the 5-HT1B receptor antagonist SB224289, but not the 
5-HT1D receptor antagonist BRL15572, attenuated sumatriptan-induced constrictions 
of these blood vessels.  Even though SB224289 attenuated sumatriptan-induced 
contractions, thus demonstrating that the 5-HT1B receptor primarily mediates 
vasoconstriction, other yet unidentified receptors/mechanisms may be involved in 
sumatriptan-induced responses in the human coronary artery. 
 
Chapter 7 provides a general discussion, limitation and precautions and implications 
in future research. 
 
In conclusion, the present studies revealed the molecular properties of porcine 
5-HT1B, 5-HT1D, 5-ht1F and 5-HT7 receptors and their high homology with other 
species homologues, including human.  Additionally, the pharmacological profiles of 
porcine 5-HT1B, 5-HT1D and 5-ht1F receptors showed a high correlation with that 
found for human recombinant receptors.  In particular, the major findings of the 
present study were: (i) molecular cloning and pharmacological characterisation of 
porcine 5-HT1B, 5-HT1D and 5-ht1F receptor; (ii) the low affinity of the human 
selective 5-HT1D receptor antagonist BRL15572 for the porcine 5-HT1D; (iii) the 
presence of threonine at position 333 in the porcine 5-ht1F receptor rather than alanine 
as found in other species; and (iv) the low affinity of some triptans for porcine 5-ht1F 
receptor.  It is anticipated that this knowledge may be useful in characterising 5-HT 
receptor ligands for therapeutic purposes. 
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Summary in Dutch; Samenvatting in het Nederlands 
Dit proefschrift behandelt voornamelijk de moleculaire aspecten van een aantal 
serotonine (5-HT) receptoren, die mogelijkerwijs een belangrijke rol spelen in de 
pathogenese en behandeling van migraine.  Verschillende studies hebben aangetoond 
dat de therapeutische waarde van een specifieke groep acuut werkende antimigraine 
medicijnen (voornamelijk triptanen, zoals sumatriptan) voornamelijk bepaald wordt 
door een directe werking op subtypen van de 5-HT1 receptor sub-familie.  Sinds de 
laatste jaren wordt er veel onderzoek gedaan om uit te zoeken welke van deze 
subtypen (5-HT1B, 5-HT1D en/of 5-ht1F receptoren) verantwoordelijk is voor de 
therapeutische waarde, of voor de ongewilde bijwerkingen, van deze speciale klasse 
van antimigraine middelen.  Naast de acute behandeling van migraine (bijvoorbeeld 
met de triptanen), is er mogelijkerwijs ook een belangrijke rol weggelegd voor 5-HT7 
receptoren in de profylactische behandeling van deze aandoening.  Het is belangrijk 
om te vermelden dat constrictie van arterioveneuze anastomoses in het vaatbed van de 
arteria carotis (halsslagader) van genarcotiseerde varkens een voorspellend model is 
voor antimigraine activiteit.  Zoals beschreven in onderstaande paragrafen, hebben we 
de 5-HT1B, 5-HT1D en 5-ht1F receptoren gekloneerd, farmacologisch gekarakteriseerd 
in cellen van varkens en gelokaliseerd in weefsels van het varken van de mens.  Voor 
een beter begrip is het nodig om te vermelden dat hoofdletters (5-HT) worden 
gebruikt om die receptoren aan te duiden waarvan de moleculaire structuur en 
farmacologische eigenschappen (affiniteit en activiteit) volledig bekend zijn 
(bijvoorbeeld 5-HT1B receptoren) en kleine letters (5-ht) daarentegen worden gebruikt 
voor die receptoren die nog niet volledig farmacologisch zijn gekarakteriseerd 
(bijvoorbeeld 5-ht1F receptoren). 
De huidige resultaten bieden belangrijke informatie voor een betere 
ontwikkeling van verschillende stoffen die selectiever op deze receptoren werken, 
waarmee een belangrijke stap kan worden gezet voor betere migraine therapie in de 
nabije toekomst. 
 
Hoofdstuk 1 geeft een overzicht over de huidige kennis van 5-HT receptoren alsmede 
de beweegredenen voor de studies, die beschreven zijn in de komende hoofdstukken.  
Omdat men nog steeds in het duister tast over de onderliggende biologische processen 
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die verantwoordelijk zijn voor het ontstaan van een migraine aanval, worden de 
huidige theorieën en de mogelijke werkingsmechanismen van enkele belangrijke 
antimigraine middelen in het kort beschreven.  Zoals reeds vermeld, is er een aantal 
receptoren (5-HT1B, 5-HT1D, 5-ht1F en 5-HT7) dat mogelijkerwijs als aanknopingspunt 
fungeert voor antimigraine middelen.  In de hoofdstukken 2,3,4, en 5 beschrijven we 
de isolatie (klonering) en farmacologische karakterisering van deze receptoren in het 
varken en vergelijken deze met de moleculaire en farmacologische aspecten die 
beschreven zijn voor andere species, voornamelijk die in de mens (humaan).  In de 
hoofdstukken 2, 3 en 4 wordt respectievelijk de 5-HT1B, 5-HT1D en 5-ht1F receptor 
behandeld.  Hoewel de moleculaire structuren van deze receptoren overeenkomstig 
zijn met die van humane receptoren (hoge mate van homologie), zijn enige specifieke 
aminozuren verschillend in sommige receptoren; deze verschillen kunnen grote 
gevolgen hebben voor de affiniteit van stoffen en de activiteit van de receptor.  
Bijvoorbeeld, in de varkens 5-HT1B receptor (Hoofdstuk 2), bevindt het aminozuur 
asparagine zich in positie 355 (in het zevende transmembraan domein) zich bevindt in 
de muis en rat, terwijl er op deze positie in het varken, konijn, cavia en de mens het 
aminozuur threonine wordt gevonden.  In tegenstelling tot de 5-HT1B receptor in de 
rat, hebben we aangetoond dat verschillende stoffen een verwachte affiniteit 
(interactie met receptor) vertonen en een activatie van de receptor veroorzaken in 
varkens, vergelijkbaar met die beschreven in de mens.  Ondanks de verwachte 
verschillen in receptorstructuur met die van de varkens 5-HT1B receptor (een 
homologie van 61%), hebben we vergelijkbare resultaten voor de varkens 5-HT1D 
(Hoofdstuk 3) en 5-ht1F receptor (Hoofdstuk 4).  Een interessante bevinding omtrent 
de varkens 5-ht1F receptor is dat we op positie 333 het aminozuur threonine hebben 
gevonden in tegenstelling tot het aminozuur alanine in deze receptor in andere species 
(bijvoorbeeld de mens).  Tevens waren de farmacologische profielen (directe en 
indirecte binding) van deze receptoren vergelijkbaar met die van humane receptoren.  
Om uit te zoeken welk 5-HT1 receptor subtype (5-HT1B en/of 5-HT1D) betrokken is bij 
de vasculaire effecten (samentrekking van bloedvaten) effecten van de 5-HT1B/1D 
receptor agonist sumatriptan, hebben we met behulp van in situ hybridisatie het 
receptor messenger RNA (mRNA) gelokaliseerd in verschillende humane bloedvaten 
(coronair arterie, arteria meningea media en vena saphena).  Deze lokalisatie hebben 
we getracht te correleren aan de effecten van selectieve 5-HT1B (SB224289) en 
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5-HT1D (BRL15572) receptor antagonisten op door sumatriptan geïnduceerde 
samentrekking van deze bloedvaten (zie Hoofdstuk 6).  In alle bloedvaten werd het 
effect van sumatriptan alleen geblokkeerd door SB224289, wat aanduidt dat 
voornamelijk 5-HT1B receptoren deze vasculaire effecten van sumatriptan mediëren; 
tevens is er aangetoond dat er ook andere receptoren meespelen in het geval van de 
coronair arterie.  Daar de 5-HT1B, 5-HT1D en 5-htF receptoren in zowel centrale als 
perifere weefsels van varkens voorkomen, is het gebaseerd op deze resultaten moeilijk 
om een eenduidig antwoord te geven op de vraag welk 5-HT1 receptor subtype de 
antimigraine effecten van sumatriptan mediëert. 
 In Hoofdstuk 5 wordt de klonering van 5-HT7 receptoren uit de cerebrale 
cortex van varkens beschreven.  Ondanks het feit dat de onderliggende mechanismen 
nog niet volledig bekend zijn, produceert stimulatie van deze receptor een tal van 
biologische effecten, zoals bijvoorbeeld relaxatie van gladde spieren in verschillende 
weefsels, waaronder bloedvaten.  Daar er wordt gedacht dat verwijding van craniële 
bloedvaten een belangrijke rol speelt in de pathofysiologie van een migraine aanval, 
zou een 5-HT7 receptor antagonist effectief kunnen zijn in de profylactische 
behandeling van deze aandoening.  We hebben in dit hoofdstuk laten zien dat de 
moleculaire structuur van de varkens 5-HT7 receptor volledig (100%) is gecorreleerd 
aan die van de humane 5-HT7 receptor.  We hebben, weliswaar, nog niet het 
farmacologische profiel van deze receptor onderzocht.  De beschreven verdeling van 
deze receptor in verschillende weefsels, zowel centraal als perifeer, geeft belangrijke 
informatie omtrent de mogelijke rol van de 5-HT7 receptor in de behandeling van 
vasculaire aandoeningen zoals migraine.  Eventuele resultaten van potente en 
selectieve 5-HT7 receptor antagonisten in de behandeling van migraine worden met 
veel interesse tegemoet gezien. 
 In Hoofdstuk 7 worden de resultaten van afgelopen hoofdstukken dichter 
onder de loep genomen en nauw met elkaar in verband gebracht.  Tevens worden de 
tekortkomingen van de methoden en mogelijke (toekomstige) implicaties van de 
huidige resultaten beschreven. 
 
In het kort samenvattend, hebben we in de huidige studie laten zien dat de 
moleculair structuren van de varkens 5-HT1B, 5-HT1D, 5-ht1F and 5-HT7 receptoren 
een hoge mate van homologie vertonen met die in andere species, waaronder de mens.  
Chapter 8 Summaries 
180 
Hiermee nauw samenhangend, hebben we aangetoond dat de farmacologische 
profielen van zowel de 5-HT1B and 5-HT1D, alsmede van de 5-ht1F receptoren een 
hoge correlatie vertonen met die van de humane receptor.  Naast deze observatie, zijn 
de drie meest interessante bevindingen dat: (i) de 5-HT1D receptor antagonist 
BRL15572 een veel lagere affiniteit vertoonde in varkens in vergelijking met die in de 
mens; (ii) de varkens 5-ht1F receptor het aminozuur threonine op positie 333 bevat, in 
tegenstelling tot alanine in andere species, dit kan belangrijke gevolgen hebben op het 
farmacologische profiel van de receptor; en (iii) de lage affiniteit van triptanen (acuut 
werkende antimigraine middelen) voor de varkens 5-ht1F receptor. 
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